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Abstract 
Background: Multiple Myeloma (MM) is currently incurable despite many novel 
therapies. Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) is a 
potential anti-tumour agent although the effects as a single agent are limited. This 
investigation determined whether the Histone Deacetylase (HDAC) inhibitor SAHA, or 
inhibitors of the histone methyltransferases G9a and EZH2 (BIX 01294 and GSK343) 
and Nuclear export inhibitor (NEI) LMB, enhance TRAIL-induced apoptosis and 
overcome TRAIL resistance in both suspension culture, and 3D cell culture as a model 
of solid disseminated MM lesions that form in bone. 
Methods: The effects of TRAIL sensitizers and/or TRAIL treatment were investigated 
in both suspension cultures and in an alginate-based 3D culture model. Apoptosis was 
detected by assessment of nuclear morphology using Hoechst 33342/PI staining. 
TRAIL-resistant cells were generated by acute exposure of TRAIL sensitive cells to 
TRAIL followed by the selection of TRAIL-resistant cells (TRAILR). Apoptotic effects 
in quiescent cells (labelled as PKH26Hi) were also determined. Subsequently, an 
investigation was undertaken to identify potential mechanisms of action of these agents 
when used alone and in combination with TRAIL. 
Results: TRAIL significantly induced apoptosis in a dose-dependent manner in OPM2, 
RPMI 8226, NCI-H 929, U266, JJN3 human MM cell lines and ADC-1 plasma cell 
leukaemia cells. All epigenetic modifiers and NEI synergistically enhanced TRAIL 
responses in several lines and responses were potentiated in 3D culture. Interestingly, 
TRAILR cells were sensitive to BIX 01294 and LMB; however, TRAIL responses in 
cells that had been selected for TRAILR were not further enhanced by SAHA and 
GSK343. Quiescent PKH26Hi cells were resistant to dual therapy. Mechanistically, 
TRAIL and TRAIL sensitizers induced apoptosis via both extrinsic and intrinsic 
pathways in addition to decreasing the expression of oxidative enzyme catalase.  
Conclusions: Inhibitors of HDAC, EZH2 and G9a and NEI are potent sensitisers of 
TRAIL responses both in suspension, and crucially in 3D cell culture, which may mimic 
physiological aspects of bone metastases. These agents may be a therapeutic option in 
combination with TRAIL and may increase TRAIL sensitivity in insensitive cells, but 
not in cells that have specifically been selected for acquired TRAIL-resistance, and not 
in quiescent cells.  
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1.1 An Overview of Cancer 
The term cancer is derived from the Greek word referred to a crab or crayfish because 
of the resemblance of the finger-like dissemination bulges from cancer to the legs of a 
crab (Hecht., 1987). Cancer is a disease characterised by an uncontrolled division and 
spread of abnormal cells into surrounding body tissues (American Cancer Society., 
2014; Cancer Research UK., 2014; National Cancer institute., 2015). Cancer is a most 
important public health problem worldwide and is the second-leading cause of death in 
the USA (Siegel et al., 2016). According to American Cancer Society and Cancer 
Research UK (2014) approximately 4.7 million and 3.5 million cases of deaths were 
estimated in male and female respectively (American Cancer Society., 2014; Cancer 
Research UK., 2014). In the UK, more than 331,000 people are diagnosed with cancer 
each year and the most common cancers are prostate, colorectal, and melanoma among 
males, and breast and colorectal among females (Cancer Research UK., 2014).  
Cancer caused by multiple changes and mutations in genes that control the cell function 
and division result in disrupts the normal cell processes (Hanahan and Weinburg., 
2011). These genetic changes can be either inherited (germline) or arise during the 
lifetime (somatic) as a result of environmental exposure to chemicals or radiation.  
These internal and external are many factors which may act together in order to initiate 
and support the development of cancer by trigger the cells to undergo unrestricted 
proliferation and invasion (American Cancer Society.,  2014).  
Malignant solid tumours have the ability to spread into, or invade adjacent tissues or 
metastasis by travel to distant places in the body through the blood or the lymphatic 
system and give rise new secondary tumours far from the original primary cancerous 
tumour. In contrast, benign tumours do not spread into, or invade, adjacent tissues. 
Benign tumours are usually not threating human life if it is excised, and they usually 
don’t undergo local recurrence grow back, however, in some cases, they can be life 
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threatening due to pressing on surrounding tissues such as benign brain tumours 
(American Cancer Society., 2014; Cancer Research UK., 2014). Most cancers form 
masses of solid tumour tissue, however, many blood cancer, such as leukemias, 
commonly do not form solid mass tumours (American Cancer Society., 2014; Cancer 
Research UK, .2014), but multiple myeloma (MM) and lymphoma do form solid masses 
(Teo and Peh., 2004). 
1.2 Normal Haematopoiesis 
Haematopoiesis is the processes of formation of blood cellular components from 
common haematopoietic stem cells (HSCs) reside in bone marrow (Kondo., 2010; 
Jagannathan-Bogdan and Zon., 2013). Haematopoietic stem cells are self-renewing cells 
with the capability to produce at least some of their daughter cells with identical 
characteristics of HSCs for developmental and proliferative potential. These cells have 
the unique ability to differentiate to all of the different classes of mature blood cell types 
and tissues (Passegue et al., 2003; Kondo., 2010; Jagannathan-Bogdan and Zon., 2013). 
During haematopoiesis, HSCs give rise myeloid and lymphoid progenitor lineage, 
which further differentiate into more specific blood cell types (Passegue et al., 2003; 
Kondo., 2010; Jagannathan-Bogdan and Zon., 2013).  
The lymphoid progenitors produce immune T- and B-cell lymphocytes and natural 
killer cells (NKCs). Whilst the myeloid progenitor lineage produce, erythrocytes and 
granulocytes which include: eosinophils, basophils, neutrophils, and monocytes which 
differentiate into the macrophage (Orkin and Zon., 2008). T-cells play an important role 
in cell mediate immunity and their proliferation and differentiation requires the 
detection of specific antigen, which is also essential to help other immune response cell 
types such as B-cells and NKCs cells. The activation of T-cells by detection of specific 
antigen by T-cell receptor (TCR) in addition to activation by co-stimulatory signals 
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delivered by accessory surface molecules on T-cells (Alegre et al., 2001). Moreover, B-
cells activated in response to foreign antigen, which recognized by membrane-bound 
immunoglobulin (IgM) and turns into antibody producing plasma cells. B-cells originate 
in the bone marrow and released into blood or lymph as B-cells prior to their final 
differentiation into antibody producing plasma cells (Figure 1.1) (Calame., 2001; 
Bernasconi et al., 2002).  
Haematopoiesis is a highly organized cellular process that regulates cellular 
proliferation and differentiation capacity as well as bone marrow release of cells in 
order to ensure there is a compliment of each type of blood cells and optimal 
haematopoiesis status is maintained (Sachs., 1996). Therefore, impaired haematopoiesis 
is a feature of malignant disorders such as multiple myeloma (MM) (Bommert et al., 
2006) and studying the process of hematopoiesis can help to clear understand the 
underlying mechanisms behind blood disease and cancers (Jagannathan-Bogdan and 
Zon., 2013). 
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Figure 1.1: Illustration of the development of different blood cells from HSCs 
 
Figure 1.1: Illustration of the development of different blood cells HSCs. During 
haematopoiesis, HSCs give rise lymphoid and myeloid progenitors which in turn 
differentiate into more specific cell types including all white blood cells, red blood cells, 
and platelet. Modified from Passegue et al., 2003. 
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1.3 Multiple Myeloma Overview 
Multiple myeloma (MM) is a clonal plasma cell malignancy characterised by a 
proliferation of antibody secreting plasma cells in the bone marrow (Lemancewicz et 
al., 2013) and subsequently by an increase of monoclonal para-protein (Cook and 
Macdonald., 2007). The bone marrow accumulation of B-cells interferes with the 
production of other blood cells, which may result in the formation of soft-tissue masses 
(plasmacytomas) and osteolytic bone lesions (Ciolli., 2012). Multiple myeloma 
accounts for 1% of the malignant diseases and approximately 10% of all hematological 
cancers (Jemal et al., 2009). It is considered the most common blood malignancy in the 
USA, after non-Hodgkin lymphoma (Zaravinos et al., 2014). Furthermore, it is mainly a 
disease of the elderly with a median age at diagnosis is 66 years (Salameh et al., 2013). 
The common clinical manifestations of multiple myeloma are the bone lesion that 
appears as painful osteolytic bone lesions caused by tumour cells disrupting normal 
bone turnover, with long-lasting pain or vertebral crush fractures, renal impairment and 
hematologic abnormalities including anemia and hypercalcemia. In addition, the 
reduction of humoral immunity may lead to recurrent infection (Laubach et al., 2011). 
1.3.1 Molecular Pathogenesis of Multiple Myeloma 
In recent years, significant efforts have been exerted to identify the underlying cellular 
and molecular changes in the multiple myeloma pathogenesis (Piazza et al., 2013). The 
myeloma cells are developed from premalignant maturation of monoclonal plasma cells 
that originate at the post-germinal center B-cells. Furthermore, increasing evidence 
indicates that multi-step genetic impairments and micro-environmental changes play a 
key role in the transformation of these premalignant cells into malignant neoplasms. 
Multiple myeloma represents the final evolution of a premalignant precursor phase, 
known as monoclonal gammopathy of unknown significance (MGUS) that progresses 
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to smoldering  myeloma and finally to intra-medullary and extra-medullary 
symptomatic myeloma (Figure 1.3). (Palumbo and Anderson., 2011). Monoclonal 
gammopathy of unknown significance (MGUS) has an age-dependent prevalence of 3% 
of individuals > 50 years old and the sporadic progression of MGUS to MM has an 
average rate of 1% per year (Zaravinos et al., 2014). Similar to multiple myeloma, 
MGUS produces a monoclonal immunolglobin (Ig) (mostly non-IgM) and it is 
distinguished clinically from multiple myeloma by <10% of mononuclear cells in bone 
marrow with no secondary end-organ damage (Paszekova et al., 2014). The progress of 
MGUS to smoldering and symptomatic multiple myeloma respectively is related to 
acquisition or suseguent oncogenic mutation. Despite the recent advances to understand 
the pathogenesis of multiple myeloma, it remains unclear which patient with MGUS 
will progress to multiple myeloma, and which one will not (Chesi and Bergsage, 2013). 
Multiple myeloma plasma cells have low proliferation rate and dependent on bone 
marrow microenvironment regulation for growth (Menu et al., 2004). The interaction of 
myeloma plasma cells with the other extracellular matrix (ECM) cells in the bone 
marrow environment represents the key requirements for the pathogenesis of MM, 
migration, growth and survival of myeloma cell (Piazza et al., 2013). Moreover, the 
secretion of growth factors and cytokines by multiple myeloma cells and by other cells 
in the bone marrow microenvironment such as bone marrow stromal cells (BMSCs) 
(Valentin-Opran et al., 1982), which is regulated by cell–cell adhesion activates 
signalling cascades including the NFκB-pathway (Chauhan et al., 1996), the 
Ras/Raf/MEK/MAPK-pathway (Leow et al., 2013), the PI3K/Akt-pathway (Li et al., 
2013; Mao et al., 2011), the Wnt-pathway (Dutta-Simmons et al., 2009; Qiang et al., 
2003), and the JAK/Stat3-pathway (Kawano et al., 1988) that have provided promising 
targets approach for novel multiple myeloma therapies (Figure 1.2) (Podar et al., 2009). 
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1.3.1.1 Interaction of Multiple Myeloma with Bone Marrow Environment 
The bone marrow  (BM) milieu consists of mesenchymal stem cell-derived bone 
marrow stromal cells, osteoblast and adipocytes among other haemopoietic cells 
together with vascular endothelial cells and the extracellular matrix (Gooding and 
Edwards., 2016). The interaction of myeloma plasma cells with stromal cells via the 
adhesion molecules including intercellular adhesion molecules (ICAMs), vascular cell 
adhesion molecules (VCAMs) and very late antigen-4 (VLA-4) results in up-regulating 
the expression of tyrosine kinase receptors and chemokine receptors (Raab et al, 2009). 
This binding, in turn, stimulates the secretion of a wide range of cytokines/growth 
factors and chemotactic agents such as IL-6 (Figure 1.4) (Raab et al, 2009). In addition, 
the internal signals and external stimuli such as hypoxia promote the secretion of 
Hypoxia-inducible factor-1 (HIF-1) and angiogenic cytokine vascular endothelial cell 
growth factor (VEGF) (Kuehl1 and Bergsagel., 2012). The pro-angiogenic molecule 
VEGF enhances the bone marrow microvascular density and accounts for the abnormal 
myeloma tumour vessels structure (Figure 1.2). 
Moreover, the complex interaction among these varieties of cells leads to an imbalance 
in the osteoblasts and osteoclasts function. As a result suppression in the activity of 
osteoblast which is mediated by Dickkopf-related protein 1 (DKK1). Dickkopf-related 
protein 1 (DKK1) produced by MM prevents Wnt signalling, preventing osteoblast 
differentiation (Qiang et al, 2008) and promoting adipocyte differentiation (Ruan et al., 
2013). Whereas the action of Macrophage Inflammatory Protein 1 α (MIP1α) enhances 
the osteoclast function (Palumbo, and Anderson., 2011) (Figure 1.4). In addition, 
dysregulation of Receptor Activator of NF-κB Ligand (RANKL) and osteoprotegerin 
(OPG) has been shown be play a crucial role in the pathogenesis of MM bone disease 
(Shipman and Croucher., 2003). Receptor Activated of NF-kB Ligand (RANKL), is 
expressed by stromal cells and osteoblasts in the BM microenvironment (Anderson et 
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al., 1997; Lacey et al., 1998) and bind to its receptor RANK, on the surface of 
osteoclast precursors in order to promote osteoclast differentiation and bone resorption 
(Burgess et al., 1999). A soluble decoy receptor, OPG, has also been identified that can 
bind to RANKL and inhibiting its interaction with RANK, thus preventing bone 
osteoclastic bone resorption (Simonet et al., 1997). Myeloma cells may increase 
expression of RANKL, activating RANK on pre-osteoclasts. In addition, decrease 
expression of OPG has been reported in bone marrow of MM patients (Shipman and 
Croucher., 2003). This results in bone lytic disease, immunodeficiency and stimulates 
the growth and the survival of multiple myeloma cells (Kyrtsonis et al., 2010). 
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Figure 1.2: The role of the bone marrow microenvironment in multiple myeloma 
pathogenesis 
 
Figure 1.2: The role of the bone marrow microenvironment in multiple myeloma 
pathogenesis. Complex Interactions of MM tumour cells with the BM cells via the 
adhesion molecules resulting in the release of survival and growth factors e.g. IL-6. 
Moreover, they promote the secretion of angiogenic factor including HIF-1 and VEGF, 
and decreases the activity of osteoblast by DKK1 produced by myeloma prevents Wnt 
signalling and  preventing osteoblast differentiation, Whereas the increased RANKL 
and decrease in OPG (a negative  regulator of RANKL) enhances the osteoclast activity 
and ultimately stimulates the survival and growth of MM cells. Modified from Kuehl 
and Bergsagel., 2012, and Kyrtsonis et al., 2010. 
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1.3.2 Genetic Alteration of Multiple Myeloma 
At the molecular level, multiple myeloma is associated with considerable heterogeneity 
and chromosomal abnormalities suggesting two distinct categories: Hyperdiploid 
myeloma (HRD) and non-hyperdiploid myeloma (NHD) (Herve et al., 2011). 
Hyperdiploid myeloma is characterized by multiple trisomies of chromosomes 3, 5, 7, 9 
11, 15, 19 and 21 and primary IgH translocations in ~10% of cases, while non-
hyperdiploid myeloma is associated with primary IgH translocations in ~ 70% of cases 
(Fonseca et al., 2003).  Hyperdiploid tumour patients have a better prognosis than non-
hyperdiploid tumour patients (Kumar et al., 2012) (Figure 1.3). 
1.3.2.1  Primary IgH Translocations as an Early Genetic Event in Multiple 
Myeloma 
During the development of B-cells, the rearrangement of immunoglobulin heavy chain 
(IgH) locus on chromosome 14 and immunoglobulin light chain (IgL) locus on 
chromosomes 2 and 22 takes place in about half the cases of MM. There are three 
Primary IgH translocation groups identified by fluorescent in situ hybridization (FISH). 
These IgH translocations target three genes, including the cyclin D (CCND) family 
(11q13-CYCLIN D1: 15 %; 6p25-CYCLIN D3: 2 %; 12p13-CYCLIN D2: 1 %), Wolf-
Hirschhorn syndrome candidate 1/FGFR3 (MMSET/FGFR3) genes (4p16-FGFR3 
/MMSET: 15 %) and the MAF family (16q23-MAF: 5 %; 20q12-MAFB: 2 %; 8q24.3-
MAFA: 1 %) (Chesi and Bergsage., 2013). Breakpoints usually happen in the region 
near, or within IgH switch regions as related to error in somatic hypermutation (SHM) 
or isotype class switch recombination (CSR) (Kuehl and Bergsagel., 2002), hence being 
selected to recognize a certain antigen, they sometimes occur near V(D)J sequences of 
IgH on chromosome 14q32. It is supposed that these chromosomal translocations 
represent the initiating oncogenic events involved in developing normal B-cells 
(Bergsagel and Kuehl., 2001). 
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1.3.2.2 Cyclin D and MAF Genes Dysregulation in Multiple Myeloma Tumours 
Almost in all cases of MGUS and multiple myeloma tumours, there is an increase in the 
expression of the cyclin D (CCND) genes that results from cis-dysregulation and trans-
dysregulation of cyclin D and MAF gene translocation respectively. Moreover, it has 
been found that the level of expression of CCND1 mRNA in MM and MGUS tumour is 
high compared to the lack of expression by normal B-cells and the majority of 
hyperdiploid myeloma tumours express CCND1 bi-allelically, which may be due to 
trisomy of chromosome 11. A few percent of multiple myeloma tumours (˂5%) that do 
not express high CCND gene level have a inactivated retinoblastoma gene (pRb1) 
(Figure 1.3) (Kuehl and Bergsagel., 2012; Chesi and Bergsage., 2013). 
Additionally, it is thought that translocations of CCND dysregulate only CCND gene 
expression while MAF translocations dysregulate MAF transcription factor expression 
which in turn up-regulates the expression of many genes such as CCND2 and adhesion 
molecules, the key factor in the interaction of MM tumour cells with the BM 
microenvironment (Kuehl and Bergsagel., 2012; Chesi and Bergsage., 2013). 
1.3.2.3 Multiple Myeloma Su(var) 3-9, Enhancer-of-zest, Trithorax (SET domain) 
(MMSET) 
Multiple myeloma Su(var) 3-9, Enhancer-of-zest, Trithorax (SET domain) (MMSET) is 
a major epigenetic regulator in MM patients with t(4;14) translocation that harbours the 
worst prognosis (Asangani  et al., 2013) and it is thought to be the driving factor  in  
MM pathogenesis of this specific subtype (Popovic et al., 2014). MMSET is a nuclear 
protein with multiple domains important for the regulation of genes including the 
function SET domain, which codes histone methyltransferase (HMTase) activity (Licht 
et al., 2011). HMTases are chromatin modifiers that control the transcriptiomic 
landscape in normal and development of disease including tumour progression and 
formation (Asangani et al, 2013). HMTases catalyse the binding of 1-3 methyl groups at 
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a specific lysine or arginine residues on H3 and H4 histones, altering the transcriptional 
activity of chromatin (Wood and Shilatifard., 2004). 
It has been found that MMSET over-expression enhances the global increase in the 
dimethylation of H3K36 which is associated with actively transcribed genes in addition 
to the genome-wide loss of H3K27 trimethylation (Popovic et al., 2014) and re-
expression of developmental gene Hox (Wang et al., 2007). Moreover, this effect is 
associated with the significant change in DNA methylation (Xiao et al., 2013). The 
effects of over-expression of MMSET include increased cell cycle, altered/reduced 
response to DNA damage and reduced apoptosis (Licht et al., 2011). Matinez-Garcia.,  
(2011) established that the knock-down of MMSET expression inhibits growth, 
modifies cell adhesion properties and consequently triggers apoptosis in the MM cell 
lines (Martinez-Garcia., 2011). 
Additional oncogenic events in the pathogenesis of multiple myeloma tumours are 
chromosome 13 deletions disrupting RB1 which are often an early event in both 
hyperdiploid myeloma  and non-hyperdiploid myeloma pathways (Chiecchio et al., 
2009), mutations of BRAF and RAS and increased c-MYC expression (Chng et al., 
2011), deletions of TP53 and loss of chromosome 17p (Lode et al., 2010). Moreover, 
the translation of MGUS to MM is associated with secondary Ig translocations 
including mostly IgK and IgL (Gabrea et al., 2008). In addition, mutations in genes 
involving in protein translation, homeostasis and RNA regulating metabolism are 
recognized in MM patients (Figure 1.3) (Chapman et al., 2011). 
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Figure 1.3: Molecular pathogenesis and genetic alteration of Multiple Myeloma 
 
 
Figure 1.3: Molecular pathogenesis and genetic alteration of Multiple Myeloma. The 
primary transition is shared by plasma cells in MM and in MGUS; they involve 
partially overlapping genetic events include primary IgH translocations, multiple 
trisomies, and deletion of chromosome 13 associated with CCND gene dysregulation.  
The progression from MGUS to MM is associated with the increase in the expression of 
MYC and sometimes the mutation of KRAS in addition to chromosome 13 deletion. 
Further progression of multiple myeloma is associated with MYC rearrangements at Ig 
locus, NF-κB pathway mutations, p53 mutation or deletion as well as p18INK4c and 
RB1 inactivation. Modified from Kuehl and Bergsagel., 2012, and Palumbo and 
Anderson., 2011. 
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1.4 Cell Cycle 
The cell cycle process is a sequence of firmly integrated events that allow the cell 
growth division, and DNA duplication to give two daughter cells (Alison., 2011; 
Garrett., 2001; Schwartz and Shah., 2005). This process occurs in two major phases: 
interphase and mitosis.  During interphase, the cell grows and DNA replication occurs 
and cell prepared to enter mitotic phase by amplifying it organelles, cellular contents, 
and proteins. While the mitotic phase (M) is a relatively short period during which the 
cell undergoes division to generate two new cells (Alison., 2011; Garrett., 2001; 
Schwartz and Shah., 2005). Interphase is subdivided into further distinct phases G1, S 
(DNA synthesis), G2 and G0 (Figure 1.4) (Nurse., 2000).  
1.4.1 Regulation of Cell Cycle Process 
The cell cycle is controlled by a family of protein dependent kinase holoenzymes which 
are activated by cyclins.  
1.4.1.1 Cyclin-Dependent Kinases (CDKs)  
Cyclin dependent kinases (CDK) is serine/threonine kinases family which have a crucial 
role in regulating cell division cycle (Garrett., 2001). Progression through the cell 
division cycle requires coordinated activation of the CDK by association with the 
regulatory cyclin subunit. Specific cyclin-CDK complexes activate during different cell 
cycle phases and these activated cyclin-CDK complexes, in turn, phosphorylate target 
substrates such as Retinoblastoma (pRb) (Carnero., 2002).  
Cellular entry into G1 phase of cell cycle controlled by binding of cyclin D1, D2 and D3 
to cyclin D-dependent kinases CDK4 and CDK6. Progression from G1 to synthesis 
phase (S) is regulated by cyclin E-CDK2 complex in order to commit the cell to 
synthesis DNA. In addition, the progression into S-phase regulated by complexed of 
cyclin A with CDK2. Progression the cell from G2 phase into mitosis requires the 
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binding of the CDK1 with cyclin A as well as cyclin B which has a role in protein 
phosphorylation during mitosis (Figure 1.4) (Garrett., 2001; Schwartz and Shah., 2005; 
Malumbers and Barbacid., 2007). 
1.4.1.2 Cyclin Dependent Kinase Inhibitor (CDKi) 
CDK activity is regulated by inhibitory proteins, named Cyclin Dependent Kinase 
Inhibitor (CDKi) which can bind either to CDK alone or to the complex of CDK and 
cyclin partner and cause cell cycle arrest at different cell cycle phases (Garrett., 2001; 
Schwartz and Shah., 2005; Malumbers and Barbacid., 2007). There are two families of 
CDKi regulatory proteins: the inhibitor of CDK4 (INK4) family which include different 
protein member, including p16INK4a, p15INK4b, p18INK4c and p19INK4d. These specifically 
inhibits the activity of CDK4 and CDK6 resulting in G1 arrest. The other CDKi inhibitor 
families are the CDK interacting protein or kinase inhibitory protein CIP/KIP family, 
comprising of p21cip1/waf1, p27kip1 and p57kip2, which lead to cell cycle arrest specifically 
in G/S boundary, S and G2/M (Figure 1.4) (Carnero., 2002). 
Progression of the cell through the cell division cycle can be inhibited by modulating of 
specific mechanisms involved in different phases of cell cycle. Arrest in G1 phase is 
triggered by inhibition of Cyclin D-CDK4 and Cyclin D-CDK6 complex. While S phase 
arrest stimulated by DNA damage as well as the reduction in Cyclin A-CDK2 and 
Cyclin E-CDK2 complex expression (Figure 1.2). In response to DNA damage or stress, 
the tumour suppressor gene  p53 is activated which in turn upregulates the expression of 
p21CIP and p27KIP1 inhibiting Cyclin A-CDK2 and Cyclin E-CDK2 complexes resulting 
in S-phase arrest (Figure 1.5). Moreover, arrest in G2/M phase is triggered by inhibition 
of Cyclin B-CDK1 complex via p53 activation (Garrett., 2001; Schwartz and Shah., 
2005; Malumbers and Barbacid., 2007; Turner et al., 2012). Dis-regulation of cell cycle 
regulatory molecules play an essential role in cancer progression (Dai and Grant., 2003) 
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and altered CDK activity has been showed in most human cancer cells (Fischer and 
Gianella-Borradori., 2003).  
1.4.1.3  Cell Cycle Checkpoints 
Regulation of CDK activity is crucial for the ordered control of cell growth, DNA 
duplication and mitotic chromosome distribution to new daughter cells. In order to 
ensure this, surveillance processes operate as checkpoints to regulate cell cycle 
progression (Carnero., 2002). These sensor processes ensure that cell completing each 
phase of cell cycle prior to the start of the next phase by ensuring that proper controlling 
growth stimulating and inhibiting signals transmit their influences on the progression of 
the cell cycle (Garrett., 2001; Schwartz and Shah., 2005; Malumbers and Barbacid., 
2007). For example, DNA damage activates the checkpoints mechanism by transmitting 
a signal to the cell cycle progression apparatus resulting in a slowing the cell cycle 
progression until the risk has been either removed or repaired. Failure to restore the 
DNA damage stimulate the cell cycle arrest at this phase (Vermeulen et al., 2003; 
Schwartz and Shah., 2005) (Figure 1.4). The cell cycle checkpoints are regulated by two 
main tumour suppressor proteins p53 (Golias et al., 2004) as well as pRb (Burkhart and 
Sage., 2008). 
1.4.1.4 Irreversible Cell Cycle Arrest: Cell Senescence 
Cell senescence or replicative senescence is a phenomenon by which cells undergo 
irreversible growth arrest in order to prevent unlimited cellular proliferation (Campisi., 
2000). Besides aging, senescence may be activated by DNA double strand breaks and 
premature telomere shorting or in response to oxidative stress. Senescence is essential in 
order to avoid continuous cell proliferation which could lead to DNA damage due to 
telomere shorting as a result of incomplete replication of telomeric end of the 
chromosome (Blasco., 2005; Collado and Serrano., 2010).  However, senescence cells 
contribute to many diseases and aging (Collado et al., 2007). Telomeres are the caps at 
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the end of chromosomes, containing a repetitive nucleotide sequences, which protects 
the chromosome. Over time, the telomere ends become shorter and loss of telomeres 
result in loss of genes in chromosome cap and ultimately DNA damage and stimulating 
of p53 and pRb signaling pathways (Ferbeyre et al., 2002). 
 
 
Figure 1.4: A schematic representation phases of cell cycle and regulation 
 
 
Figure1.4: A schematic representation phases of cell cycle and regulation. Cell cycle 
has four phases: G1 phase, S-phase, G2 phase and M phase and the progress through 
the cycle is regulated by the activity of numerous CDK–cyclin complexes (CDK) and 
cyclin dependent kinase inhibitor (CDKi). Modified from Vermeulen et al., 2003; and 
Malumbers and Barbacid., 2007.  
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Figure 1.5: A schematic representation the role of p53 in regulation of cell cycle 
 
 
Figure 1.5: A schematic representation the role of p53 in the regulation of cell cycle. 
In response to DNA damage or stress, p53 is activated and up-regulates the expression 
of p21CIP/WAF1 and CDK–cyclin complexes, resulting in cell cycle arrest. Modified from 
Golias et al., 2004, and Zilfou and Lowe., 2009. 
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1.4.2 Cancer Initiating Cells (CICs)  
All tissues are originated from the organ-specific stem cells that are defined by their 
ability to undergo self-renewal and differentiate into cell types of a particular organ 
(Wicha, et al., 2006). Through the self-renewal processes and differentiation, stem cells 
able to maintain tissue homeostasis by asymmetric cell divisions (Mitalipov and Wolf., 
2009). Self-renewal is tightly regulated process by which stem cells produce progeny 
identical to themselves. In addition, stem cells produce differentiated cells of 
multipotent progenitors, which generate more committed progenitors as well as 
differentiated cells via asymmetrical division (Ginestier et al., 2007).  
Numbers of molecular markers have been used for detections of stem cell 
subpopulations, including, enzyme activity such as aldehyde dehydrogenase (ALDH1), 
expression of specific cell surface antigen and transcription factors (Uchida et al., 2000; 
Richardson et al., 2004; Barker et al., 2007). These biomarkers are restricted to stem 
cell population and distinguish them from more differentiated cells. The common 
methods of identification and isolation of stem cell subpopulation is by utilization of 
function assays in combination with the expression of tissue specific biomarker which 
deficient in more differentiated cells (Reya., 2001). In addition to expression of these 
markers in both embryonic and adult stem cells, have been shown to be expressed in 
many cancer types, including breast and prostate cancer (Al-Hajj et al., 2003; Alison et 
al., 2011; Wang and Dick., 2005; Collins et al., 2005). These cancer cells sub-
population are proposed to play a role in cancer progression, metastasis, self-renewal, 
relapse and drug resistant in many types of cancer and therefore may represent cancer 
stem cells (CSCs) (Yang et al., 2015).  Examples of CSC markers in some types of 
human cancers used in CSC detection are shown in Table 1.1. 
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Representative Cell Surface Markers Used in CSCs Detection 
Cancer type Positive Negative 
Breast adenocarcinoma CD44, ALDH CD24 
Acute myeloid leukemia CD34, ALDH CD38 
Colon adenocarcinoma CD133, CD44 N/A 
Prostate adenocarcinoma CD44, CD133, α2 β1 CD24 
Pancreatic adenocarcinoma CD44, CD133 CD24 
Hepatocellular carcinoma CD133, EpCAM, CD90 N/A 
Multiple Myeloma CD45, CD19, CD20, and CD22 CD138 
 
Table 1.1: Examples of CSC markers in some human cancers types used CSCs 
detection 
(adapted from Al-Hajj et al., 2003; Bae et al., 2010; Bhatia et al., 1997; Brychtova et 
al., 2007; Collins et al., 2005; Corti et al., 2006; Corbin et al., 2011; Dean ., 2009; Du 
et al., 2008; Ginestier et al., 2007; Hart et al., 2005; Huang et al., 2009; Jeter et al., 
2011; Johansson et al., 1999; Kim et al.,2002; Lin et al., 2006; Liu et al., 2011; 
Looijenga et al., 2003; Matsuo and Drexler., 1998; Podberezin et al., 2013; Quinatana 
et al., 2008; Richardson et al., 2004; Santagata et al., 2007; Singh and Topham., 2003; 
Uchida et al., 2000; Wang et al., 2012; Yin et al., 1997).  
 
1.4.2.1 Multiple Myeloma Initiating Cells  
The determination of cells responsible for the initiation, maintenance and progression of 
multiple myeloma is not fully understood due to the difficulty of growing of MM cells 
in vivo and in vitro. Multiple myeloma is characterized by the clonal expansion of 
neoplastic plasma cells that appear to be quiescent due to the low cloning efficiency and 
proliferative index of the patient’s bone marrow samples (Drewinko et al., 1981; 
Hamburger and Salmon., 1977). As a result, it is still unclear whether plasma cells of 
MM have the proliferative capability needed for the initiation and maintenance of 
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disease. On the other hand, plasma cells are phenotypically similar to mature B-cells as 
well as expressing the identical idiotype and sequences of immunoglobulin gene have 
been seen in the peripheral blood and bone marrow of multiple myeloma patients 
(Matsui et al., 2004). A number of studies pointed out those clonal B-cells represent the 
MM proliferating compartment or progenitor cells (Mitterer et al., 1999; Davies et al., 
2000). 
Most of the myeloma cell lines as well as the patient specimens of multiple myeloma 
are characterized by neoplastic plasma cells that expressed the Syndecan-1 (CD138) cell 
surface antigen (Kuehl and Bergsagel., 2002). During the development of B-cells, the 
expression of CD138 is limited to terminally differentiated normal plasma cells due to 
the absence of highly proliferative normal plasmablasts and all earlier stages of B-cell. 
Furthermore, it has been shown that human cell lines of MM are composed of a small 
percentage (<5%) CD138-Ve cells these have greater clonogenic potential than the 
corresponding CD138+Ve plasma cells in vitro. In addition, the CD138-Ve cells from the 
multiple myeloma patient sample are clonogenically similar both in vivo and in vitro 
while CD138+Ve cells are not. CD138-Ve cells phenotypically resemble post-germinal 
center B-cells, and their clonogenic growth is repressed by the anti-CD20 monoclonal 
antibody Rituximab. These observations suggested that CD138-Ve B-cells serve as 
myeloma progenitor stem cells that have an ability to replicate and consequently 
differentiate into malignant cells (Matsui et al., 2004; Peacock et al., 2007). Clinical 
studies suggest that most cancer cells are eradicated by chemotherapy but the cells with 
the clonogenic potential features are responsible for tumour regrowth and are relatively 
drug resistant (Matsui et al., 2008). 
It has been documented that Syndecan1/CD138-Ve cells, which represents clonogenic 
progenitor myeloma cells are more resistant to TRAIL-mediated apoptosis than 
CD138+Ve cells due to the lower expression levels of TRAIL receptors (R1 and R2) 
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(Vitovski et al., 2012). Moreover, isolated quiescent PKH26Hi MM cell using PKH dye 
exhibited enriched stem-like properties and more resistant to anti-myeloma therapeutic 
agents including cyclophosphamide, bortezomib, vincristine, prednisone, and rituximab 
in vitro compared with PKHLo cell populations (Chen et al., 2014).  
1.4.3 Current Multiple Myeloma Therapy 
In the last decade, major advances in multiple myeloma treatment have improved the 
outcome of myeloma patients. The introduction of anti-tumour drugs Thalidomide, the 
proteasome inhibitor Bortezomib, and Lenalidomide caused a paradigm shift in 
myeloma therapy. The combination of these novel agents with traditional cytotoxic 
drugs has also increased response rates. In addition, chemotherapy followed by 
autologous stem cell transplantation (ASCT) has established an improved response rate 
and survival benefit compared with traditional chemotherapy (Attal et al., 2006; 
Barlogie et al., 2004). ASCT is a preferred treatment strategy for young MM patients 
either as part of the initial course therapy or at the time of progression of disease 
(Mohty and Harousseau., 2014). Recently, the use of this novel approach for elderly 
patients has also resulted in an improved outcome (Mateos et al., 2015). 
1.4.3.1 Autologous Stem-Cell Transplantation (ASCT) 
Autologous stem-cell transplantation (ASCT) has become a standard treatment strategy 
for young patients of (Mateos et al., 2015). Although this option is not curative, ASCT 
advances response rates and extends median overall survival by around one year in MM 
(Attal et al., 1996; Child et al., 2003). The most widely used regimen is Melphalan, 200 
mg/m2 (Kyle and Rajkumar., 2007). Randomized trials demonstrated that overall 
survival is almost the same whether ASCT is done immediately after the induction 
therapy or delayed at the time of relapse. Therefore, the decision on ASCT timing is 
depend on both patient and physician preference (Blade et al., 2005). 
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In some cases, Multiple Myeloma patients receive a second course of ASCT next to 
recovery from the first procedure. This approch is called tandem (double) ASCT (Attal 
et al., 2003; Cavo et al., 2005). On the other hand, allogeneic transplantation is the only 
treatment option to a limited number of multiple myeloma patients because of age and 
histocompatibility. The high treatment-related mortality mainly liked to severe graft-
versus-host disease (GVHD) and opportunistic infections has made this transplants 
approach intolerable for most of MM patients (Barlogie et al., 2004; Kyle and 
Rajkumar., 2007). Unfortunately, the median duration of response among myeloma 
patients after receiving the course of chemotherapeutic agents and ASCT does not 
exceed 3 years as well as almost all myeloma patients experience relapse progress (Attal 
et al., 2006). 
1.4.3.2 Thalidomide Analogues  
The discovery of thalidomide represented a key milestone in the myeloma therapy 
(Barlogie et al., 2004). However, several thalidomide analogs were developed in an 
attempt to enhance efficacy and reduce the toxicity of anti-myeloma therapy especially 
after thalidomide was established to be a teratogen.  Lenalidomide is 
immunomodulatory agent belongs to a class of thalidomide analogs display 
occasionally neurotoxicity (Kyle and Rajkumar., 2007). 91% of newly diagnosed 
myeloma patients in a phase II trial attained a good response with lenalidomide in 
combination with dexamethasone (Rajkumar et al., 2005). In June 2006, Lenalidomide 
and dexamethasone treatment regimen was approved by the FDA for the treatment of 
MM patients who have failed one prior treatment (Kyle and Rajkumar., 2007). 
1.4.3.3 Bortezomib 
A new class of anti-myeloma agents includes the proteasome inhibitor Bortezomib or 
Velcade with remarkable activity in a patient who relapses to standard therapy such as 
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thalidomide (Barlogie et al., 2004). Patients with relapsed refractory myeloma in a 
phase II clinical trial confirmed that approximately one-third of patients respond to 
Bortezomib treatment (Richardson et al., 2003). In a subsequent randomized trial, time 
to disease progression was found to be greater with bortezomib compared with 
dexamethasone alone in relapsed myeloma patients (Kyle and Rajkumar., 2007). 
Bortezomib is effectively combined with DNA-damaging cytotoxic agents such as 
melphalan and doxorubicin (Barlogie et al., 2004). In addition, a number of 
combination therapy regimens containing bortezomib, e.g. bortezomib, thalidomide and 
dexamethasone (VTD) regimen, Bortezomib plus cyclophosphamide (VD) regimen 
have been examined in randomised phase III trials pre ASCT with some encouraging 
results (Mateos et al., 2015).  
1.5 Targeted Cancer Therapies 
Targeted anti-cancer therapies are designed to have the ability to modulate a particular 
pathway or molecular signal important for tumour progression and development 
(Signore et al., 2013). The identification of appropriate target depends on understanding 
the underlying tumour molecular changes (Niemoeller and Belka., 2013). These 
approaches trigger the generation of therapeutic agents that modulate the cell cycle 
pathways, stimulate cancer cell death, and hinder tumour angiogenesis. This includes 
apoptotic therapeutics, immune-therapeutics and the hormonal therapy that are applied 
in cancers treatment (Queirolo and Acquati., 2006; Gray-Schopfer et al., 2007). 
1.5.1 Apoptosis as a Target Cancer Therapy 
The major goal of targeted anti-cancer therapy aims to selectively eradicate the 
malignant cells via triggering the apoptotic pathways. Increasing evidence points to the 
loss of the apoptotic process playing a key role in establishing tumour formation and 
resistance to chemotherapy (Pore et al., 2013; Vitovski et al., 2012). Therefore, 
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elucidating the apoptotic signals and the underlying mechanistic changes in the cancer 
cell may result in the development of novel therapeutic approaches (Niemoeller and 
Belka, 2013). 
Apoptosis or programmatic cell death is an essential regulatory mechanism for 
maintaining tissue homeostasis and development (Stuckey and Shah., 2013). A number 
of caspases are instrumental for both initiation and execution of apoptotic signals 
(Alnemri et al., 1996). These caspase proteases usually originate in an inactive form 
(pro-caspase) and its activation takes place by proteolysis at certain Asp-amino acid 
residues via the participation of other caspases (Green and Reed., 1998; Wolf and 
Green., 1999). Two main forms of initiator caspase exist depending on the presence and 
lack of particular regulatory amino-terminal domain motifs that facilitate homotypic 
interactions, the Death Effector Domain (DED) present in caspase-8/10 and the Caspase 
Recruitment Domain (CARD) present in caspase-9. The human apoptotic signal cascade 
contains initiator caspases (2, 8, 9, and 10) and effector caspases (3, 6 and 7) 
(Henderson and Brancolini., 2003; Philchenkov., 2012). 
1.5.2 Apoptotic Cascade Signals 
Though there are various numbers of signals that activate apoptotic pathways, the 
induction of upstream caspases is produced mainly by a restricted number of signaling 
pathways (Adrian and Martin, 2001; Adams and Cory, 2002). Two primary caspase 
activating pathways are extrinsic, or the death receptor pathway, and intrinsic, or the 
mitochondrial pathway (Krammer, 1998; Suliman et al., 2001). Moreover, additional 
apoptotic cascades have been identified including caspase-2 genotoxic stress-dependent 
stimulation through p53 (Lassus et al., 2002) and p53-Induced Death Domain protein 
(PIDD) (Berube et al., 2005). 
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1.5.2.1 Extrinsic Pathways 
The extrinsic signalling pathway is stimulated by binding specific ligands such as the 
Tumour Necrosis Factor (TNF) to specific death cell surface receptors such as TNFR. 
These receptors are type I transmembrane proteins characterised by the existence of 80 
residue length death domain (DD) within the cytoplasmium (Philchenkov., 2012). 
Additionally, FasL binds to Fas and TRAIL binds to Death Receptor-4 and -5 
(Ashkenazi., 2002) 
Ligand binding stimulates the recruitment of many cytosolic proteins resulting in the 
formation of the death inducing signaling complex (DISC) leading to the recruitment of 
the adaptor molecule Fas Associated protein with death domain (FADD) which has a 
death effector domain (DED). FADD interacts with the activated death receptors 
allowing the binding of FADD with procaspases-8 and -10 which then become activated. 
Once procaspase is activated by cleavage, it stimulates the downstream effector 
caspases-3, -6 and -7 and the apoptotic signals in turn are activated (Figure 1.6) (Fox et 
al., 2010; Pennarun et al., 2010). 
1.5.2.2 Intrinsic Pathways 
In some cells (Type I cells), caspase -8 and -10 stimulation is adequate for the initiation 
of apoptotic cascade, however, in other cells (Type II cells), the involvement of the 
mitochondrial pathways is essential (Philchenkov., 2012). The latter is triggered in 
response to hypoxia and DNA damage and results in the outer-mitochondrial membrane 
pore formation and thus promotes pro-apoptotic factor release such as cytochrome c into 
the cytosol (Green and Reed., 1998; Kraemer., 1998). The mitochondrial membrane 
disruption depends on the Bcl-2 protein family (Desagher and Martinou., 2000) that 
contains anti-apoptotic proteins including Mcl-1, Bcl-XL, Bcl-2, and the pro-apoptotic 
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protein including Bax, Bak, Bad and Bid in addition to the stress sensors BH3-proteins 
such as NOXA and PUMA (Pore et al., 2013). 
The release of mitochondrial pro-apoptogenic cytochrome c results in the formation of a 
functional signal complex called apoptosome that consists of procaspase-9 along with 
Apaf-1. This leads to activating caspase-9 by cleavage and consequently activation of 
the executioner caspases-3 and -7 (Figure 1.6) (Wu., 2009). 
These signals are regulated on numerous levels. For instance, c-flip is a negative 
caspase stimulation regulator in the DISC which catalytically inactivates caspase-8 and 
-10. Another class of negative regulators is the inhibitors of apoptosis proteins (IAPs) 
which directly inhibit the caspase activity or induce caspase degradation and their action 
is linked to Smac/DIABLO, a pro-apoptotic factor released from mitochondria (Figure 
1.6) (Niemoeller and Belka., 2013). 
1.5.3 Apoptotic Mediated Anti-Cancer Drugs 
1.5.3.1   TRAIL as a Target in Anti-cancer therapy 
Since it was discovered, the tumour necrosis factor-related apoptosis inducing ligand 
(TRAIL) obtained extensive interest for its potent anti-cancer killing activity by 
triggering tumour cells to undergo apoptosis in a variety of tumour cell types and 
producing a negligible effect on the normal cells (Stuckey and Shah., 2013). This ability 
has led to an investigation of the therapeutic potential of TRAIL as a promising 
apoptotic anti-cancer drug (Kruyt., 2008; Siegelin et al., 2009). 
TRAIL belongs to the TNF cytokine superfamily that induces the apoptotic cascades 
(Liu et al., 2013). It is type II transmembrane protein inserted into the membrane of the 
cells by exposing carboxyl terminus that contains the death receptor binding domain. By 
the action of metalloproteases enzyme, the membrane-bound form of TRAIL can be 
cleaved to a soluble TRAIL form. Both the membrane-bound as well as the soluble 
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TRAIL form form trimers that trigger apoptosis via their interaction with the DR4/5. In 
contrast, the TRAIL receptor is mainly transmembrane type I with N-terminus binding 
domains extra-cellularly (Kimberley and Screaton., 2004; LeBlanc and Ashkenazi., 
2003). 
Four different membrane-bound TRAIL receptors have been identified.  They are 
TRAIL-R1 (DR4), TRAIL-R2 (DR5), TRAIL-R3 (LIT, Decoy Receptor (DcR1), 
TRAIL-R4 (TRUNDD and DcR2) (Ashkenazi et al., 2002) in addition to the circulating 
soluble decoy receptor Osteoprotegerin (OPG) (Emery et al., 1998). DR4 and DR5 
characterized by the existence of cytoplasmic functional tail Death Domain (DD) that is 
able to recruit apoptosis signalling molecules and stimulate cell death. On the other 
hand, DcR1 and DcR2 are decoy receptors that do not have the function DD in their 
intracellular part, while OPG has no intracellular domain, but has the ability to bind 
with TRAIL but with a low affinity in comparison to DR4 and DR5, attenuating 
downstream death signaling (Holen et al., 2002; Kimberley and Screaton., 2004). 
1.5.3.2 TRAIL-Based Therapy and Apoptotic Signaling 
The interaction of TRAIL with its membrane receptors DR4 and DR5 leads to the 
induction of receptor cross-linking, caspase cascade and subsequently to apoptosis via 
two different irreversible apoptotic signals (Liu et al., 2013). This binding facilitates 
and activates the initiator pro-caspase-8 that induces apoptosis signals either directly via 
the activation of effector caspases-3 and -7 in the extrinsic pathway (Pan et al., 1997) or 
by stimulating the intrinsic, mitochondrial death cascade indirectly through the cleavage 
of Bid to its active form (t-Bid) in the intrinsic pathway. As a consequence of these 
events, cleaved Bid stimulates Bax/Bak oligomerization resulting in the release of the 
pro-apoptotic factors cytochrome c which in turn activates caspase-9 followed by the 
activation of downstream executioner caspases (Figure 1.6) (Yamada et al., 1999).  
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Executioner caspases, such as caspase-3, -6 and -7, have only a small prodomain and 
cleave diverse cellular substrates including ICAD/ DFF45, gelsolin, fodrin, poly (ADP 
ribose) polymerase (PARP), and others (Engels  et al., 2000). 
 
Figure 1.6: A schematic representation the apoptotic pathways 
 
 
Figure1.6: A schematic representation the apoptotic pathways. a) The extrinsic 
pathway is stimulated by binding of ligands to a death receptor. This binding facilitates 
and activates the initiator pro-caspase 8 that induces the apoptosis via the activation of 
effector caspases-3, -6 and -7. b) The intrinsic pathways of apoptosis activated by 
cellular stress such as DNA damage or hypoxia. This cellular stress promotes the 
release of mitochondrial pro-apoptotic factors such as cytochrome c into the cytosol 
and in turn activating the caspase-9 by cleavage and consequently the executioner 
caspases-3, -6 and -7 activations. Modified from Fox et al., 2010, and Hersey and 
Zhang., 2001. 
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1.5.3.3 TRAIL Based Therapy (TRAIL Mimetic) 
A number of agonistic antibodies and novel variants of recombinant human (rh) TRAIL 
have been generated (De Wilt., 2013). Number of clinical phase I studies have revealed 
that the soluble TRAIL (AMG951, Dulanermin) exerts a partial anti-cancerous response 
in hematologic malignancies and solid tumour displaying a short half-life without any 
adverse events related to its administration (Herbst et al., 2006; Ling et al., 2006; Pan et 
al., 2007). In addition, the combination of TRAIL AMG951 with rituximab in other 
clinical trial study appears safe and shows evidence of activity in patients with low-
grade non-Hodgkin lymphoma (Yee et al., 2007).  
Similar to soluble TRAIL, the agonistic monoclonal antibodies (mAbs) have been used 
both as an anti-tumour agent to stimulate TRAIL-mediated apoptotic response (Lee et 
al., 2011). A number of agonistic anti-TRAIL-R mAbs has been generated and 
introduced into clinical trail, including Mapatumumab (anti-TRAIL-R1, Human 
Genome Science) (Hotte et al., 2005; Younes et al., 2005), Lexatumumab (anti-TRAIL-
R2, Human Genome Sciences) (Patnaik et al., 2006; Plummer et al., 2007) as well as 
APOMAB (anti-TRAIL-R2, Genentech) (Camidge et al., 2007). These agonistic anti-
TRAIL-R1/-R2 mAbs activate the DR4 and DR5 TRAIL via agonist-mediated 
oligomerization resulting in clustering of intra-cellular DD, subsequently inducing the 
apoptotic pathway (Lee et al., 2011; Testa., 2010). Notably, these agents bypass decoy 
receptors and OPG (Locklin et al., 2007).  
1.5.3.4 The Role of TRAIL-Based Therapies in Multiple Myeloma  
Gene expression studies provided an interesting observation that TRAIL and its 
receptors DR4/5 are highly expressed in myeloma cells compared to plasma cells, and 
this could stimulate an autocrine apoptotic signaling mechanism (Jourdan et al., 2009). 
However, in multiple myeloma the apoptotic cascades are depressed by the over-
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expression of TRAIL decoy receptors especially DcR2 as well as OPG which act as a 
paracrine survival factor for myeloma cells by inhibiting TRAIL-induced apoptotic cell 
death (Shipman and Croucher., 2003). It has been found that the TRAIL-base therapies 
induce the apoptosis of MM cell lines as well as the primary myeloma cells both in vitro 
and in vivo (Gazitt., 1999; Mitsiades et al., 2001; Vitovski et al., 2012). Studies suggest 
that agonistic DR4/5 mAbs might have an advantage over recombinant soluble TRAIL 
in the stimulation of apoptosis of myeloma cells due to its ability to bypass the 
inhibition of TRAIL-mediated apoptosis by the decoy receptors (Menoret et al., 2006; 
Locklin et al., 2007). TRAIL resistance in myeloma is developed not only due to the 
effect of the decoy receptors but it is also associated with c-flip over-expression even 
though this observation was not supported by other studies (Mitsiades et al., 2002). In 
addition, it was reported that the secretion of the survival factor IL-6 by bone marrow 
stroma plays an important role in the TRAIL resistance of myeloma cells by stimulating 
the signalling pathways in addition to the increased level of c-flip (Perez et al., 2008). 
1.5.4 TRAIL Sensitizers 
In order to restore or enhance the TRAIL-mediated apoptosis signaling combined 
therapy of TRAIL and other agents have demonstrated promising results (Sayers and 
Cross., 2014; Booth et al., 2009; Henrich et al., 2012). In vitro studies have displayed 
that several classes of anti-tumour agents were shown to sensitize to TRAIL-induced 
apoptosis in leukemia, multiple myeloma and solid tumours (De Wilt., 2013). These 
agents used in combination with TRAIL either induce the expression of TRAIL-R1/-R2 
or reduce the expression of anti-apoptotic proteins expression such as c-flip, Bcl-2 and 
XIAP (Testa., 2010). Amongst those are the proteasome inhibitors bortezomib (Balsas 
et al., 2009; Sayers et al., 2006), doxorubicin (Vitovski et al., 2012) and HDACi (Fandy 
et al, 2005). Moreover, unpublished studies have documented Nuclear Export Inhibitors 
as highly effective TRAIL sensitisers (Figure 1.7). 
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Figure 1.7: Re-sensitization of cancer cells to TRAIL-
mediated apoptosis. 
Triggers of Death Receptors by TRAIL can be blocked by 
decoy receptors and agonist antibodies to DR4 and DR5 
can bypass this inhibition. TRAIL signalling can be 
inhibited by a number of negative regulators on various 
levels such as c-FLIP, anti-apoptotic Bcl-2 family 
members and inhibitors of apoptosis proteins (IAPs). 
Most standard chemotherapy DNA-damaging agents and 
radiotherapy cause up-regulation of DR4 or DR5 and 
pro-apoptotic Bcl-2 family members such as Bax, Puma, 
and Noxa possibly through the stimulation of p53. Newer 
anti-cancer agents that target cell processes such as 
proteasome inhibitors or histone modification and 
changes in gene expression (HDACi) Histone 
Methyltransferase (HMTase) inhibitor may allow the 
bypass of multiple anti-apoptotic pathways as shown. 
Additionally, Nuclear Export Inhibitor (NEI) Leptomycin 
B may also enhance apoptosis signalling by inhibiting the 
export of CRM1-mediated protein from the nucleus 
causing entrapment of nuclear p53. Modified from Sayers 
and Cross., 2014. 
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1.6 General Hypothesis 
The general hypotheses of this investigation are: (1) TRAIL responses in multiple 
myeloma can be enhanced by small molecules inhibitor to enhance apoptotic cell death. 
(2) Generation of TRAILR cells will inhibit NEI/HMTi/HDACi-induced TRAIL-
sensitization. (3)  TRAIL insensitive cells represent CD138-ve PKH-26Hi quiescent CSC 
populations.  
The specific aims ofthis study were to: 
1. Investigate the efficacy of TRAIL to induce apoptotic cell death either alone or 
in combination with potential TRAIL sensitizers in term of induction of 
apoptosis and cell cycle arrest.  
2. Screen the effect of TRAIL either alone or in combination with TRAIL 
senstizers on established colonies of multi-cellular alginate spheroid model of 
human multiple myeloma cell lines and compare the effect of these drugs in both 
suspension and 3D cultures models. 
3. Develop TRAILR cell lines and test for sensitization with small moleculues 
inhibitors. 
4. Isolate PKH26Hi quiescent multiple myeloma populations and assessed for 
sensitivity to TRAIL/TRAIL sensitizers vs. parental cells. 
5. Identify the potential mechanistic pathways for the TRAIL sensitizers.  
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2. Effect of NEI, HDACi, and HMTasei on TRAIL 
Response in Multiple Myeloma Cells 
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2.1 Introduction 
Clinical trials to assess the safety and anti-cancer activity of Tumour Necrosis Factor-
Related Apoptosis-Inducing Ligand (TRAIL) and agonistic Death Receptor antibodies 
have been completed in several tumour types (Doi et al 2011; Herbst et al., 2010, Von 
Pawel  et al., 2014) including multiple myeloma (Matthews et al., 2013). Unfortunately, 
TRAIL resistance develops in vitro (Jian et al., 2016) and in clinical trials, TRAIL 
insensitivity may be present in most tumours (Abdulghani et al., 2013). Consequently 
combined therapy of TRAIL with other anti-tumour agents is required to restore the 
TRAIL sensitivity (Deleu et al., 2009; Sayers and Cross., 2014; Booth et al., 2009; 
Henrich et al., 2012). 
2.1.1 Nuclear Export Inhibitors (NEIs) as an Inhibition of Nuclear Cytoplasmic 
Trafficking  
NEIs are potential anti-tumour agents that inhibit the transport of proteins containing a 
nuclear export signal (NES) from the nucleus to the cytoplasm resulting in the alteration 
of the cell cycle and the induction of apoptosis (Figure 2.1) (Turner et al., 2012). One of 
the first NEI discovered was Leptomycin B (LMB) which as an anti-fungal antibiotic 
unsaturated branched-chain fatty acid is isolated from Streptomyces bacteria (Fan et al., 
2013). 
The nuclear envelope is a selective physical barrier that plays an important role in cell 
cycle regulation and transcription. The nuclear-cytoplasmic transport of RNA, the 
essential regulators of cell cycle suppression, transcription or specific therapeutic agent 
(Turner et al., 2012) are tightly controlled by pores embedded in the nuclear envelop 
membranes known as the nuclear pore complex (NPC). The small molecules and 
proteins are passively diffused through the NPC while the movement of large molecules 
(>5 kDa) through NPS needs the assistance of particular nuclear-cytoplasmic transport 
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receptors protein (karyopherins). Most of these transport proteins belong to the 
karyopherin-β protein family (Cook et al., 2007) and each of the karyopherin-β 
transport signals recognition of specific cargo protein or RNA. The movement of 
intracellular protein is regulated by unique amino acids or signaling sequences present 
within each cargo protein called a nuclear localization signal (NLS). These are required 
for the movement of cargo out of the nucleus and nuclear export signals (NES) for the 
exporting of nucleus cargo to the cytoplasm (Figure 2.1) (Lange et al., 2007). 
The ubiquitous transport receptor chromosome region maintenance protein 1 
(CRM1/exportin 1) plays a role in binding and exporting proteins as well as RNA. In 
humans, 19 transport receptor molecules karyopherin have been recognized.  Among 
those are importins, exportins, and transportins (Das et al., 2015). However, the specific 
recognition signals (NLS/NES) for most of these transport molecules have not been 
identified yet. For CRM1, the NES contains hydrophobic amino acids sequences such 
as leucine, isoleucine, methionine, valine and phenylalanine (Turner et al., 2014). The 
NES consensus motif is HX2–3HX2–3HXH, where H is a hydrophobic amino acid and 
X is any amino acid. This sequence could be present in a more complex structure of 
proteins e.g. α-helical proteins (Figure 2.1) (Turner et al., 2012). 
For nuclear import, the NLSs of cargo protein is recognized by Importin of the Importin 
α/β heterodimer, and is nucleus docking and translocation via the nuclear pore complex 
is facilitated by Importin β subunit that is bounded to a small GTPase molecule, known 
as RAs-related Nuclear protein (RAN-GTP) which in turn displaces the Importin α 
subunit to mediate cargo release. In the export route from the nucleus, NES on the cargo 
protein or the export substrate is recognized and bound to the RAN-GTPase-dependent 
export mediators or Exportin such as CRM1. These complexes are produced in the 
nucleus binding together with the high affinity. Once the CRM1-RAN-GTP-cargo 
protein complex is synthesized in the nucleus, it is exported to the cytoplasm via NPC. 
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By the action of RAN-GTPase, RAN-GTP is hydrolyzed to RAN-GDP that facilitates 
the dissociation of the export complex into its separate components releasing export 
substrate into the cytoplasm and recycling the CRM1 receptor proteins and RAN-GTP 
back into the nucleus to undergo another nuclear export cycle (Figure 2.1) (Leprêtre, et 
al., 2008; Wagstaff and Jans., 2009). 
2.1.1.1 Leptomycin B as exportin1/CRM1-dependent Nuclear Export Inhibitor 
Leptomycin B (LMB) is a highly specific and potent CRM1 inhibitor that has the ability 
to bind and inhibit CRM1 Exportin by a Michael-type covalent addition at cysteine 528. 
The alkylation of the reactive site cysteine 528 residue blocks the binding of CRM1 to 
the cargo protein leucine-rich nuclear export sequence and prevents the CRM1-cargo-
RAN-GTP export complex formation; thus, it obstructs the nuclear export of CRM1-
mediated protein into the cytoplasm. Most inhibitors of CRM1 function by modifying 
the reactive site cysteine 528 either permanently or reversibly. Thus, LMB is a potent 
CRM1 inhibitor that mediates the inhibition of the nuclear protein export and the 
existence of leucine-rich nuclear export signals that are used as standards to label 
whether a protein is exported via CRM1 (Figure 2.1) (Wagstaff and Jans., 2009). 
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Figure 2.1: The Nuclear-cytoplasmic transport and LMB mechanism of action 
 
Figure 2.1: The Nuclear-cytoplasmic transport and LMB mechanism of action. NLS 
of cargo protein is recognized by α Importin of the Importin α/β heterodimer.  Docking 
and translocation into the nucleus facilitated by β Importin binding to RAN-GTP which 
displaces the Importin α to mediate the release of the cargo. For export, NES on cargo 
protein is recognized and bound to Exportin/CRM-1 bound with RAN-GTP and 
translocation into the cytoplasm occurs. Hydrolysis of RAN-GTP into RAN-GDP 
facilitates cargo dissociation. The site of action of LMB is indicated by the red arrow. 
Modified from Wagstaff and Jans., 2009. 
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2.1.1.2 Leptomycin B and Apoptosis 
Leptomycin B is a highly specific and potent CRM1 inhibitor that triggers the apoptosis 
and cell cycle arrest at the G1 and G2 phases in a certain cancerous cell. As a result, the 
nuclear accumulation of CRM1-dependent export proteins occurs including the tumour 
suppressor protein p53, p21CIP, p27KIP1, APC, BRAC1, FOXO proteins, N-WASP/FAK, 
galectin-3, INI1/hSNF5, Bok, nucleophosmin, RASSF2, Merlin (Turner et al., 2012) 
and NFκB transcription factors (Miskolci et al., 2006). 
p53 is a tumour suppressor protein which is produced in the cytoplasm in response to 
stresses, DNA damage and oncogene activation (Green and Kroemer., 2009). As a 
nuclear transcription factor, it controls the expression of genes involved in some cell 
processes such as the cell cycle, apoptosis and autophagy. The tumour suppressor 
protein p53 possesses sequences of both nuclear localization signal and nuclear export 
signal. Moreover, it is nuclear localization depending on its import in α/β binding while 
the nuclear export of p53 requires binding to CRM1. 
Nuclear p53 versus cytoplasmic localization is controlled by a number of post-
translational modifications. Basal levels of p53 in normal healthy cells are maintained 
by Mouse double minute 2 homolog (MDM2) -stimulated proteasomal 
polyubiquitination and degradation. MDM2 mediated p53 C-terminus 
monoubiquitination, and sumoylation and this monoubiquitination exposes the NES, 
allowing nuclear export via a CRM1-dependent manner (Lindenboim et al., 2011; Shao 
et al., 2011).  
LMB significantly induces the activation of p53 resulting in apoptosis stimulation and 
growth arrest (Mutka et al., 2009). Although LMB toxicity at concentrations <5 nM for 
1h has limited it is clinical usefulness as a single agent (Fan et al., 2013). Treatment 
with LMB has proved to induce cell death in lung adenocarcinoma cell lines and in 
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esophageal cancer (Shao et al., 2011). Moreover, the p53 wild type in adenocarcinoma 
cell line was more LMB resistant than the null or mutant p53.  Besides, LMB treatment 
sensitized the drug-resistant cancer cells to chemotherapeutic agents (Lu et al, 2012). As 
a TRAIL sensitizer, preliminary work from our laboratory showed that LMB/TRAIL 
co-treatment enhanced the apoptotic responses of PC3 prostate cancer cells to TRAIL 
(Haywood-Small et al., 2011). The underlying molecular mechanisms of how LMB 
induces apoptosis is not clearly understood, however, as it has been shown that the 
apoptotic effect of LMB is associated with cytochrome c-mediated caspases-3 activation 
as well as the selective XIAP and Mcl-1 down-expression (Jang et al., 2004). 
2.1.2 Epigenetic Modifiers as Anti-Cancer Agents 
2.1.2.1 Histone Deacetylase Inhibitors (HDACi) 
Recently, growing evidence has suggested that not only gene impairment, e. g. deletions, 
structural chromosomal abnormalities, and point mutations are responsible for initiation 
and progression of malignancies, but also the epigenetic alterations play an essential 
role in tumour suppressor gene down-regulation and oncogene up-regulation (Baylin 
and Ohm., 2006; Lund and Lohuizen., 2004). Remodeling of chromatin is one of the 
major epigenetic regulations processes (Baylin and Ohm., 2006; Lund and Lohuizen., 
2004). 
Modifications either on the histone level or the DNA level result in altering the 
chromatin state into an open or closed configuration. The core histone post-translational 
modifications are mainly on the amino-terminal tail, which is rich in lysine. These 
modifications include methylation, acetylation, and deimination which are important for 
the alteration of gene expression as they facilitate the DNA accessibility and binding 
with other complexes of non-histone protein that could include transcriptionally co-
activating or co-repressing factors (Deleu et al., 2009). 
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The chromatin acetylation is controlled by two main enzymes, histone 
acetyltransferases (HAT) and histone deacetylases (HDAC) (Peterson and Laniel., 
2004). The HAT acetylates core histones lead to more relaxed and transcriptionally 
active chromatin structure, whereas HDAC catalyses the removal of the acetyl group 
leading to a more compact, transcriptionally inactive chromatin form. Histone 
hyperacetylation permits the occurrence of transcription; while histone deacetylation 
prevents transcription; therefore, HDAC inhibitors (HDACi) induce transcription of 
epigenetically silenced genes (Figure 2.2) (Bradner et al., 2010). Deimination allows 
decondensation of chromatin and induces a stem-like phenotype. Specifically, 
deimination of histones has recently been associated with haematopoietic stem cell 
behavior (Nakashima et al., 2013), and targeting this pathway has been showing to 
enhance TRAIL responses (Khalid., 2016). 
2.1.2.2 The Role of HDACi in Controlling Gene Expression 
The non-selective HDACi suberoylanilide hydroxamic acid (SAHA) or Vorinostat 
inhibits HDAC I and II class activity and its anti-cancer action has been widely 
investigated in many cancer types. SAHA directly binds to HDACs catalytic site and 
inhibits their activity (Figure 2.2). Blocking the activity of HDAC by SAHA leads to 
gene expression modification in a wide range of tumour cell lines such as multiple 
myeloma and it inhibits the activity of HDAC with IC50s of high nM to low µM range 
in vitro in many cancer cells (Hideshima and Anderson., 2013). 
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Figure 2.2: The role of HDACi SAHA in the regulation of gene expression 
 
Figure 2.2: The role of HDACi SAHA in the regulation of gene expression. The 
chromatin acetylation is controlled by two main enzymes, histone acetyltransferases 
(HAT) and histone deacetylases (HDAC). The HAT catalyses the acetylation of core 
histones lead to open and transcriptionally active chromatin structure, whereas HDAC 
catalyses the removal of the acetyl group leading to closed and transcriptionally 
inactive chromatin form. Inhibition of HDAC by HDACi SAHA re-expressed the tumour 
suppression genes and activating apoptosis and promotes growth inhibition. Modified 
from Pons et al., 2009. 
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The mechanisms of action of HDACi as an anti-myeloma agent in preclinical studies 
have not yet been fully understood. Inhibition of histone deacetylation mainly induces 
gene transcription and as a result, HDACi trigger transcription. Therefore, HDACi 
triggers the transcription of positive and negative regulators of proliferation and/or the 
survival of the cell and growth inhibition or cytotoxicity (Hideshima and Anderson., 
2013). 
In multiple myeloma, the non-selective HDAC inhibitors vorinostat or SAHA trigger 
p21CIP/WAF1 up-regulation, and induce the expression of p53 protein and, pRb 
dephosphorylation and subsequently triggers apoptosis. It has been found that p21 
CIP/WAF1
 up-regulation occurs before the induction of p53, therefore, the up-regulation of 
p21 CIP/WAF1 by SAHA may be p53 independent (Mitsiades et al., 2003). Moreover, the 
regulation of the anti-apoptotic proteins Bcl-2 plays a key role in SAHA-mediated 
apoptosis in multiple myeloma cells via a caspase-independent pathway in addition to 
caspase-dependent cascade via cleaving of PARP (Mitsiades et al., 2003).  Furthermore, 
SAHA activity suppresses the growth factors such as IL-6, IGF-1, blocks angiogenesis, 
inhibits the activity of proteasome and inhibits osteoclastogenesis (Mitsiades et al., 
2004). 
SAHA augments the anti-MM effect of other therapeutic agents. Among these are 
dexamethasone, proteasome inhibitors and immunomodulatory therapy (Mitsiades et al., 
2004). In addition, SAHA enhances TRAIL-induced cytotoxicity due to the pro-
apoptotic proteins up-regulation including Bak, Bim, Bax, PUMA and Noxa and anti-
apoptotic proteins down-regulation such as Bcl-2 and Bcl-xL (Fandy et al., 2005).  
2.1.2.3 Histone Methyltransferase Inhibitors (HMTasei) 
In addition to the histone acetylation, another epigenetic modification that is play an 
important role in the regulation gene expression and identified in oncogenesis is the 
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histone methylation status of histones. This post-transcriptional modification can target 
either lysine or arginine residues of histone tail (Nebbioso et al., 2012). The histone 
lysine methylation is catalyzed by two classes of enzymes: histone lysine 
methyltransferases (KMTs) and demethylases (KDMs) (Ding et al., 2013). Histone 
methylation has been normally associated with silencing of gene, however, some lysine 
methylation patterns can link to active genes (Figure 2.3). For example, methylation of 
histones residues H3K4, H3K36, and H3K79 is correlated with gene activation, while 
methylation on H3K9 or H3K27 linked to transcriptional suppression and methylation 
of H4, K20 is a known mark of gene silencing (Cho et al., 2011; Casciello et al., 2015). 
Moreover, histone lysine methylation controls the transcription according to the 
methylation status. For example, trimethylation of H3K9 has served as a transcriptional 
repressive mark. H3K9 monomethylation has been associated with active promoters 
(Cho et al., 2011; Casciello et al., 2015). 
2.1.2.4 The role of G9a as a Histone Methyltransferase in Controlling Gene 
Expression  
G9a, also known as a nuclear histone lysine methyltransferase (HMT), mainly catalyzes 
monomethylation and dimethylation of H3 lysine 9 in euchromatin. It is vital for early 
embryonic development and associated with transcriptional silencing of tumour 
suppressor genes (Figure 2.3) (Casciello et al., 2015; Ding et al., 2013; Nebbioso et al., 
2012). G9a is comprised of a catalytic SET domain, ankyrin repeats which identify 
mono- and -dimethyl histone by SET domain and an automethylation site the N-
terminal end (Casciello et al., 2015). 
High G9a levels have been reported in several types of human cancers such as lung 
cancer cells (Chen et al., 2010), bladder carcinomas (Cho et al., 2011), ovarian cancer 
(Hua et al., 2014) and haematological malignancy (Lehnertz et al., 2014) and 
knockdown of G9a has been presented to suppress the growth of tumour cells (Chen et 
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al., 2010; Cho et al., 2011; Kondo et al., 2008). However, the underlying molecular 
basis of G9a role in sustaining tumour cell survival is not fully understood.  
In addition, G9a has tumour growth and survival advantages through control the amino 
acid metabolism and transcriptional triggering of genes involved in a serine-glycine 
biosynthetic pathway (Ding et al., 2013). This finding suggesting the key role of G9a in 
the tumour development and progression and targeting this enzyme might represent a 
new approach for cancer therapy.  
2.1.2.5 G9a Inhibitor BIX 01294  
BIX 01294 or a diazepin-quinazolinamine derivative is a specific G9a inhibitor by 
suppression the H3K9Me2 level (Figure 2.3) (Kim et al., 2013). Moreover, BIX 01294 
stimulates apoptosis in human neuroblastoma cells by increasing caspase-8 and -3 
activity (Lu et al., 2013) as well as decrease the growth of bladder cancer cells (Cho et 
al., 2011). In addition, knockdown of G9a or treatment with BIX 01294 suppressed the 
growth of bladder, breast, lung and prostate tumour cells (Chen et al., 2010; Ding et al., 
2013; Kubicek et al., 2007). 
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Figure 2.3: The role of HMTasei in the regulation of gene expression 
 
 
Figure 2.3: The role of HMTasei in the regulation of gene expression. G9a, a nuclear 
histone lysine methyltransferase (HMT), mainly catalyzes monomethylation and 
dimethylation of H3K9 and EZH2 catalyzes trimethylation of H3K27. Inhibition of G9a 
and EZH2 HMTase by BIX 01294 and GSK343 respectively associated with silences 
TSGs, inhibits proliferation and induces apoptosis. Modified from Yoo and 
Hennighausen., 2012. 
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2.1.2.6 EZH2 Inhibitor GSK343 
Similar to G9a, Enhancer of Zeste Homologue 2 or EZH2 is a member of HMTase 
family which transcriptional silencing the expression of target genes (Figure 2.3). EZH2 
is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), which has been 
involved in cancer progression (Verma et al., 2012). EZH2 catalyzes trimethylation of 
lysine 27 (Lys 27) on histone H3 (H3K27) (Figure 2.3) (Popovic et al., 2014). Over-
expression of EZH2 is found in many types of solid tumours such as breast cancer 
(Kleer et al., 2006), prostate cancer (Varambally et al., 2002) and gastric cancer 
(Matsukawa  et al., 2006) as well as multiple myeloma (Croonquist and Van Ness., 
2005; Kalushkova et al., 2010). High levels of EZH2 are correlated with cancer growth, 
metastasis, as well as the poor outcome (Yamaguchi1 and Hung., 2014). EZH2 inhibits 
apoptosis in a number of tumours, including bladder cancer (Wang et al., 2014), 
prostate cancer (Li et al., 2013), and leukemia (Zhou et al., 2011). Therefore, targeting 
EZH2 in cancer cells is an effective therapeutic approach (Zhang et al., 2014).  
However, the exact mechanisms of apoptosis inhibition by EZH2 still poorly 
understood. It has been found that EZH2 mediate apoptosis resistance in prostate cancer 
by epigenetic silencing of two pro-apoptotic microRNAs (miRNA), miR-205 (target 
Bcl-2) and miR-31 target E2F transcription factor 6 (E2F6) encoding (Zhang et al., 
2014). A number of small molecule EZH2 inhibitors have been identified and 
demonstrated potent anti-cancer activity (Van Aller et al., 2013; Garapaty-Rao et al., 
2013). Recently, highly potent and selective EZH2 inhibitors, GSK126 and GSK343 
(Figure 2.3) (Amatangelo et al., 2013; Verma et al., 2012) inhibited the proliferation of 
breast and prostate cancer cell lines (Verma et al., 2012) and hepatocellular carcinoma 
(Liu et al., 2016).  
Inhibition of EZH2 by GSK343 and UNC1999 decreased myeloma cells viability and 
induced apoptotic cell death and UNC1999 up-regulated the expression of genes in 
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signaling pathways related to apoptosis, Wnt, MAPK, ID and cellular differentiation 
such as DNA binding 2 (ID2) (Agarwal et al., 2016). Moreover, down-regulation of the 
expression of a number of oncogenes involved in myeloma most notably CD69, 
transcription factor jun-B (JUNB) and X-box binding protein 1 (XBP1) (Agarwal et al., 
2016) which have been shown to stimulate cell growth, survival and therapy resistance 
in MM (Fan et al., 2014). Furthermore, GSK343 inhibits growth, induced cell cycle 
arrest as well as induced cell death of osteosarcoma by targeting on EZH2-c-Myc and 
fuse binding protein 1 (FBP1)-c-Myc signal pathways (Xiong et al., 2016). Co-
treatment with the Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) inhibitor 
UNC0638 significantly inhibited the growth of breast cancer cells (Brown et al., 2014), 
suggesting that EZH2 inhibitors GSK343 could be a potential therapeutic option for 
cancer (Xiong et al., 2016). 
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Figure 2.4: The role of epigenetic modifiers agents HDACi and HMTasei in the 
regulation gene expression 
 
Figure 2.4: Summary of the role of epigenetic modifiers agents HDACi and HMTasei in 
the regulation gene expression and inhibits proliferation inhibition and induces 
apoptosis. Modified from Asangani et al., 2013, and Pons et al., 2009, and Yoo and 
Hennighausen., 2012. 
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2.1.3 Hypothesis 
The current investigation has focused on the hypothesis that Nuclear export inhibitor 
(NEI), epigenetic modifiers Histone Deacetylase (HDAC) inhibitor and inhibitors of the 
histone methyltransferases G9a and EZH2 enhance TRAIL sensitivity in multiple 
myeloma cells. 
2.1.4 Aims  
The aim of this study to assess the efficacy of TRAIL to induce apoptotic cell death 
either alone or in combination with the TRAIL sensitizers in order to overcome intrinsic 
resistance and render tumour cells more sensitive to TRAIL. 
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2.2 Materials and Methods 
2.2.1 Cell Lines  
Five human Multiple Myeloma cell lines (NCI-H 929, RPMI 8226, OPM2, JJN3, and 
U266) and one primary cell culture generated from a case of plasma cell leukaemia 
(ADC-1); together with non-tumour CD34+ and CD133+ (Stem Cell Technology) 
positive haematopoietic progenitor stem cells (HSC) and a primary Human Renal 
Epithelial Cells (HREC) (Innoprot) were used.  All the MM cell lines were tested 
regularly for Mycoplasma infections throughout the study using MycoAlert™ 
mycoplasma detection kit and were all tested negative (Lonza).  
2.2.1.1 Multiple Myeloma Cell Lines 
NCI-H 929, source – obtained from the pleural fluid of a 67-year-old caucasian female 
with an IgA-producing plasmacytoma (Euorpean Collection of Cell Cultures (ECACC), 
Salisbury, UK; cat no 95050415) 
RPMI 8226, source – obtained from the peripheral blood of a 61year old man with 
multiple myeloma at diagnosis (ECACC, Salisbury, UK; cat no 87012702) 
OPM2, source – obtained from the peripheral blood of a 56-year-old woman with 
multiple myeloma in terminal leukaemic phase (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (DSMZ), Braunschweig, Germany; DSMZ 
no ACC 50) 
JJN3, source – plasma cell leukaemia (kind gift from Professor I Franklin, University 
of Glasgow, UK) 
U266 cells (derived from the peripheral blood of a 53-year-old man with MM) were 
purchased from LGC Standards (UK) 
ADC-1 – ex vivo cell line taken from the peripheral blood of a patient with plasma cell 
leukaemia presenting to the Dept of Haematology, Sheffield Teaching Hospitals.Patient 
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cells were acquired with appropriate ethical permission (REC reference: 
05/Q2305/96). All participants provided written consent. Original consent forms are 
stored in a secure location and patient demographics and disease feature entered into an 
encrypted database governed by the Research and Development Service Sheffield 
Teaching Hospitals, NHS Foundation Trust UK. This consent procedure was approved 
by the South Sheffield Research Ethics Committee in August 2005 and subsequently 
ratified by the NHS Health Research Authority, National Research Ethics Committee 
Yorkshire and the Humber - Sheffield in November 2012. 
2.2.1.2 Non-tumour Cell Lines 
CD34+ and CD133+ cells are haematopoietic stem cells and can be isolated from 
human cord blood. These stem cells are capable of self–renewal and high proliferative 
capacity into multiple haematopoietic lineages.  
Human Renal Epithelial Cells (HREC) are isolated from human kidney. Renal 
Epithelial cells play a key role in renal function. Similar to most other epithelial cells, 
renal epithelial cells show a polarized morphology which is vital for their 
function. They are also a major site of injury in a variety of congenital, metabolic, and 
inflammatory diseases.  
2.2.2 Cell Culture Medium  
Multiple myeloma cell lines and haematopoietic progenitor stem cells (CD133+ and 
CD34+) were cultured in RPMI-1640 media (Invitrogen) supplement with L-Glutamine 
supplemented with 10% fetal calf serum, 1% penicillin/streptomycin and 1% non-
essential amino acid. The non-tumour primary human renal cells HREC were cultured 
in special Epithelial Cell Medium (EpiCM) supplemented with 10 ml of fetal Bovine 
Serum (FBS), 5 ml of Epithelial Cell Growth, Supplement (EpiCGS), and 5 ml of 
penicillin/streptomycin.  
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2.2.3  Cell Sub-Culture  
For suspension cells: multiple myeloma and HSC (CD133+ and CD34+) cells were 
seeded into T75 cm2 flask (Invitrogen) containing complete RPMI-1640 media. Cultures 
were maintained at 37ºC with 5% CO2 in humidified incubator.  Cell typically split at a 
1:5 split ratio twice a week.   
For the adherent cells (HREC), cells were maintained up to 80% confluence before 
passaging:  culture media was removed and 10 ml of Phosphate Buffered Saline (PBS; 
Gibco) was used to wash the cells and 3 ml of Trypsin (0.05%) - EDTA (0.02%) 
(Gibco) was added and incubated at 37ºC until detachment of cells was achieved. Then, 
cells were incubated in 10 ml of complete special Epithelial Cell Medium (EpiCM). The 
resulting cell suspension was seeded at a 1:5 split ratio twice a week. The cells then 
incubated under standard cell culture conditions at 37ºC with 5% CO2 atmosphere. 
2.2.4 Seeding Cells into 96 Well Plate 
Suspension cells were centrifugation at 400 g for 5 minutes, then the cell re-suspend in 
complete media and the cells counted by the Countless system (Invitrogen) using trypan 
blue staining (Invitrogen) and the number of cells/ml was determined. After that, 200 µl 
of the cells at a density of 350,000 cells/ml is passed into 96-well plate and settled in the 
incubator at 37 ºC for 2-3 h before drugs were added. 
Adherent cells were centrifugation after trypsinisation and the cells counted as above 
(Section 2.2.4) 200 µl of the cells at a density of 250,000 cells/ml is passed into 96-well 
plate and incubated at 37 ºC for 24 before drugs were added.  
2.2.5 Treatment of MM and Non-Tumour Cells with Cytotoxic Agents 
TRAIL (Pepro Tech EC Ltd) was dissolved in media (10 g/ml), Leptomycin B 
(Nuclear export Inhibitor) (Enzo Life Science) was dissolved in absolute ethanol (10 
µM), SAHA (Sigma) was dissolved in DMSO (10 mM), BIX01924 (Sigma) was 
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dissolved in media (10 mM); and finally GSK343 (Sigma) was dissolved in DMSO (10 
mM). A stock solution of  10 g/ml of TRAIL, 10 nM of LMB, 10 mM of SAHA, BIX 
01294 and GSK343 were prepared to generate desired treatment concentrations and 
aliquoted into 10 µl/aliquot and stored at -20 ºC.  
 In order to induce apoptosis, TRAIL at 50 ng/ml, 25 ng/ml, 10 ng/ml and 2 ng/ml were 
added to the cells in a 96-well plate in triplicate, three wells for each concentration. The 
cells were treated with escalating the concentrations of LMB (10 nM) at a dose from 0- 
5 nM, SAHA at 0-10 µM, BIX 01294 at 0-20 µM and GSK343 at 0-20 µM. In addition, 
these drugs used either alone or in combination with TRAIL in order to determine the 
synergistic response. Control cells were dilution in 1/1000 DMSO or Ethanol, so control 
and treated cells treated with the same concentration of vehicle control. Table 2.1 
illustrates the drug dilutions used in this work. After stimulation, the cells were 
incubated for 24 hours in the humidified incubator.  
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Drugs Investigated 
concentration 
1ml drug concentration prepared (enough for 5x 
wells of 96 well plates) 
TRAIL 
(10 mg/ml) 
 
50ng/ml 
25 ng/ml 
10 ng/ml 
2 ng/ml 
50 µl of 1/10 diluted stock (10 µg/ml) 
25 µl of 1/10 diluted stock (10 µg/ml) 
10 µl of 1/10 diluted stock (10 µg/ml) 
20 µl of 1/100 (a further 1/10 dilution) 
LMB  
(10µM) 
 
5nM 
2nM 
1nM 
0.5nM 
0.25nM 
5 µl of 1/10-diluted stock (1µM) 
20 µl of 1/100-diluted stock (0.1µM) 
10 µl of 1/100-diluted stock (0.1µM) 
5 µl of 1/100-diluted stock (0.1µM) 
2.5 µl of 1/100-diluted stock (0.1µM) 
SAHA  
(10mM) 
 
10µl 
5µl 
1µl 
10 µl of 1/10-diluted stock (1mM) 
5 µl of 1/10-diluted stock 
1 µl of 1/100-diluted stock 
BIX-01294 
(10mM) 
 
20µl 
15µl 
10µl 
5µl 
1µl 
0.5µl 
20 µl of 1/10-diluted stock (1uM) 
1.5 µl stock/well or 15µl of 1/10-diluted stock (1µM) 
1 µl stock/well or 10µl of 1/10-diluted stock (1µM) 
5 µl of 1/10-diluted stock (1µM) 
10 µl of 1/100-diluted stock (0.1µM) 
5 µl of 1/100-diluted stock (0.1µM) 
GSK343  
(10mM) 
 
20µl 
15µl 
10µl 
5µl 
1µl 
20 µl of 1/10-diluted stock (1µM) 
1.5 µl stock/well or 15µl of 1/10-diluted stock (1µM) 
1 µl stock/well or 10µl of 1/10-diluted stock (1µM) 
5 µl of 1/10-diluted stock (1µM) 
10 µl of 1/100-diluted stock (0.1µM) 
 
Table 2.1:  Illustrated the drugs dilution used in this work 
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Technique Cell line Investigated concentration 
Hoechst 33342 PI stain 
 
All six MM cell lines: OPM2, 
NCI-H 929, RPMI 8226, 
U266, JJN3 and ADC-1 
Non-tumour cell lines: HSC 
cells (CD133+ and CD34+) and 
PHRC 
LMB: 0.5, 1, 2, 5 nM 
SAHA: 1,5, 10 μM 
BIX 01294: 1, 5, 10, 15, 20 μM 
GSK343: 1, 5, 10, 15, 20 μM  
Either alone and in combination 
with lower significant dose of 
TRAIL (LSD) 
Caspase-3 substrate 
 
MM cell lines: NCI-H 929, 
RPMI 8226, U266, and ADC-1 
 
Combination treatment doses 
which synergistically enhanced 
apoptosis as determined by 
Hoechst 33342/PI staining 
CellTiter-Glo 
 
All six MM cell lines: OPM2, 
NCI-H 929, RPMI 8226, 
U266, JJN3 and ADC-1 
Non-tumour cell lines: HSC 
cells (CD34+) and PHRC 
LMB: 0.5, 1, 2, 5 nM 
SAHA: 1,5, 10 μM 
BIX 01294: 1, 5, 10, 15, 20 μM 
GSK343: 1, 5, 10, 15, 20 μM  
Either alone and in combination 
with LSD of TRAIL 
Cell cycle analysis MM cell lines: NCI-H 929, 
RPMI 8226, U266, JJN3 and 
ADC-1 
 
Combination treatment doses 
which synergistically enhanced 
apoptosis as determined by 
Hoechst 33342/PI staining 
 
Table 2.2: The cell lines and the investigated drug concentration used for different 
techniques 
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2.2.5.1 MycoAlert™ Mycoplasma Detection  
One of the most contaminants of cells in continuous cultures is Mycoplasma infections, 
which can lead to serious alteration in cell proliferation, morphology, metabolism and 
cellular responses including gene expression. (Uphoff and Drexler., 2005; Volokhov et 
al., 2011; Young et al., 2010). Moreover, their presence in cell culture go undetected for 
months thus frequent testing is essential (Uphoff and Drexler., 2005; Volokhov et al., 
2010; Young et al., 2010). The MycoAlert™ Mycoplasma Detection assay (Lonza) was 
used and cultures tested negative throughout the project. 
2.2.6 Assessment of Apoptosis  
2.2.6.1 Hoechst 33342 and Propidium Iodide (PI) of Nuclear Morphology by 
Fluorescence Microscopy 
Following treatment with drugs, induction of apoptosis was assessed using Hoechst 
33342 and Propidium Iodide (PI) staining (Sigma-Aldrich, Dorset, England). Cells were 
stained with 10 µg/ml Hoechst 33342 and 10µg/ml PI for 30 min at 37ºC and examined 
using fluorescence microscope (Olympus, IX81, UK) and images captured using Cell-F 
software. Apoptotic cells were counted manually and percent apoptosis calculated based 
on duplicate representative fields of view each containing at least 100 cells for three 
independent experiments. 
2.2.6.2 NucView Caspase 3 Activity Assay by Flow Cytometry 
NucView caspase 3 activities assay which allows assessing caspase-3 activity within 
intact cells in the real-time assay without inhibiting the process of apoptosis. The 
caspase-3 substrate is composed of a fluorogenic DNA dye and a DEVD moiety 
substrate specific for caspase-3. In apoptosis, the substrate (non-fluorescent) rapidly 
crosses the membranes of the cell to the cytoplasm, where it is cleaved to form a high-
affinity DNA dye by caspase-3 that stains the nucleus with bright green. Thus, the 
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NucView™ 488 caspase-3 substrate is bi-functional, allowing detection of activity of 
intracellular caspase-3 as well as visualization of nuclear morphology changes during 
apoptosis (Cen et al., 2008; Skommer et al., 2010; Smith et al., 2012).  
To confirm apoptosis at doses that exhibited synergistic induction of apoptosis with 
Hoechst 33342/Propidium Iodide staining, NucView Caspase-3 activity assay (Biotium) 
was used. Selected doses of LMB, SAHA, BIX 01294 and GSK343 in the presence or 
absence of TRAIL were added as above (Table 2.2). As a negative control, 1µL of the 
irreversible Caspase-3 Inhibitor Z-DEVD-FMK (R&D systems Cat # FMK004) was 
added to inhibitor wells (~100µM final concentration).  Following treatment 200µl of 
each cell suspension was transferred to a flow cytometry tube and 2.5µL of NucView™ 
488 Caspase-3 substrate (0.2 mM) (Cambridge Bioscience, Cambridge, UK) was added 
to the sample (including inhibitor sample) except 'unstained control' and incubates cells 
at room temperature for 20 minutes. Finally, the samples were analyzed on the flow 
cytometer using a Beckman Coulter Gallios flow cytometer. Ten thousand events were 
acquired per sample.  
2.2.7 CellTiter-Glo® Luminescent Cell Viability Assay 
For ATP level measurement to quantify viable cells, MM Cells were plated at 350,000 
cells/ml in a 96-well plate and treated with cytotoxic agents for 24h. Following 
incubation, 50 µl of CellTiter-Glo® Reagent were added to each well and incubated for 
10 minutes at room temperature luminescence was measured using Wallac Victor 2 
1420 luminometer. All treatments were performed in triplicate, in three independent 
experiments.  
2.2.8 Flow Cytometry for Analysis of Cell Cycle using Propidium Iodide (PI) 
Analysis of cell cycle was performed by seeding the cell at 0.5 x 106 cells per well and 
treated with TRAIL at the lowest dose that induced a statistically significant apoptotic 
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response as a single treatment, combined with the anti-tumour agents (LMB, SAHA, 
BIX 01294 and GSK343) and incubated at 37°C for 24 h. Following treatment, cells 
were harvested and centrifuged for 5 minutes at 400g prior to wash twice with 100 µl 
cold phosphate buffered saline. Subsequently, cells were fixed with 80% ethanol (v/v) 
and stored at -20°C overnight. Then, cells were centrifuged and washed twice prior to 
the addition of 300 µl of 50 µg/mL PI (Sigma) and 50 µl of 0.1 unit/mL DNase-free 
RNase A (Sigma) and stored overnight at 4ºC. Cellular DNA content was analysed 
using the flow cytometer with BD FACSCalibur™ (BD Biosciences) instrument. Ten 
thousand events were acquired per sample and data analysed with FlowJo software. 
Data quantified using the Waston (pragmatic) equation that assessed the proportion of 
diploid cells in G0/G1, S and G2/M phases of cell cycles in addition to the the quality 
control parameter such as Co-efficient of Variation (CV) and the debrise associated with 
each sample. 
2.2.9 Generation of TRAIL-resistant Multiple Myeloma Cells in vitro 
In order to generate TRAIL-insensitive cells NCI-H 929, RPMI 8226, and OPM2 were 
seeded into T25cm flasks and grown in escalating doses of TRAIL (2 ng/ml-50 ng/ml) 
for 1 year. Cell viability in response to TRAIL was checked every week and the dose of 
TRAIL is increased depending on cell viability. Also, TRAIL-resistant cells were 
generated by acute exposure of the TRAIL-sensitive cells with a high/lethal dose of 
TRAIL (50ng/ml) followed by the selection of TRAIL-resistant cells. The cytotoxic 
activity of TRAIL was determined on NCI-H 929, RPMI 8226, and OPM2 and 
compared to cell isolated from parental TRAIL-sensitive cells. Live cells were counted 
using the Cell Countless system (Invitrogen) and cell viability was determined using 
trypan blue staining. Cell death response to anti-tumour agents for the cell exposure to 
the acute toxic dose was assessed and apoptosis was assessed using Hoechst 33342/PI 
staining of nuclear morphology as described previously (Section 2.2.6.1).  
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2.2.10 Statistical Analysis 
Data was expressed as the median with range. Shapiro-Wilke test using Stats Direct 
software (Stats Direct Ltd, England) was used for analysis whether data followed a 
normal distribution. Data which did not follow a normal distribution, Kruskal–Wallis 
and Connover-Inman post hoc was using to investigate significant differences. p<0.05 
was considered statistically signiﬁcant.  The TRAIL sensitizer-mediated potentiation of 
TRAIL-induced apoptosis was determined by showing that apoptosis was induced by a 
combined treatment which was significantly greater than additive (i.e., apoptosis 
resulting from co-treatment with TRAIL and TRAIL sensitizer was significantly greater 
than the sum of apoptosis induced by TRAIL alone along with apoptosis induced by 
TRAIL sensitizer alone). 
2.2.10.1 Analysis of Effect of Anti-Tumour Agents in combination with TRAIL on 
Cell Cycle 
Cell cycle progression was analyzed using FlowJo software and the statistical 
signiﬁcant was determined by comparison the percentage of treated cells in each phase 
to the vehicle control in addition to the comparison of combined treatment to both the 
vehicle control and individual treatment. This effect was classified as: 
Interactive Effect when the combination treatment of anti-tumours agents with TRAIL 
induces a highly significant cellular accumulation in cell cycle phase when compared to 
both the vehicle control and individual treatment (p˂0.05). 
Antagonistic Effect when the combination therapy showed no significant difference 
compared to control, but there was significantly decreased of cell cellular accumulation 
compared to phases arrested by individual agents alone (p˂ 0.05).  
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2.3 Results 
2.3.1 Effect of TRAIL Treatments on Apoptosis using Hoechst 33342 and PI 
Nuclear Staining on Multiple Myeloma Cell Lines 
Multiple myeloma cell lines (NCI H 929, RPMI 8226, OPM2, JJN3, U266 and ADC-1) 
were treated with TRAIL (0–50 ng/ml) for 24 h. OPM2 MM cell was sensitive to 
TRAIL followed by RPMI 8226, NCI-H 929, and ADC-1 cell lines showed also 
significant apoptotic responses. In contrast, U266 and JJN3 were less sensitive to 
TRAIL but showed significant induction of apoptosis at 50 ng/ml (p0. 05) (Figure 2.5). 
Furthermore, the majority of MM cell lines showed greater sensitivity than the non-
tumour cell; HSC (CD133+) and the normal human renal cell line (HREC) there was no 
significant induction of apoptosis. However, TRAIL induces apoptosis in the HSC 
CD34+. 
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Figure 2.5: Effect of TRAIL treatment on apoptosis of multiple myeloma and non-
tumour cells 
 
 
Figure 2.5: Effect of TRAIL treatment on apoptosis of multiple myeloma and non-
tumour cells.  Cells were treated with 0-50 ng/ml TRAIL for 24 h. The treatment with 
TRAIL potently induces apoptosis of MM cells in a dose-dependent manner. U266, 
JJN3, non-tumour cells CD133+  and HREC were less sensitive to TRAIL treatment 
compared to other MM cell lines. The columns represent the mean of 3 independent 
experiments. Data are expressed as the median with range. The statistical significance 
was determined by comparison treatment with the control, statistical significance was 
set at p< 0.05= * and determined by Kruskal–Wallis test. 
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2.3.2 Effect of TRAIL Sensitizers in Combination with TRAIL on Apoptosis in 
Multiple Myeloma Cell Lines 
2.3.2.1 Effect of Leptomycin B (NEI) in Combination with TRAIL on Apoptosis in 
Multiple Myeloma 
Multiple Myeloma cells were treated with TRAIL at the lowest dose that induced 
significant apoptosis as a single treatment, and combined with LMB. LMB was found 
significantly to induce apoptosis in a dose-dependent manner in a panel of myeloma cell 
lines, OPM2, NCI- H 929, RPMI 8226, JJN3, U266 and ADC-1, although with varying 
potency following treatment with 0-5 nM LMB for 24 h (p < 0.0001) (Figure 2.6 a) and 
the combination with TRAIL synergistically enhanced TRAIL responses in all cell 
lines. The co-treatment of 2ng/ml TRAIL in ADC-1 cells in this study with sub-lethal 
doses of LMB (0-5 nM) significantly potentiated apoptosis to levels greater than those 
induced by either the agent alone or by their additive effect (Figure 2.6 a). In ADC-1 
cells, an apoptotic response of 84.3±4.1% (p < 0.0001) was measured following 
treatment with combined dose of 5 nM LMB and 2 ng/ml TRAIL for 24 h. Whereas, the 
apoptotic response for 5 nM LMB alone and 10 ng/ml TRAIL was 46.4±3.5% and 22.6 
±4.5% respectively (Figure 2.6 a, b). The synergistic effect of TRAIL and LMB varied 
on other MM cells line depending on the drug concentration. However, no synergistic 
response was observed following the treatment with LMB combined with a high dose of 
TRAIL in non-tumour cell line HSC CD133+ and human renal cell line HREC. On the 
other hand, CD34+ stem cells significantly responded to LMB either alone or in 
combination with TRAIL (Figure 2.6). An example of morphological assessment of 
apoptosis using Hoechst 33342/PI nuclear staining in ADC-1 cells after treatment with 
different concentration for LMB either alone or in combination with TRAIL is shown in 
Figure 2.6 b.  
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Figure 2.6: Effect of apoptosis on the multiple myeloma cell lines and non-tumour 
cells after the treatment with LMB +/-TRAIL for 24 h 
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b)  
 
 
 
 
 
 
 
 
Figure 2.6: Effect of apoptosis on the multiple myeloma cell lines and non-tumour cells after the treatment with LMB +/-TRAIL for 24 h. a) The 
percentage of apoptotic Multiple Myeloma cells treatment with LMB for 24h was increased in a concentration-dependent manner. The synergistic 
response was defined as a comparison of combination treatment group with the sum of the effects of TRAIL alone +  LMB alone and significance 
determined by using by the Kruskal–Wallis test (p< 0.05). (*) showing that apoptosis was induced by a combined treatment which was significantly 
greater than additive. b) Morphological assessment of apoptosis using Hoechst 33342/PI nuclear staining, after treatment shows LMB synergistically 
enhances TRAIL apoptosis in ADC-1 cell line. Apoptotic cells were identified by condensation and or fragmentation of the nucleus and intense staining 
while live cells were clear-edged, round, regular and uniformly stained nuclei. The red cells are permeabilised (necrotic or late apoptotic).
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2.3.2.2 Effect of SAHA (HDACi) in Combination with TRAIL on Apoptosis in 
Multiple Myeloma Cell Lines  
Multiple myeloma cells were treated with TRAIL at the lowest dose that induced 
significant apoptosis as a single treatment, and combined with SAHA. Hoechst 33342 
and PI staining of nuclear morphology indicate that SAHA induces apoptotic activities 
in MM cell lines (Figure 2.8). SAHA induced apoptosis of myeloma cells in a dose-
dependent manner in all multiple myeloma cell lines athough effect sizes were smallest 
in NCI-H 929, JJN3 and OPM2 (Figure 2.7). SAHA combined with TRAIL 
synergistically inducing apoptosis in all myeloma cell lines (p<0.001, Kruskal–Wallis) 
except OPM2 (Figure 2.7). There was no significant induction of apoptosis with TRAIL 
in non-tumour HSC CD133+and HREC. However, SAHA induced apoptosis in the HSC 
CD34+ with a synergistic response with TRAIL. An example of morphological 
assessment of apoptosis using Hoechst 33342/PI nuclear staining in U266 cells after 
treatment with different concentration for SAHA either alone or in combination with 
TRAIL is shown in Figure 2.7 b.  
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Figure 2.7: Effect of apoptosis on the multiple myeloma cell lines and non-tumour 
cells after the treatment with SAHA +/-TRAIL for 24 h 
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b) 
 
 
 
 
 
 
 
Figure 2.8: Effect of apoptosis on the multiple myeloma cell lines and non-tumour cells after the treatment with SAHA +/-TRAIL for 24 h. a) The 
percentage of apoptotic multiple myeloma cells treatment with SAHA for 24h was increased in a concentration-dependent manner (p< 0.05, Kruskal–
Wallis). The synergistic response was defined as a comparison of combination treatment group with the sum of the effects of TRAIL alone +  SAHA 
alone and significance determined by using by the Kruskal–Wallis test (*= p< 0.05). b) Morphological assessment of apoptosis using Hoechst 33342/PI 
nuclear staining, after treatment shows SAHA synergistically enhances TRAIL apoptosis in U266 cell line. Apoptotic cells were identified by 
condensation and or fragmentation of the nucleus and intense staining while live cells were clear -edged, round, regular and uniformly stained nuclei. 
The white arrow indicated the apoptotic cells. The red cells are permeabilised (necrotic or late apoptotic).  
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2.3.2.3 Effect of the G9a HMTasei BIX 01294 Treatment in Combination with 
TRAIL on Apoptosis in Multiple Myeloma Cell Lines  
MM cells were treated with BIX 01294 alone and in combination with TRAIL at the 
lowest dose that induced significant apoptosis as a single treatment to investigate their 
effect on induction of apoptosis following 24 hours (Figure 2.8 a). The data are 
illustrated in Figure 2.8 which demonstrates that MMSET positive cells (NCI-H 929, 
OPM2 and ADC-1) uniquely sensitive to BIX 01294 alone (p<0.001). However, BIX 
01294 synergistically significant enhanced TRAIL responses in MMSET-negative cell 
lines (RPMI 8226, U266 and JJN3) (p<0.001) (Figure 2.8). In addition, there was no 
significant induction of apoptosis with TRAIL in non-tumour HSC CD133+ and renal 
cell line HREC and no synergistic response was seen when BIX 01294 was combined 
with a high dose of TRAIL for 24 h. However, BIX 01294 induced apoptosis in the 
haematopoietic stem cell CD34+ with synergistic response with TRAIL. An example of 
morphological assessment of apoptosis using Hoechst 33342/PI nuclear staining in 
U266 cells after treatment with different concentration for BIX 01294 either alone or in 
combination with TRAIL is shown in Figure 2.8 b.  
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Figure 2.8:  Effect of apoptosis on the multiple myeloma cell lines and non-tumour 
cells after the treatment with BIX 01294 +/-TRAIL for 24 h 
a) 
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b) 
 
 
 
 
 
 
Figure 2.8: Effect of apoptosis on the multiple myeloma cell lines and non-tumour cells after the treatment with BIX 01294 +/-TRAIL for 24 h. a) 
The percentage of apoptotic multiple myeloma cells treatment with BIX 01294 for 24h was increased in a concentration-dependent manner (p <  0.05, 
Kruskal–Wallis). The synergistic response was defined as a comparison of combination treatment group with the sum of the effects of TRAIL alone +  
BIX 01294 alone and significance determined by using by the Kruskal–Wallis test (p< 0.05). (*) showing that apoptosis was induced by a combined 
treatment which was significantly greater than additive. b) Morphological assessment of apoptosis using Hoechst 33342/PI nuclear staining after 
treatment shows BIX 01294 synergistically enhances TRAIL apoptosis in U266 cell line. 
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2.3.2.4 Effect of the HMTasei GSK343 (EZH2i) in Combination with TRAIL on 
Apoptosis in Multiple Myeloma Cells 
Cells were treated with GSK343 alone and in combination with TRAIL at the lowest 
dose that induced significant apoptosis as a single treatment to investigate their effect on 
induction of apoptosis following 24 h (Figure 2.9). GSK343 alone potently induced 
apoptosis in U266 and synergistic enhancement of TRAIL responses seen in all cells. 
The synergy effect of TRAIL and GSK343 varied on multiple myeloma cells line 
depending on the drug concentration. For example, NCI-H 929 cell line showed a 
significant increase in apoptotic cells following the individual treatment with 17.5% 
with 10 µM GSK343 alone and 4.9% with 2 ng/ml TRAIL alone, whilst the 
combination treatment showed 46.9% when assessed following 24 h (p<0.001) (Figure 
2.9). In contrast, no synergistic response was observed when GSK343 used in 
combination with TRAIL in non-tumour cell line CD133+ and renal cell line HREC. 
However, the haematopoietic stem cell CD34+ was less sensitive to GSK343 than MM 
cells with a synergistic response with TRAIL. An example of morphological assessment 
of apoptosis using Hoechst 33342/PI nuclear staining in RPMI 8226 cells after 
treatment with different concentration for GSK343 either alone or in combination with 
TRAIL is shown in Figure 2.9 b.  
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Figure 2.9: Effect of apoptosis on the multiple myeloma cell lines and non-tumour 
cell after the treatment with GSK343 +/-TRAIL for 24 h 
a) 
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b) 
 
 
 
 
 
 
Figure 2.9: Effect of apoptosis on the multiple myeloma cell lines and non-tumour cell after the treatment with GSK343 +/-TRAIL for 24 h. (a 
Morphological assessment of apoptosis using Hoechst 33342/PI nuclear staining after treatment shows GSK343 synergistically enhances TRAIL 
apoptosis in RPMI 8226 cell line. The percentage of apoptotic multiple myeloma cells treatment with GSK343 for 24h was increased in a 
concentration-dependent manner (p <  0.05, Kruskal–Wallis). The synergistic response was defined as a comparison of combination treatment group 
with the sum of the effects of TRAIL alone +  GSK343 alone and significance determined by using by the Kruskal–Wallis test (p< 0.05). (*) showing that 
apoptosis was induced by a combined treatment which was significantly greater than additive. b) Morphological assessment of apoptosis using 
Hoechst 33342/PI nuclear staining after treatment shows GSK343 synergistically enhances TRAIL apoptosis in RPMI 8226 cell line. 
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2.3.3 Effect of TRAIL Sensitizers on Proliferation in Multiple Myeloma Cell 
Lines  
2.3.3.1 Effect of Leptomycin B (NEI) in Combination with TRAIL on Proliferation 
in Multiple Myeloma Cell Lines  
To examine the effect of LMB, both alone and in combination with TRAIL on cell 
proliferation, the CellTiter-Glo® Luminescent Cell Viability Assay was performed. The 
data are illustrated in Figure 2.10 which demonstrates that LMB significantly inhibited 
the proliferation of multiple myeloma. Furthermore, the co-treatment of LMB with 
TRAIL reduced cell proliferation. When LMB was combined with TRAIL in NCI-H 
929, U266, RPMI 8226, JJN3 and ADC-1 were more effective than individual drug in 
order to cause a significant inhibition in ATP level, used as a marker of cellular 
proliferation (p<0.05) (Figure 2.10). However, the non-tumour cell line HREC was the 
least sensitive to LMB alone compared to the multiple myeloma cells lines and the 
synergistic effect was seen in combination with TRAIL. On the other hand, LMB 
significantly inhibited the proliferation of CD34+ and the co-treatment of LMB with 
TRAIL further reduction cell proliferation (Figure 2.10). 
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Figure 2.10: Effect of LMB on ATP levels 
 
 
 
 
 
Figure 2.10: Effect of LMB on ATP levels, as evaluated by CellTiter-Glo® assay. The 
cells were treated as indicated for 24 hours. Data was normalized to the vehicle control 
which was assigned 100% cell viability. The data is expressed as median with range 
(three independent experiments, each in triplicate). The statistical significance was 
determined by comparison with the vehicle control, statistical significance was set at 
p< 0.05 by the Kruskal–Wallis test. Synergistic reduction in viable cell numbers is 
denoted by (*). 
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2.3.3.2 Effect of SAHA (HDACi) in Combination with TRAIL on Proliferation in 
Multiple Myeloma Cell Lines  
The cytotoxic effects of SAHA on myeloma cell lines NCI-H 929, RPMI 8226, OPM2, 
JJN3, U266 and ADC-1 cells following treating with increasing concentrations of 
SAHA for 24 h were studied using CellTiter-Glo® Luminescent Cell Viability Assay. 
Viability assays identified that treatment with SAHA for 24h resulted in reduced viable 
cells in multiple myeloma cell lines in a dose dependent manner (Figure 2.11). SAHA 
alone significantly reduced cell numbers in all cell lines (p<0.05) (Figure 2.11). TRAIL 
was used at the lowest dose that resulted in significant apoptosis by Hoechst 33342/PI 
staining, and as such, weak effects seen with TRAIL alone are expected. Combination 
treatment with SAHA + TRAIL resulted in synergistic reduction in ATP levels in 
OPM2, RPMI 8226, NCI-H 929, U266, ADC-1 and JJN-3, however, effect sizes in the 
latter two cell lines were smaller. However, the non-tumour cell lines HREC did not 
show any significant reduction in ATP level following treatment with SAHA and the 
synergistic effect was seen in when SAHA was combined with TRAIL. On the other 
hand, high dose of SAHA significantly inhibited the proliferation of CD34+ and the co-
treatment of SAHA with TRAIL induced more reduction in cell proliferation (Figure 
2.11). 
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Figure 2.11: Effect of SAHA on ATP levels 
 
 
 
 
Figure 2.11: Effect of SAHA on ATP levels, as evaluated by CellTiter-Glo® assay. 
The cells were treated as indicated for 24 hours. Data was normalized to the vehicle 
control which was assigned 100% cell viability. The data is expressed as median with 
range (three independent experiments, each in triplicate). The statistical significance 
was determined by comparison with the vehicle control, statistical significance was set 
at p< 0.05 by the Kruskal–Wallis test. Synergistic reduction in viable cell numbers is 
denoted by (*). 
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2.3.3.3 Effect of the G9a HMTasei BIX 01294 Treatment in Combination with 
TRAIL on Proliferation in Multiple Myeloma Cell Lines  
Cells were treated with BIX 01294 alone and in combination with TRAIL at the lowest 
dose that induced significant apoptosis as a single treatment to investigate their effect on 
inhibition of ATP levels after 24 h (p<0.001) (Figure 2.12). MMSET-positive cells 
(NCI-H 929 and, OPM2) demonstrated a significant decrease in the percent of ATP 
following treatment with BIX 01294 alone for 24 h (p<0.001) (Figure 2.12). BIX 01294 
synergistically enhanced TRAIL responses in MMSET-negative cell lines (U266 and 
JJN3) (Figure 2.12). A neglible effect on cell proliferation was observed in the non-
tumour cell line HREC with BIX 01294 treatments alone. In contrast, a synergistic 
effect was observed with a high dose of BIX 01294 in combination with a high dose of 
TRAIL. On the other hand, high dose of BIX 01294 significantly inhibited the 
proliferation of CD34+ and the co-treatment of BIX 01294 with TRAIL induced more 
reduction in cell proliferation (Figure 2.12). 
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Figure 2.12: Effect of BIX 01294 on ATP levels 
 
 
 
 
Figure 2.12: Effects of BIX 01294 on ATP levels, as evaluated by CellTiter-Glo® 
assay. The cells were treated as indicated for 24 hours. Data was normalized to the 
vehicle control which was assigned 100% cell viability. The data is expressed as 
median with range (three independent experiments, each in triplicate). The statistical 
significance was determined by comparison with the vehicle control, statistical 
significance was set at p< 0.05 by the Kruskal–Wallis test. Synergistic reduction in 
viable cell numbers is denoted by (*). 
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2.3.3.4 Effect of the HMTasei GSK343 (EZH2i) Treatment in Combination with 
TRAIL on Proliferation in Multiple Myeloma Cell Lines 
The effect HMTasei GSK343 on cell proliferation following treatment with GSK343 at 
0-20 µM for 24 h showed a significant decrease in ATP level in MM cell lines in dose 
dependent manner (p<0.05) (Figure 2.13). However, within the multiple myeloma cell 
lines different response to GSK343 treatment was observed, where JJN3 and U266 were 
the most affected and demonstrated a significant decrease in ATP level (p<0.05) (Figure 
2.13). Combination treatment with TRAIL resulted in synergistic reduction of ATP 
levels in U266, NCI-H 929, RPMI 8226, and OPM2. In contrast, JJN3 and ADC-1, cell 
lines failed to show any synergistic response to GSK343 treatment when combined with 
TRAIL. A neglible effect on cell proliferation was observed in the non-tumour cell lines 
CD34+ and HREC GSK343 treatments alone. In contrast, a synergistic effect was 
observed with a high dose of GSK343 in combination with a high dose of TRAIL 
(Figure 2.13). 
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Figure 2.13: Effect of GSK343 on ATP levels 
 
 
 
 
Figure 2.13: Effect of GSK343 on ATP levels, as evaluated by CellTiter-Glo® assay. 
The cells were treated as indicated for 24 hours. Data was normalized to the vehicle 
control which was assigned 100% cell viability. The data  is expressed as median with 
range (three independent experiments, each in triplicate). The statistical significance 
was determined by comparison with the vehicle control, statistical significance was set 
at p< 0.05 by the Kruskal–Wallis test. Synergistic reduction in viable cell numbers is 
denoted by (*). 
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2.3.4 Effect of TRAIL Sensitizers on Caspase Activity in Multiple Myeloma Cells 
2.3.4.1 Effect of LMB (NEI) in Combination with TRAIL on Caspase-3 Activity in 
Multiple Myeloma Cells 
To confirm the morphological assessment of apoptosis by Hoechst 33342/PI staining, 
caspase-3 activity assays using flow cytometry was used. Combination treatment doses 
which synergistically enhanced apoptosis as determined by Hoechst 33342/PI staining 
showed significant induction of apoptosis following caspase-3 activation assay in NCI-
H 929, RPMI 8226, ADC-1 and U266 (p<0.05) (Figure 2.14). 
 
Figure 2.14: Effects of LMB in combination with TRAIL on caspase-3 activity in 
multiple myeloma cells 
 
 
Figure 2.14: Effects of LMB in combination with TRAIL on caspase-3 activity in 
multiple myeloma cells. The cells were treated with LMB and TRAIL alone and in 
combined for 24 h. The data is expressed as median with range. The statistica l 
significance was determined by comparison with the vehicle control, statistical 
significance was set at p< 0.05 by the Kruskal–Wallis test.  
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2.3.4.2 Effect of SAHA (HDACi) in Combination with TRAIL Caspase-3 Activity in 
Multiple Myeloma Cells 
The effectiveness of SAHA in inducing apoptosis was conforming by caspase-3 activity 
assays using flow cytometry. Multiple myeloma cell lines were treated with 
combination treatment doses which synergistically enhanced apoptosis as determined by 
Hoechst 33342/PI staining. SAHA induced significantly higher levels of apoptosis 
determined by caspase-3 activity in NCI-H 929, U266 and RPMI 8226 (p< 0.05) 
(Figure 2.15).  
 
Figure 2.15: Effects of SAHA in combination with TRAIL on caspase-3 activity in 
Multiple Myeloma cells 
 
 
Figure 2.15: Effects of SAHA in combination with TRAIL on caspase-3 activity in 
multiple myeloma cells. The cells were treated with SAHA and TRAIL alone and in 
combined for 24 h. The data is expressed as median with range. The statistical 
significance was determined by comparison with the vehicle control, statistical 
significance was set at p< 0.05 by the Kruskal–Wallis test.  
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2.3.4.3 Effect of the G9a HMTasei BIX 01294 in Combination with TRAIL on 
Caspase-3 Activity in Multiple Myeloma Cells 
NCIH 929, U266, RPMI 8226 and ADC-1 cells showed significant induction of 
apoptosis as shown by increased caspase-3 activation following 24 h incubation when 
treated with BIX 01294 alone and after the combination treatment of BIX 01294 and 
TRAIL (Figure 2.16) (p< 0.05). 
 
Figure 2.16: Effects of BIX 01294 in combination with TRAIL on Caspase-3 
activity in Multiple Myeloma cells 
 
 
 
 
Figure 2.16: Effects of BIX 01294 in combination with TRAIL on Caspase-3 activity 
in multiple myeloma cells. The cells were treated with BIX 01294 and TRAIL alone and 
in combined for 24 h. The data is expressed as median with range. The statistical 
significance was determined by comparison with the vehicle control, statistical 
significance was set at p< 0.05 by the Kruskal–Wallis test.  
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2.3.4.4 Effect of the HMasei GSK343 (EZH2i) in Combination with TRAIL on 
Caspase-3 Activity in Multiple Myeloma Cells 
GSK343 and TRAIL induced a significant level of apoptosis.  GSK343 interacted with 
TRAIL producing a synergistic effect that significantly increased the caspase activity in 
RPMI 8226 and ADC-1 MM cell line (Figure 2.17) (p< 0.05). These result confirmed 
the induction of apoptosis shown by Hoechst 33342/PI staining. 
 
Figure 2.17: Effects of GSK343 in combination with TRAIL on caspase-3 activity 
in multiple myeloma cells 
 
 
Figure 2.17: Effects of GSK343 in combination with TRAIL on Caspase 3 activity in 
multiple myeloma cells. The cells were treated with GSK343 and TRAIL alone and in 
combined for 24 h. The data is expressed as median with range. The statistical 
significance was determined by comparison with the vehicle control, statistical 
significance was set at p< 0.05 by the Kruskal–Wallis test.  
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2.3.5 Effect of TRAIL Sensitizers (LMB, SAHA, BIX 01294 and GSK343) on Cell 
Cycle in Multiple Myeloma Cells 
To determine if inhibition of multiple myeloma cell proliferation is due to an increase in 
the cell cycle arrest, NCI-H 929, RPMI 8266, U266, JJN3 and ADC-1 were treated with 
LMB, SAHA, BIX 01294 and GSK343 for 24 h and stained with propidium iodide to 
study the cell cycle progression (Figure 2.18, 2.19, 2.20, 2.21). Multiple myeloma cell 
lines showed a different response in terms of cell cycle arrest with different 
concentration of anti-tumour agents. Treatment with LMB showed significant 
accumulation in S and G2/M phase in NCI-H 929, G0/G1 and S phases in RPMI 8226 
and in G2/M for JJN3 cells (p˂ 0.05) (Figure 2.18).  ADC-1 cells showed a significant 
increase in S and G2/M phases of the cell cycle when assessed after 24 h following 
treatment with LMB compared to control cells (p˂ 0.05) (Figure 2.18). Treatment with 
SAHA caused significant induced cell cycle arrest in G2/M in ADC-1, S-phase in NCI-
H 929 and U266, G0/G1 and G2/M in JJN3 cells (p˂ 0.05) (Figure 2.19).  BIX 01294 
significantly induced cell cycle arrest in G0/G, S-phases and G2/M in RPMI 8226, S-
phase in ADC-1 and NCI-H 929 cells (p˂ 0.05) (Figure 2.20). In addition, significant 
cellular accumulation at G0/G1 and G2/M in ADC-1, S-phase in NCI-H 929, RPMI 8226 
and U266, G0/G1 in JJN3 following GSK343 treatment alone (p˂ 0.05) (Figure 2.21  
Moreover, analysis of combination treatment on cell cycle performed, however, due to 
increase levels of apoptosis, cell cycle in each phase was unreliable. All data are shown 
in the appendix (Figure I, II, III, and IV).  In addition, some multiple myeloma cells 
illustrated an increase in sub-G1 population, which an apoptotic cells indicator when 
treated combination treatment of anti-tumour agents with TRAIL (Figure 2.22). An 
example of histograms for the cell cycle phases (G0/G1, S, G2/M) for the U266 multiple 
myeloma cells after treatment with LMB, SAHA, BIX 01294 and GSK343 either alone 
or in combination with TRAIL following 24 h is shownin Figure 2.22.  
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Figure 2.18:  Effect of LMB on cell cycle progression in multiple myeloma cells 
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Figure 2.18:  Effect of LMB on cell cycle progression in multiple myeloma cells. The 
cells were treated with selected concentrsations of LMB for 24h. The data is expressed 
as median with range (three independent experiments). The statistical significance was 
determined by comparison with the vehicle control (*= p< 0.05) (Kruskal–Wallis). 
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Figure 2.19:  The effect of SAHA on cell cycle progression in multiple myeloma 
cells 
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Figure 2.19: Effect of SAHA on cell cycle progression in multiple myeloma cells. The 
cells were treated with selected concentrsations of SAHA for 24 h. The data is expressed 
as median with range (three independent experiments). The statistical significance was 
determined by comparison with the vehicle control (*= p< 0.05) (Kruskal–Wallis).  
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Figure 2.20:  Effect of BIX 01294 on cell cycle progression in multiple myeloma 
cells 
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Figure 2.20: Effect of BIX 01294 on cell cycle progression in multiple myeloma cells. 
The cells were treated with selected concentrsations of BIX 01294 for 24 hours. The 
data is expressed as median with range (three independent experiments). The statistical 
significance was determined by comparison with the vehicle control and statistical 
significance (*= p< 0.05) (Kruskal–Wallis).                     
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Figure 2.21: Effect of GSK343 on cell cycle progression in multiple myeloma cells 
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Figure 2.21:  Effect of GSK343 on cell cycle progression in multiple myeloma cells. 
The cells were treated with selected concentrsations of GSK343 for 24 hours. The data 
is expressed as median with range (three independent experiments). The statistical 
significance was determined by comparison with the vehicle (*=p<0.05) (Kruskal–
Wallis). 
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Figure 2.22: An example of histograms for the cell cycle phases (G0/G1, S, G2/M) 
for the U266 multiple myeloma cells after treatment with LMB, SAHA, BIX 01294 
either alone or in combination with TRAIL following 24 h 
 
 
Figure 2.22:  An example of histograms for the cell cycle phases (G0/G1, S, G2/M) for 
the U266 multiple myeloma cells after treatment with LMB, SAHA, BIX 01294 either 
alone or in combination with TRAIL following 24 h. The percentage of cells in each 
phase was analyzed with Flow Jo software. In addition, the U266 cells illustrated an 
increase in sub-G1 population, which an apoptotic cells indicator when treated with 5 
µM SAHA either alone or in combination with TRAIL and co- treatment of BIX 01294 
and TRAIL. The statistical significance was determined by comparison with the vehicle 
(p< 0.05) (Kruskal–Wallis). 
 94 
 
2.3.6 Prolonged Incubation of TRAIL Sensitive Multiple Myeloma Cells with 
TRAIL Resulting in the Appearance of TRAIL-Resistant Cells 
In order to facilitate the development of TRAIL-resistant culture, this study 
intentionally chose growth conditions which support the appearance of resistant 
colonies by prolonged exposure to accelerating dose of TRAIL over 1 year in culture. 
Measurement of cell number and viability confirmed the TRAIL-insensitive phenotype 
in NCI-H 929, RPMI 8226 and OPM2 with a highly significant increase of cell viability 
of TRAIL-resistant cells compared to parental TRAIL sensitive cells in response to 
high-dose TRAIL (p<0.0001) (Figure 2.23). An alternative method used to generate 
TRAIL-insensitive population by stimulating the TRAIL sensitive cells with a 
high/lethal dose of TRAIL (50 ng/ ml) and long term culture of the surviving cells 
(Figure 2.24). Our data showed that there was an increase in cell viability of TRAIL 
resistant cells compared to parental TRAIL sensitive cells (p<0.0001) (Figure 2.23 and 
24).  
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Figure 2.23: Generation of TRAIL-resistant population by chronic exposure to 
escalating TRAIL over 1 year 
 
 
 
Figure 2.23: Generation of TRAIL-resistant population by incubated TRAIL sensitive 
cells (NCI-H 929, RPMI 8226, and OPM2) with escalating of TRAIL, result in an 
increase in cell viability in TRAIL resistant cells compared to parental TRAIL sensitive 
cells. (*= p< 0.01,     **= p< 0.001, ***= p< 0.0001, Kruskal–Wallis test). 
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Figure 2.24: Generation of TRAIL-resistant population by stimulating the TRAIL 
sensitive cells with a high/lethal dose of TRAIL 
 
 
Figure 2.24: Generation of TRAIL-resistant population by stimulating the TRAIL 
sensitive cells with a high/lethal dose of TRAIL (50 ng/ ml) for one year result in an 
increase in cell viability in TRAIL resistant cells compared to parental TRAIL sensitive 
cells. (*= p< 0.01,     **= p< 0.001, ***= p< 0.0001, Kruskal–Wallis test). 
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2.3.6.1 Effect of TRAIL on Apoptosis in TRAIL-resistant Cell Lines. 
Moreover, treatment of the TRAIL-resistant cells with 10 ng/ml and 50 ng/ml TRAIL 
result in significant reduction of apoptosis in TRAIL resistant cells compared to 
parental TRAIL sensitive cells or vehicle control (Figure 2.25). An example of 
morphological assessment of apoptosis using Hoechst 33342 nuclear staining in RPMI 
8226 after treatment with different concentration TRAIL is shown in Figure 2.25 a. 
 
Figure 2.25: Effect of TRAIL on apoptosis in TRAIL-resistant population 
a) 
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b) 
 
 
Figure 2.25: Effect of TRAIL on apoptosis in TRAIL-resistant population. a) 
Stimulation of TRAIL-resistant cells by TRAIL result in significant reduction of the 
percentage of apoptosis in TRAIL resistant cells compared to parental TRAIL sensitive 
cells. b) Morphological assessment of apoptosis using Hoechst 33342 /PI nuclear 
staining, after treatment with TRAIL in parental and TRAIL-resistant RPMI 8226 cell 
lines. (Kruskal–Wallis test *= p< 0.01,     **= p< 0.001, ***= p< 0.0001). 
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2.3.6.2 Effect of LMB in Combination with TRAIL in TRAIL-Resistant Multiple 
Myeloma Cells  
The potential of LMB to induce apoptotic cell death in TRAIL resistant populations was 
investigated using Hoechst 33342 staining of nuclear morphology. The data are 
illustrated in Figure 2.26 which demonstrates that TRAIL resistant populations are not 
sensitized to TRAIL by LMB, whereas there was significant increased sensitivity to 
LMB and loss of LMB-induced TRAIL-sensitization in TRAIL-resistant RPMI 8226 
cells and there was no significant increased sensitivity to LMB in TRAILR NCI-H 929 
(Figure 2.26). An example of morphological assessment of apoptosis using Hoechst 
33342 nuclear staining on parental and TRAIL-resistant RPMI 8826 population after 
treatment with LMB alone and in combined with TRAIL is shown in Figure 2.26 b. 
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Figure 2.26: Effect of LMB on apoptosis in TRAIL-resistant population 
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Figure 2.26 b: Morphological assessment of the effect of LMB on apoptosis in 
RPMI 8826 TRAIL-resistant population 
 
Figure 2.26: a) Effect of LMB on apoptosis in TRAIL-resistant population. Data is 
expressed as median with range (three independent experiments, each in triplicate). The 
statistical significance was determined by comparison with the vehicle control, 
statistical significance was set at p< 0.05 by the Kruskal–Wallis test. b) Morphological 
assessment of apoptosis using Hoechst 33342 /PI nuclear staining, after treatment with 
LMB in combination with TRAIL in parental and TRAIL-resistant RPMI 8226 cell lines.  
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2.3.6.3 Effect of SAHA in Combination with TRAIL in TRAIL-Resistant Multiple 
Myeloma Cells  
To investigate the effect of SAHA to induce apoptotic cell death in TRAIL resistant 
populations Hoechst 33342 staining of nuclear morphology was used. The data are 
illustrated in Figure 2.27 which demonstrates that TRAIL resistant populations are not 
sensitized to TRAIL by SAHA. Both SAHA and combination responses significantly 
reduced in TRAILR NCI-H 929 cells (p<0.05) and significant loss of SAHA-induced 
sensitization to TRAIL in TRAILR RPMI 8226 cells (p<0.05) (Figure 2.27). An 
example of morphological assessment of apoptosis using Hoechst 33342 nuclear 
staining on parental and TRAILR NCI-H 929 population after treatment with SAHA 
alone and in combined with TRAIL is shown in Figure 2.27 b.  
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Figure 2.27: Effect of SAHA on apoptosis in TRAIL-resistant population 
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Figure 2.27 b a: Morphological assessment of the effect of SAHA on apoptosis in 
NCI-H 929 TRAIL-resistant population 
 
Figure 2.27: a) Effect of SAHA on apoptosis in TRAIL-resistant population. Data is 
expressed as median with range (three independent experiments, each in triplicate). The 
statistical significance was determined by comparison with the vehicle control, 
statistical significance was set at p< 0.05 by the Kruskal–Wallis test. b) Morphological 
assessment of apoptosis using Hoechst 33342 /PI nuclear staining, after treatment with 
SAHA in combination with TRAIL in parental and TRAIL-resistant NCI-H 929 cell 
lines.  
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2.3.6.4 Effect of the G9a HMTasei BIX 01294 in Combination with TRAIL in 
TRAIL-Resistant Multiple Myeloma Cells 
The effect of BIX 01294 to induce apoptotic cell death in TRAIL resistant populations 
was investigated using Hoechst 33342 staining of nuclear morphology. The data are 
illustrated in Figure 2.10 which demonstrates that significant increased BIX 01294 
sensitivity on TRAIL-resistant NCI-H 929 cells while significant loss (p<0.05) of 
TRAIL sensitivity and BIX 01294-enhanced TRAIL responses in TRAIL-resistant 
RPMI 8226 cells (Figure 2.28). An example of morphological assessment of apoptosis 
using Hoechst 33342 nuclear staining on parental and TRAIL-resistant RPMI 8226 
population after treatment with BIX 01294 alone and in combined with TRAIL is 
shown in Figure 2.28 b.  
 
 
 
 
 
 
 
 
 
 
 106 
 
 
Figure 2.28: Effect of BIX 01294 on apoptosis in TRAIL-resistant population 
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Figure 2.28 b: Morphological assessment of the effect of BIX 01294 on apoptosis in 
RPMI 8226 TRAIL-resistant population 
 
Figure 2.28: a) Effect of BIX 01294 on apoptosis in TRAIL-resistant population. 
Data is expressed as median with range (three independent experiments, each in 
triplicate). The statistical significance was determined by comparison with the vehicle 
control, statistical significance was set at p< 0.05 by the Kruskal–Wallis test. b) 
Morphological assessment of apoptosis using Hoechst 33342 /PI nuclear staining, after 
treatment with BIX 01294 in combination with TRAIL in parental and TRAIL-resistant 
RPMI 8226 cell lines.  
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2.3.6.5 Effect of the HMTasei GSK343 (EZH2i) in Combination with TRAIL in 
TRAIL-Resistant Multiple Myeloma Cells 
To determine the effect of GSK343 to induce apoptotic cell death in TRAIL resistant 
populations parental and TRAILR were treated with GSK343+/-TRAIL for 24 h. The 
data are shown in Figure 2.10 which demonstrates that there was a significant reduction 
of the percentage of apoptosis in response to TRAIL and GSK343 in TRAILR 
populations compared to parental cells and significant loss GSK343-induced TRAIL-
sensitization in TRAIL-resistant RPMI 8226 cells (p<0.05) (Figure 2.29). An example 
of morphological assessment of apoptosis using Hoechst 33342 nuclear staining on 
parental and TRAILR RPMI 8226 population after treatment with GSK343 alone and in 
combined with TRAIL is shown in Figure 2.29 b.  
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Figure 2.29: Effect of GSK343 on apoptosis in TRAIL-resistant population 
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Figure 2.29 b: Morphological assessment of the effect of GSK343 on apoptosis in 
RPMI 8226 TRAIL-resistant population 
 
Figure 2.29: a) Effect of GSK343 on apoptosis in TRAIL-resistant population. Data is 
expressed as median with range (three independent experiments, each in triplicate). The 
statistical significance was determined by comparison with the vehicle control, 
statistical significance was set at p< 0.05 by the Kruskal–Wallis test. b) Morphological 
assessment of apoptosis using Hoechst 33342 /PI nuclear staining, after treatment with 
GSK343 in combination with TRAIL in parental and TRAIL-resistant RPMI 8226 cell 
lines.  
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2.4 Discussion 
In spite of the constant progress that has been made for available therapy, MM still 
remains an incurable disease and the relapse from therapy consequently occurs due to 
the eventual emergence of resistance to the currently used chemotherapeutic agents; 
therefore, an urgent need arises to find therapies that eradicate all tumour cells (Vitovski 
et al., 2012). Recently, the therapeutic potential of TRAIL-based therapy both in vivo 
and in vitro against various tumour cells including MM cells suggests that it may be a 
promising anti-myeloma therapeutic candidate. However, the susceptibility of multiple 
myeloma cells to TRAIL-based therapy has been established to be low in most of the 
myeloma cells lines, which limits its clinical applications (Kagawa et al., 2012). This 
study aimed to investigate the susceptibility and resistance of the MM cells line to 
apoptosis mediated by TRAIL-based therapies in addition to the combined treatment of 
TRAIL with other chemotherapeutic therapeutic agents in order to overcome the TRAIL 
resistance and target TRAIL resistance population.   
These results suggest that TRAIL induces apoptosis of different myeloma cells lines 
with no induction of apoptosis in non-tumour cells haematopoietic stem cell CD133+ 
and normal renal cells HREC. Importantly we have illustrated that TRAIL treatment in 
combination with other TRAIL sensitizers including LMB, SAHA, BIX 01294 and 
GSK343 results in sensitising some Multiple Myeloma cell lines to TRAIL; besides, the 
synergistic effect of TRAIL and these anti-tumour agents varied depending on the drug 
concentration. A summary of the synergistic apoptotic effect in multiple myeloma cell 
lines in response to different drugs in combination with TRAIL is shown in Table 2.4.  
Moreover, stimulation with TRAIL sensitizers reduced the proliferation of myeloma 
cells that increases with the co-treatment with TRAIL. This investigation has generated 
a TRAILR population; however, TRAIL responses in cells that had been selected for  
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TRAIL resistance were not further enhanced by SAHA and GSK343 in both multiple 
myeloma cell lines. However, responses to BIX 01294 were increased in TRAILR NCI-
H 929 cells and to LMB in TRAILR RPMI cell. 
 
Multiple 
Myeloma 
cell line 
 
MMSET 
 
TRAIL 
Sensitivity 
Apoptotic synergistic effect 
LMB 
+ 
TRAIL 
SAHA 
+ 
TRAIL 
BIX01294 
+ 
TRAIL 
GSK343 
+ 
TRAIL 
OPM2 + + + - - + 
RPMI 8226 - + + + + + 
NCI-H 929 + + + + + + 
ADC-1 + + + + + + 
U266 - - + + + + 
JJN3 - - + + + + 
 
Table 2.3: A summary of the synergistic apoptotic effect in multiple myeloma cell 
lines in response to different drugs in combination with TRAIL 
2.4.1 Leptomycin Restores the TRAIL Sensitivity and Inhibits Cell Proliferation 
of multiple myeloma Cell Lines. 
TRAIL can initiate both extrinsic and intrinsic apoptotic cascades that converge on the 
executioner caspases-3 or -7 to trigger cell death (Testa., 2010). Of the cell lines 
investigated, RPMI 8226, NCI-H 929 and OPM2 as well as primary cell line ADC-1 
exhibited the greatest apoptotic response following treatment with TRAIL, although the 
magnitude of response may differ among these cell lines, whereas the U266 and JJN3 
cell lines were the least sensitive (Figure 2.5). The reason for the variation in sensitivity 
between MM cells lines is unclear, but it may reflect differences in the levels of the 
expression of TRAIL receptors (R1 and R2) and/or downstream signalling components 
between cell lines. Moreover, TRAIL induced apoptosis in CD34+ HSC with no 
induction of apoptosis in non-tumour cells haematopoietic stem cell CD133+ HSC and 
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renal cells HREC (Figure 2.5). However, in earlier work, TRAIL showed no apparent 
toxicity to hematopoietic stem cells CD34+ (Gazitt., 1999). 
Consistent with this study, Vitovski et al., (2012) demonstrated that Flow cytometric 
analysis of Annexin V labelled myeloma cells (RPMI8226, NCI H929 and the OPM-2) 
after TRAIL treatment demonstrates the presence of TRAIL-induced apoptosis in all 
three cell lines. Additionally, TRAIL induced apoptosis in the MM cell lines apoptosis 
was mediated via the activation of both extrinsic and intrinsic apoptotic pathways 
(Vitovski et al., 2012). 
Similar responses were observed in the previous studies that investigated the TRAIL 
sensitivity on the RPMI 8226 cell line. Cheriyath et al, (2007) displayed that treating 
the RPMI 8226 cell line with (25 ng/ml) TRAIL markedly increased cell death from 
0.3% to 46.8% after 24 hours and from 1.2% to 11.1% after 72 hours and that the co-
treatment with IFN-α2b (250 IU/ml) for 24 hours enhanced the susceptibility to TRAIL-
induced apoptosis. Moreover, it has been found that the apoptotic effect of TRAIL was 
mediated via inducting the cleavage of molecular parameters of apoptosis PARP, MST1, 
and DFF-45A by 6 hours, an effect that sustained to 24 hours (Cheriyath et al, 2007). 
The NEI LMB was shown to be a very potent anti-cancer drug against a range of cancer 
cell lines in vitro by inhibiting the export of CRM1-mediated protein from the nucleus 
such as a tumour suppressor protein p53 that mediates its nuclear activation (Mukta et 
al., 2009). This results in inducing the expression of pro-apoptotic p53 responsive genes 
including Bax and p21 in order to exhibit different cell responses e.g. apoptosis and cell 
cycle arrest (Mukta et al., 2009). Here, LMB was found to induce apoptosis in a dose-
dependent manner in a panel of myeloma cell lines although with varying potency 
following treatment with 0-5 nM LMB for 24 h (Figure 2.6). In this study, the co-
treatment of ADC-1 cells with sub-toxic doses of LMB (0-5 nM) and 2 ng/ml TRAIL 
significantly potentiated apoptosis to levels greater than those induced by either the 
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agent alone or by their additive effect (Figure 2.6). The synergistic effect of TRAIL and 
LMB varied on the other multiple myeloma cells line depending on the drug 
concentration. Moreover, LMB induced the inhibitory cell growth in the MM cell lines 
that further increased with the combined treatment with TRAIL. The co-treatment of 
TRAIL and LMB acted synergistically to inhibit cell proliferation in the MM cell lines 
U266, RPMI 8226, ADC-1 and additively in JJN3 and OPM2 (Figure 2.11) as well as 
arresting cell cycle (Figure 2.18).  
In recent work, the co-treatment of a CRM1 inhibitor, selinexor and doxorubicin 
synergistically induced DNA damage and subsequent apoptosis in myeloma cells in 
vivo, in vitro and in ex vivo samples obtained from patients with relapsed or refractory 
multiple myeloma (Turner et al., 2016). 
This work is considered as the first study investigating the effect of co-treatment of NEI 
(LMB) and TRAIL in multiple myeloma cells. One previous unpublished work carried 
out by Haywood et al., (2011); working on PC3 prostate cancer cells found out that 
LMB induced the responses of TRAIL sensitive PC3 cells to TRAIL. This finding 
suggested that LM and TRAIL act in synergy and that the combination of TRAIL and 
LM is an effective promising therapy against prostatic cancer.  
In previous work, LMB induced apoptosis in leukemia cells through cytochrome c 
release, caspase activation, and decrease expression of Mcl-1 and XIAP while there was 
no change in the expression Bcl-2 or Bax (Jang et al., 2004). Other study established 
that LMB induces apoptosis in the prostate cell line LNCaP cell that contains wild-type 
p53 gene increased the transcription activity of p53 by trapping pro-apoptotic p53 
responsive genes in the nucleus, includes p21, Bax and DR5 by interfering with their 
nucleo-cytoplasmic export and subsequent proteosomal degradation. However, the null-
p53 DU-145 cells did not activate the downstream target genes (Lecane et al., 2003). 
This is consistent with later work that found out NEIs induces cytotoxic effects and 
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trigger apoptosis and cells cycle arrest in G2 and/or G1 phase in tumour cell lines by the 
block of nuclear export CRM1 dependent protein resultant in p53 nuclear localization 
and activation in cancer cells (Mutka et al., 2009).   
2.4.2 SAHA Augmenting TRAIL-Induced Apoptosis and Cytotoxicity in Some 
Multiple Myeloma Cell Lines 
Modification of histone acetylation status has been involved in carcinogenesis 
(Gillenwater et al., 2007). HDAC inhibitors are a class of anti-tumour agents that are 
able to induce apoptosis and/or cell cycle arrest in tumour cells although the underlying 
anti-tumour effects of molecular mechanisms are not fully understood. SAHA was 
developed by modifying the HDAC-inhibitory compound; it has proved to be efficient 
in cancer treatment both in vivo and in vitro due to its low toxicity SAHA activity is 
evaluated in clinical trials (Fandy et al., 2005). HDAC inhibitor, SAHA can potentially 
re-expressed activate aberrantly silenced tumour suppressed genes via restoring histone 
acetylation and permitting gene transcription (Gillenwater et al., 2007). Inhibition of 
histone deacetylation mainly induces transcription of positive and negative regulators of 
proliferation and/or the survival of the cell and growth inhibition or cytotoxicity. 
(Mitsiades et al., 2003; Fandy et al., 2005; Hideshima and Anderson, 2013) 
In this study, we have evaluated the effect of HDAC inhibitor SAHA on human 
different multiple myeloma cell lines. The findings established that together with the 
SAHA induced apoptosis, inhibition growth and arresting cell cycle, the augmented 
apoptotic and the cytotoxic effects of TRAIL on U266 and NCI H929 (TRAIL+ 5 or 10 
µM SAHA) cell lines (Figures 2.7). Additionally, the co-treatment with SAHA acted 
synergistically inhibiting cell proliferation in the multiple myeloma cell lines NCI-H 
929, U266, OPM2, JJN3 and ADC-1 (Figure 2.11). In addition, the arrests of cell cycle 
at S phase in U266 when treated with SAHA (Figure 2.19). These results are consistent 
with a study carried out by Fandy et al., (2005) who found out that the two HDAC 
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inhibitors SAHA and TSA induced growth arrest and apoptosis in human multiple 
myeloma cell lines and that the augmented apoptotic and cytotoxic effects of TRAIL.  
However, the cell lines used were different from this study. SAHA and TSA induced 
the transcription and the expression of surface TRAIL DR4/DR5 death receptors, up-
regulated the expression of the pro-apoptotic protein and down-regulated the expression 
of other anti-apoptotic proteins Bcl-2 and IAPs. Moreover, the cytotoxic effect of 
SAHA on MM cell lines was shown to be caspase-independent and was mediated via 
the release of AIF mitochondrial protein. In addition, SAHA induced G1 phase cell 
cycle arrest via upregulating p21WAF1 and p27Kip1 expression and by reducing E2F 
transcriptional activity (Fandy et al., 2005).  
A previous study on B-cell tumour including myeloma has shown SAHA sensitized 
MM cells to death receptor-induced apoptosis by induction in the level of p21 and p53, 
and Bid cleavage suggesting a role for Bcl-2 family protein in regulation of SAHA-
mediated apoptosis. Moreover, reduction expression of the anti-apoptotic proteins 
XIAP, flip, and cIAP2 has been reported following treatment with SAHA. However, 
SAHA alone did not activate caspase-3, -8, or -9 cleavages in multiple myeloma cell 
line (Mitsiades et al., 2003). 
Earlier work investigated the potential of combining HDACi with TRAIL in multiple 
myeloma and compared the effects of combination treatment in vitro in MM cell lines 
with efficacy in vivo preclinical screening. In vitro, cell line-based studies showed 
synergistic induction of apoptosis in MM cell lines OPM2, RPMI 8226, JJN3, and U266 
following treatment with HDACi in combination with TRAIL. In addition, the HDACi 
and TRAIL combination established dose-limiting toxicities that prohibited long term 
treatment (Matthews et al., 2013). 
More recently, co-treatment of SAHA and TRAIL have shown synergistic induction of 
apoptosis, inhibition of cell proliferation and change in cell cycle distribution in breast 
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cell cancer (Zhou et al., 2016). Moreover, combination therapy significantly induced the 
pro-apoptotic modulating molecules DR5 and caspase-3, and they also significantly 
suppressed the expression of anti-apoptotic molecules Bcl-2 (Zhou et al., 2016). 
Consistent with these findings Rosato., et al (2003) demonstrated that that co-
administration of TRAIL with HDAC inhibitors SAHA or sodium butyrate 
synergistically induces apoptosis in human myeloid leukaemia cells by cleavage of Bid 
and Bcl-2, down-regulation of XIAP, moderate reduction on Bcl-XL, depletion of pro-
apoptotic Bax as well as cytoplasmic release of cytochrome c, AIF and Smac/DIABLO. 
This provides further evidence that TRAIL/HDAC Inhibitor activate both the extrinsic 
and intrinsic pathways of apoptosis by activation of caspase-3 and -8.  Furthermore, 
SAHA treatment showed a marked increase in the percentage of the cell population 
arrested in G0/G1 in addition to the modest increase in the sub-G0 population which an 
apoptotic cells indicator. These events were accompanied by marked up-regulation of 
p21WAF1/CIP1 (Rosato et al., 2003). In other study carried by Gillenwater et al., (2007) 
demonstrated that SAHA selectively inhibited growth, induced apoptosis and cell cycle 
change in head and neck squamous carcinoma cell lines via both intrinsic and extrinsic 
apoptotic pathways. SAHA–mediated apoptosis through mitochondrial pathway via 
increase release of cytochrome c, caspase-3 and PARP cleavage in addition to activation 
of extrinsic pathways signaling via up-grade the expression both Fas and Fas ligand, 
caspase-8 activation and Bid cleavage (Gillenwater et al., 2007). Furthermore, SAHA 
induced apoptosis in colon cancer through down-regulation of anti-apoptotic survivin 
(Huang and Guo., 2006). 
This study examined the relation of SAHA and the activities of cellular caspase 3, in 
MM cell lines. It was found that HDAC inhibitors SAHA can activate caspases 3, in 
these cell lines (Figure 2.15). These earlier studies and with evidence shown in this 
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study support that the combination of SAHA and TRAIL could have promise in the cure 
of a number of tumours including MM. 
2.4.3  The G9a HMTasei BIX 01294 Restores the TRAIL Sensitivity and Inhibits 
Cell Proliferation of MM Cell Lines. 
Multiple myeloma SET domain (MMSET)/ (NSD2) is a lysine histone 
methyltransferase (HMTase) found abnormally expressed in many tumours, emerging 
as a potential target for therapeutic strategies against MM, especially t(4;14) myeloma 
subtype that is associated with a significantly poor prognosis (di Luccio., 2015). Loss of 
MMSET expression change adhesion properties, inhibits growth, and trigger apoptosis 
in myeloma cells by alter the genes involved in the regulation of apoptosis and the p53 
pathway such Bax, Bcl-2, the cell cycle such as Cyclin E2, E2F2, and CDC25A, DNA 
repair genes such as ATM and GADD45A (Martinez-Garcia et al., 2011). Unfortunately, 
clinically useful HMTase inhibitors have yet to be developed.  
BIX 01294 is a histone-tail mimetic inhibitor targeting the SET domain of G9a like 
protein HMTase and crystal structure basis of BIX 01294 illustrated that it is binding 
into the histone-tail cleft of the NSDs SET domain (Chang et al., 2009). It has been 
found that the selective inhibition of the NSDs may be achieved by small selective 
molecules targeting the histone-tail site (di Luccio., 2015). The expression of G9a is 
upregulated in various cancers type compared with normal tissue and G9a knockdown 
in cancer cell lines caused growth inhibition and apoptotic cell death with an increase in 
sub-G1 population (Shankar et al., 2013), suggesting that BIX 01294 is potential 
therapeutic agent (Kim et al., 2013; Varier and Timmers, 2011).  
In this study, BIX 01294 was found to produce significant increasing of apoptosis and 
decreasing the ATP levels in MMSET-positive cells (NCI-H929, OPM2 and ADC-1) 
(Figure 2.8 and 2.12) whereas in combination with TRAIL, BIX 01294 synergistically 
enhanced TRAIL responses on induction of apoptosis and reduction of ATP production 
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in MMSET-negative cell lines (RPMI 8226, U266 and JJN3) (Figure 2.8 and 2.12) and 
arresting cell cycle (Figure 2.20). G9a inhibitor BIX 01294 inhibits cell growth and 
apoptosis in a time-dependent manner in oral squamous cell carcinoma cell lines (Ren et 
al., 2015). Moreover, BIX 01294 inhibited the growth, induced apoptosis of bladder 
cancer cell lines and significantly decreased the cells proportion in the S-phase with 
increased in the sub-G1 phase in a dose-dependent manner (cho et al., 2011). 
Furthermore, a recent study demonstrated that BIX 01294 stimulated caspase-dependent 
apoptotic cell death in bladder cancer cells lines by up-regulated the pro-apoptotic 
protein PMAIP1 and down regulation the expression of the anti-apoptotic protein (Cui 
et al., 2015). Another study has shown that BIX 01294, a specific G9a inhibitor reduced 
proliferation of neuroblastoma cells and promotes apoptosis by activating caspase-3 and 
-8 as well as increased a doxorubicin-induced inhibitory effect on cell proliferation (Lu 
et al., 2013).  
However, the specific mechanism of the apoptosis mediated by G9a-mediated apoptosis 
in cancer cells still unclear. Lysine methylation of histone by the methyltransferase G9a 
is mostly linked to transcriptional repression. Transcriptional suppression of genes, 
including myogenin, p21, embryonic β-globin and JAK2 is dependent on G9a 
methyltransferase activity (Shankar et al., 2013). Inhibition of G9a activity with BIX 
01294 re-expressed tumour suppressor genes (Shankar et al., 2013). Moreover, G9a was 
demonstrated to be present in a complex with E2F6 and other polycomb group proteins 
on E2F responsive promoters in G0 stage so it will repress Ef2 responsive genes and 
block cell cycle progression (Ogawa et al., 2002). In gastric cancer, G9a is involved in 
repression of Runt-related transcription factor 3 (Runx3) which is inactivated in gastric 
cancer. In Runx3- expressing gastric cell, hypoxia induces the accumulation of G9a and 
H3K9me2 marks which cause silencing of Runx3 gene. G9a over-expression in gastric 
cancer cells grown under hypoxic conditions leads to further repression the expression 
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of tumour suppressor gene Runx3 (Chen et al., 2006). Furthermore, knockdown of 
histone lysine methyltransferase in breast cancer upregulated the expression of seven in 
absentia homolog (SIAH1), tumour suppressor gene which induces apoptosis by 
activation the JNK pathway and suppresses invasion by inactivating the ERK pathway 
and the apoptosis stimulation following G9a siRNA treatment was recovered by 
knockdown of SIAH1 (Cho et al., 2011). 
A recent study on osteosarcoma cells has shown that G9a inhibitor agent either alone or 
in combination with double-strand breaks (DSBs)-inducing agents phleomycin 
selectively inhibited growth, induced G2 delay and synergistically trigger apoptosis in a 
p53-independent manner without noticeably effect on non-tumourigenic cells. In 
addition, Agarwal and colleagues (2016) established that inhibition of G9a catalytic 
activity inhibits repair of double-strand breaks  and possibly another type of DNA 
damage, resulting in damage persistence and ensuing inhibited proliferation and death 
of tumour cells (Agarwal et al., 2016), potentially as a cause of increase TRAIL 
sensitivity seen here. For the first time, this study has shown that combination treatment 
of TRAIL and specific G9a inhibitor BIX 01294 in any tumour type could act in a 
synergistic manner.  
2.4.4 The EZH2 inhibitor, GSK343 Enhances TRAIL-Induced Apoptosis and 
Cytotoxicity in some Multiple Myeloma Cell Lines 
EZH2 is an epigenetic regulatory protein which transcriptional silencing the expression 
of target genes. EZH2 is the catalytic subunit of PRC2, which has been involved in 
carcinogenesis (Verma et al., 2012). EZH2 catalyzes trimethylation of lysine 27 (Lys 
27) on histone H3 (H3K27) (Popovic et al., 2014). Over-expression of EZH2 is found in 
many types of solid tumours as well as haematological malignancies (Matsukawa  et al., 
2006; Varambally et al., 2002; Croonquist and Van Ness et al., 2005; Kleer et al., 2003). 
High levels of EZH2 are correlated with cancer growth, metastasis, as well as the poor 
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outcome. A number of small molecule EZH2 inhibitors have been identified and 
demonstrated potent anti-cancer activity (Garapaty-Rao et al., 2013). However, the 
exact mechanisms of apoptosis inhibition by EZH2 still poorly understood. The 
discovery of inhibitors of epigenetic processes leads to a reversal of epigenetic silencing 
by EZH2 in cancer cells (Curry et al., 2015). 
The two HMTases, MMSET and EZH2, that have founded genetic links to oncogenesis. 
EZH2, which mediates trimethylation of histone H3K27 and is linked with gene 
silencing, was exhibited to be coordinately expressed and function upstream of 
MMSET, which stimulate histone H3K36 dimethylation and is connected with active 
transcription. In addition, oncogenic functions of EZH2 need MMSET activity. 
Together, these results suggest that the EZH2-MMSET HMTase may represent an 
attractive therapeutic target in cancer (Asangani et al., 2013). Earlier work demonstrated 
the interaction between MMSET and EZH2 in multiple myeloma oncogenesis and 
MMSET over-expression change patterns of EZH2 chromatin binding and methylation 
status. In addition, (4;14) translocated myeloma cells may be particularly sensitive to 
inhibition of EZH2 inhibitor as well as the ability of EZH2i stimulates miR126 
expression which can then directly suppress the expression of c-MYC (Popovic et al., 
2014).  However, in current work, EZH2 inhibitor induced apoptosis in multiple 
myeloma cells independently of MMSET expression.  
In this work, EZH2 inhibitor, GSK343 had diverse effects when combined with TRAIL, 
producing either synergist or additive depending on multiple myeloma lineage and the 
drug dose.  In this study, GSK343 alone potently induced apoptosis in U266, NCI-H 
929and RPMI 8226 in high dose of drugs whereas the significant synergistic effect was 
observed in OPM2, RPMI 8226, NCI-H929, U266, JJN 3, and ADC-1 and however 
effect sizes in the latter cell line was smaller only in combined dose of 15 µM GSK 343 
and 2 ng/ml TRAIL (Figure 2.9). Moreover, GSK 343 significantly reduced ATP levels 
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within JJN3 cells whereas the synergistic enhancement of proliferation inhibition was 
observed in RPMI 8226, NCI-H 929, and U266 (Figure 2.13) as well as arresting cell 
cycle (Figure 2.21). 
Knockdown of EZH2 by short hairpin RNA suppress cell growth, invasion and 
stimulate apoptosis of epithelial ovarian cancer human cells in conventional 2D cultures 
due to the decrease of H3K27Me3 level in these cells (Li et al., 2010; Lu et al., 2010). 
Selective EZH2 inhibitor GSK126, EPZ005687, and EPZ-6438 show their certain 
effectiveness in inhibiting the growth of the EZH2-mutant cells vs. wild-type EZH2 
(Wang et al., 2014). Treatment with GSK343 suppresses osteosarcoma cell viability, 
restrained cell cycle and induction of apoptosis in osteosarcoma via suppression both 
the EZH2-c-Myc and EZH2-FBP1 signal pathway, suggesting that GSK343 is a 
potential therapeutic agent for osteosarcoma therapy (Xiong et al., 2016). 
Other studies have demonstrated that histone demethylase (UTX) stimulates gene 
expression by deleting the repressive histone mark (H3K27me3), counteracting the 
EZH2 activity. Loss of UTX modifies the epigenetic MM cells landscape, resulting tin 
changed expression of a number of genes, eventually promoting cells through induced 
proliferation, clonogenicity as well as adhesion. Treatment of the paired multiple 
myeloma cell lines UTX wt and UTX -/- with the specific EZH2 inhibitor GSK343 for a 
week significantly reduced the viability of ARP-1 (UTX wild-type), without any effect 
on the ARD (UTX null indicate that EZH2 inhibition partially reverses mutation 
mediated by UTX loss and may represent a potential therapy for specific type of MM 
(Ezponda et al., 2014).  
In 2016, a recent study showed that inhibition of EZH2 by using UNC1999 and 
GSK343 decreases viability of MM cell lines in a dose- and time-dependent manner. 
Moreover, it stimulates apoptosis, cell cycle arrest and inhibits multiple myeloma 
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colony formation in vitro and apoptosis induction by UNC1999 was mediated by 
caspase-3, -8 and -9 cleavages. In addition to up-regulating the expression of Wnt and 
MAPK, and UNC1999 down-regulated the expression of a number of oncogenes 
involved in myeloma most notably CD69, JUNB and XBP1 in the INA-6 MM cell line 
(Agarwal et al., 2016). Hernando and colleagues (2016) demonstrate that EZH2 
inhibition leads to a global H3K27me3 reduction in MM cells and the EZH2 inhibitors 
treated cells become less proliferative and more adherent compared with EZH2 
inhibitors untreated cells (Hernando et al., 2016). Moreover, the depletion of EZH2 in 
inhibiting the senescent state of melanoma cells resulting in proliferation inhibition and 
restoring the cellular senescence. Furthermore, the co-treatment of both EZH2 and 
HDAC inhibitors synergistically increase the expression p21/CDKN1A via removing 
histone deacetylase 1 (HDAC1) form the transcriptional start site CDKN1A as well as 
the downstream sites (Fan et al., 2011).  
Previous work on 8 multiple myeloma cell lines NCI-H 929, MM.1S, U266, KMS18, 
KMS11, KMS12BM, OPM 2 and RPMI 8226 in a study undertaken by Xie et al., 
(2011) found that the EZH2i DZNep suppressed growth and trigger apoptosis only in 
NCI-H 929 and MM.1S MM cell lines. The anti-apoptotic Bcl-2 gene was up-regulated 
in DZNep insensitive MM cells and significant down-regulation of the arachidonate 5-
lipoxygenase (ALOX5) gene was reported in MM sensitive cells. ALOX5 has previously 
been known to have a role stimulating cancer growth and survival. Bcl-2 family 
inhibitor, ABT-737 synergistically suppressed growth and stimulated apoptosis of 
DZNep insensitive cells. These findings suggest that EZH2 inhibitor may be utilized 
therapeutically for a subset of multiple myeloma (Xie et al., 2011).  
This is the first study to link EZH2 inhibition to sensitisation of TRAIL in multiple 
myeloma. Only one previous work reported that EZH2 inhibitor, DZNep displayed 
large decrease in cell counts but no changes in apoptosis in colon cancer cells compared 
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to untreated cells, however, more than ten-fold increase in apoptosis was observed in 
colon cancer cells when these cells were challenged with combined DZNep and TRAIL 
therapy (Benoit et al., 2013). In addition, DZNep induced transcript levels of DR5 and 
this was adequate to sensitize colon cancer cells to TRAIL-mediated apoptosis (Benoit 
et al., 2013). Taken together, these results provide evidence that EZH2 inhibitors are a 
potential epigenetic target therapy and may senstitze MM to TRAIL-mediated apoptosis. 
2.4.5 Prolonged Incubation of TRAIL Sensitive Multiple Myeloma Cells with 
TRAIL Reduced their Anti-Tumour Sensitivity  
The anti-tumour potential of TRAIL either alone or in combination has been established 
in various in vivo models of tumour growth (Deleu et al., 2009; Doi et al 2011; Herbst 
et al., 2010; Von Pawel et al., 2014). The hypothesis that TRAILR cells might be 
resistant to all forms of apoptosis, and that sensitization to TRAIL responses would be 
lost in TRAIL resistant cells vs. parental cells was tested. Interestingly TRAILR cells 
were sensitive to BIX 01294 and LMB disproving that they were generally insensitive 
to apoptosis (Figure 2.26 and 2.28). 
Myeloma patient treatment usually involves the administration of chemotherapeutic 
drugs regularly for weeks or months and the initial treatment is usually successfully in 
that it reduces the tumour burden, but, after a period of time, the disease relapses; this is 
often the result of the appearance of a more resistant disease, which is increasingly more 
difficult to treat (Vitovski et al., 2012). In the current study, TRAIL sensitive cells 
(NCI-H 929 or RPMI 8226) were either treated with a low dose TRAIL for 1 year or 
high/lethal doses of TRAIL for 6 months. The surviving cells lost their TRAIL 
sensitivity and become more TRAIL resistances (Figure 2.23 and 2.24). Theremore 
these TRAILR cell lines were no longer sensitized by SAHA and GSK343 (Figure 2.27 
and 2.29). Consistent with these observations, Vitovski et al., (2012) demonstrated that 
the prolonged incubation with TRAIL in myeloma cells results in the emergence of 
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TRAIL-resistant CD138 cells and reduce the cell toxicity in TRAIL resistant cells 
compared to the parental, TRAIL-sensitive culture using MTS assay. However, 
responses to LMB (Figure 2.26) and BIX 01294 alone (Figure 2.28) were increased in 
TRAIL resistant cells whilst reduced in response to SAHA (Figure 2.27) and GSK343 
(Figure 2.29) in TRAILR population. This suggests that selection for TRAILR phenotype 
may have unpredictable effects on responses to other anti-tumour agents, but not 
necessarily inhibiting apoptosis. 
2.5 Conclusion 
This study has shown that TRAIL significantly induced apoptosis in a dose-dependent 
manner in multiple myeloma cell line. Moreover, anti-tumour agents LMB, SAHA, BIX 
01294 and GSK343 synergistically inducing apoptosis with TRAIL in multiple 
myeloma cell lines, and the synergy effect of TRAIL and anti-tumour agents varied in 
multiple myeloma cells lines depending on drug concentration. For the first time, this 
study has shown that combination treatment of TRAIL and NEI (LMB), HMTasei, (BIX 
01294 or EZH2i (GSK343)) in multiple myeloma could act in a synergistic manner with 
TRAIL. The combination effect of these anti-tumour agents with TRAIL on induction 
of apoptosis, reduction of ATP level and cell cycle arrest indicate that using these 
agents could be useful in improving myeloma therapy. Importantly, these findings 
suggest that these anti-tumour agents may potentially enhance the action of TRAIL and 
the combined treatment could possibly result in reduction of the treatment doses, 
avoiding toxicity and using as a novel anti-cancer agent for multiple myeloma. 
Moreover, TRAIL sensitive cells (NCI-H 929, RPMI 8226) become more TRAIL 
resistant with incubation with TRAIL. However, the response of these TRAIL resistant 
cells demonstrated difference response with anti-tumour agents either alone or in 
combination with TRAIL suggests that selection for TRAIL resistant phenotype may 
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have unpredictable effects on responses to other anti-tumour agents, but not necessarily 
inhibiting apoptosis.  
These observations are limited to cells grow in suspension and massive response to 
drugs and TRAIL on the bulk population. These results do not indicate what might 
happen in the solid bone lesion or address fully whether all cells are killed or whether a 
cancer stem cell-like population might survival therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 127 
 
 
 
 
 
 
 
 
3. Comparison of TRAIL Sensitizers in 
Combination with   TRAIL Responses in 
Suspension vs. 3D Cell Culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128 
 
3.1 Introduction 
The study of commonly used two-dimensional (2D) and suspension in vitro models 
examining tumour progression and therapy has come under criticism, particularly in 
relation to the cancer stem cells hypothesis (Ricci-Vitiani et al., 2007). This is mostly 
due to the different behavior of cells when located in in vivo animal models. In 2D and 
suspension cell culture, cancer cells cannot correctly represent the function or structure 
of a physiological activity as compared with in vivo tumour condition (Friedrich et al., 
2007). For instance, 2D culture cells exhibit uniform growth in most types of cells at the 
same stage of the cell cycle, and they do not have the phenotypic heterogeneity in terms 
of cell differentiation and gene expression in tumours (Marjanovic et al 2013; Meacham 
and Morrison., 2013).  
In vivo, the cells live in three-dimensional (3D) environments consisting of fibrous 
networks of extracellular matrix (ECM) that delivers physical and chemical signals to 
the living cells. In order to understand the cell behavior, it is helpful to study the cell in 
3D microenvironment; however, it is challenging to mimic the 3D environments in vitro 
(Chen et al 2016). Recently, numerous attempts have been made to produce a 3D cell 
culture system including free scaffolds for spheroid formation (Burdett et al., 2010; 
Tung et al., 2011), bioreactors (Rauh et al., 2011), gels (Justice et al., 2009) and 
microfluidic chips (Baker, 2011; Huh et al., 2011). The development of 3D culture 
model has many advantages; it has the potential to decrease animal testing, increases 
data prediction, and decreases the time and cost required in order to recognize novel 
candidate agents (Wang et al., 2016). 
Among the culture model is the alginate bead culture which is a naturally derived 3D 
model that relies on multi-cellular tumour spheroid formation. Spheroids models are 
formed from a number of normal as well as cancer cell lines and used to investigate the 
efficiency of anti-tumour agents and cell interaction (Wang et al., 2016). A significant 
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advantage of this 3D culture system is that the spheroid within the alginate beads can be 
successfully isolated for further analysis by dissolving the matrix.  Also, assay is clonal 
and each colony derived from a single cell, studies on clonal response are difficult in 
suspension. These properties make the alginate bead culture system an efficient and 
convenient culture system for either cell or tissue culture in vitro (Xu et al., 2014). 
Although some studies illustrated that some therapeutic agents are more effective in 2D 
culture models (Mueller-Klieser., 1997; Friedrich et al., 2007), others demonstrated the 
superior activity of anti-tumour agents in the 3D cell culture models (Wang et al., 
2016). Therefore, growing cells in spheroid such as the alginate bead is an efficient 
culture system that provides a promising alternative to the use of the monolayer systems 
or suspension systems for haematological cancers (Friedrich et al., 2007). 
The development of experimental tools to facilitate the study of myeloma cell biology 
and susceptibility to the therapeutic agents is considerably limited due to the lack of in 
vitro model systems that permits myeloma cells reproducible growth as well as the 
putative cancer stem cell compartment. Multiple myeloma grow as suspension cells, and 
3D cell culture may be used as a model of soft mass disseminated MM lesions that form 
in bone. The development of 3D model systems has recently been proposed to support 
in vitro myeloma cells expansion, facilitating modeling of in vivo responses, including 
the CD138−Ve myeloma cancer stem cells and offers a physiologically relevant platform 
on which analyse susceptibility of myeloma cells to various classes of therapeutic 
agents (Jelinek., 2008).  
3.1.1 Hypothesis 
The current investigation has focused on the hypothesis that multiple myeloma cells 
were more sensitive to TRAIL sensitizers in a 3D alginate model than in suspension. 
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3.1.2 Aims  
The aim of this study was to develop a 3D model of multiple myeloma cell lines, asses 
TRAIL response in 3D vs. suspension and finally asses TRAIL responses in presence 
and absence of TRAIL sensitizers in 3D vs. suspension. 
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3.2 Materials and Methods 
3.2.1 Experimental Design 
Six multiple myeloma cell lines were used for this study: OPM2, RPMI 8226, NCI-
H929 and ADC-1 which were previously shown to have high sensitivity to TRAIL 
treatment and U266 and JJN3 that were the most resistant multiple myeloma cells to 
TRAIL (Chapter 2). In addition to TRAILR cells (Chapter 2). Myeloma cells cultured as 
previously described (Chapter 2; Section 2.2.2 and 2.2.3) and incubated in humidified 
incubator at 37°C. Multiple myeloma cells were seeded into alginate culture in order to 
establish 3D growth. Colony formation within the alginate beads was assessed by 
Hoechst 33342 fluorescence microscope and Haematoxylin and Eosin staining of 
histological slides using an inverted microscope. Myeloma cells within the alginate 
were treated with the lowest doses of TRAIL +/- sensitizers which have previously been 
shown to synergistically enhanced apoptosis (as determined by Hoechst 33342/PI 
staining in suspension culture in Chapter 2). 
3.2.2 Alginate Bead Culture Model 
Alginate beads as a 3D culture models originally established as a model for studying the 
behavior of chondrocyte cell (Hauselmann et al., 1992).  This 3D model based on the 
properties of alginic acid derived from brown seaweed, which produces a viscous 
solution or a gel that able to polymerize in the presence of calcium or any divalent 
cations.  These properties of alginate aid the integration of isolated cells proceeding to 
polymerisation as well as the formation of semi-solid support post-polymerisation. 
Moreover, the alginate gel can be dissolved by the addition of a chelating agent; 
allowing separation of cells from a large tightly cell aggregates to produce individual 
live cells that can be analysed (Hauselmann et al., 1994; Bonaventure et al., 1994; 
Lemare et al., 1998). 
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3.2.2.1 Induction of 3D Tumour Spheroid Formation using Alginate Bead Culture 
Multiple myeloma cells were routinely sub-cultured as described in Chapter 2. To 
establish 3D alginate cultures, myeloma cells at a density of 1x106 cells/ml were re-
suspended in 1.2% (w/v) medium-viscosity sodium alginate in saline (Sigma). The 
alginate beads were then dropped through a 19-gauge needle into 200 mM CaCl2 and 
incubated at 37°C for 15 minutes to polymerise. Following incubation, beads
 
were 
washed twice with 0.15 M NaCl, and then washed in the media before the beads left in 
the media in the incubator to form spheroids. Alginate cultures were maintained for 10-
14 days and the culture medium was changed twice a week (Le Maitre et al., 2005). 
Each 1ml of 1x106 cells alginate suspension was generate approximately 40 
polymerized beads and each bead contained an average of 2.5x104 cells/bead. 
3.2.3 Treatment of Multiple Myeloma cells in Alginate Beads with TRAIl+/-
TRAIL Sensitisers 
After 10-14 days in culture, cells were treated with TRAIL +/- TRAIL sensitizer as 
described in Chapter 2, using the lowest combination treatment doses that produced 
synergistically enhanced apoptosis in suspension. Cells were stained with Hoechst 
33342/PI after 24 h as described earlier (Chapter 2). 
3.2.4 Assessment of Spheroid Formation 
3.2.4.1 Fluorescence Microscopy using Hoechst 33342 and Propidium Iodide (PI) 
Staining 
In order to assess the colony formation in the alginate beads, beads were imaged every 
two or three days. Intact alginate beads containing Multiple myeloma cells were 
dissolved in Eppendorf tube containing 500 µl of alginate dissolving buffer (55 mM 
sodium citrate (Sigma), 30 mM EDITA (Fisher), 0.15M NaCl (Fisher) at pH 6) and 
incubated rotating for 10-15 minutes prior to centrifugation at 600g for 5 minutes. 
Following centrifugation, the spheroid/cell pellet of dissolved alginate beads was 
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carefully re-suspended in media and transferred into 96 well plates. Hoechst 33342/PI 
stain (10 µg/ml) was added to both dissolved and un-dissolved beads. The latter to 
assess apoptosis of colonies in situ. Viability and morphological analyses of spheroids 
formation were carried out on IX81 fluorescence microscope (Olympus) using Hoechst 
33342/PI staining and spheroid diameters were determined from images taken. 
3.2.4.2 Histology of Cells in 3D Culture 
Alginate beads cultured for 10-14 days were fixed by immersion in 4% formaldehyde 
for 20 minutes at 4°C and then kept in 80% ethanol (v/v) in cold room. Following 
fixation, samples were processed into paraffin wax by using a Shandon Elliott Duplex 
Processor in an automated procedure of dehydration by immersion in IMS (Industrial 
Methylated Spirit, Fisher Scientific) followed by clearing in sub-X (Xylene Subsitute, 
Leica) and embedded in paraffin wax before transferred to vacuum oven (Jeio Tech 
OV-11) and incubated for 1 hour at 60°C and 60 cm Hg. Following incubation, cultured 
samples were oriented into moulds having molten wax and form a tissue block after 
cooling.  Finally, tissue blocks removed from mould and kept at room temperature and 
are ready to use for histological sectioning and staining with Haematoxylin and Eosin 
staining (H&E). 
For sectioning, tissue blocks were cut at 4 μm thickness by using a Leica SM2400 
sledge microtome and placed on the surface of a 45°C water path prior to mount on 
glass slides (positively adhesive slide, Leica). Slides were then incubated on a 40 °C 
drying rack for 30 minutes in order to dry the excess of water from the section slide. 
Mounted section was kept at 37°C in a desiccating oven until use. 
To prepare the slide for staining, section slide was de-waxed with sub-wax for 5 
minutes three times prior to rehydrating in ethanol for 5 minutes, three times for each 
respective ethanol concentration. Sample was stained with filtered Mayer's Hematoxylin 
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for 5 minutes followed by rinsing with running tap water before stained with Eosin Y 
(Leica) for 1 minute. After staining, slides were dehydrated and clearing by immersion 
in ethanol and sub-X in triplicate respectively and mounted by Pertex mountant (Leica).  
Morphological analyses of spheroids were carried out an Olympus BX60 Microscope 
and optical images were taken using Q-capture III camera and Q-capture 6 software (Q-
imaging-inc). 
3.2.5 Statistical Analysis 
Data are expressed as the median with range. Shapiro Wilke test using Stats Direct 
software (Stats Direct Ltd, England) was used for analysis whether data followed a 
normal distribution. Data which did not follow a normal distribution, Kruskal–Wallis 
and Connover-Inman post hoc was using to investigate significant differences.  p< 0.05 
was considered statistically signiﬁcant.  
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3.3 Results 
3.3.1 Multiple Myeloma Cells Formed Multicellular Spheroids 
Five out of 6 tested Multiple myeloma cell lines namely OPM2, RPMI 8226, NCIH 
929, U266 and JJN3 aggregated and had the ability to form multicellular spheroids 
structures within 10-14 days. In contrast, ADC-1 cell line form few loosely aggregated 
cells, when beads were dissolved hardly any intact spheroids were observed. However, 
TRAILR cells did not grow in 3D. Over the course of 10-14 days, the cells proliferated 
within the alginate beads and the average volume of cell spheroids increased as the 
culture day expands and the number of cell spheroids increased dramatically.  Spheroid 
colonies range from small colonies of 2-3 cells to approximately 100 cells per spheroid 
by day 10-14 (Figure 3.1 and 3.2). After being seeded with the same number of cells, 
NCI-H 929, RPMI 8226 cells grew faster than U266 and JJN3 cells after Day 2 and 
maintained long term viability up to Day 14, while OPM2 cells reached a plateau after 
Day 10.  In addition, single spheroids of approximately 100-250 μm in diameter were 
obtained from multiple myeloma cell lines after two weeks. An example of the 3D 
spheroid formation of alginate beads in situ for NCI-H 929 Multiple myeloma cell lines 
within 10-14 days is shown in Figure 3.2. Representative microscopic images of 
hematoxylin/eosin (H&E)–stained 4μm paraffin median sections of NCI-H 929 alginate 
beads which contain a number of spheroids is shown in Figure 3.3.  
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Figure 3.1: 3D colony formation of multiple myeloma cell lines at day 10 
 
Figure 3.1: 3D colony formation of multiple myeloma cell lines at day 10.  RPMI 
8226, NCI-H 929, OPM2, U266, and JJN3 multiple myeloma cells proliferated within 
the alginate beads and form spheroid while ADC-1 cell line did not reliably form 3D 
colonies.  
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Figure 3.2: Time dependence formation of the spheroids within alginate beads in 
situ in NCI-H 929 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Time dependence formation of the spheroids within alginate beads in 
NCI-H 929 cells.  a) Multiple myeloma cells had the ability to form 3D spheroids and 
the average volume of cell spheroids increased as the culture day expands. On day 2 
small colonies of 2-3 cells could see and over course of 10 -14 days, cells proliferated 
within the alginate beads to form large spheroid colonies. 
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Figure 3.3: H&E staining of NCI-H 929 cell spheroids cultured in alginate beads 
on Day 14. 
 
 
Figure 3.3: H&E staining of NCI-H 929 cell spheroids cultured in alginate beads on 
Day 14.  
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3.3.2 Effect of TRAIL Sensitizers in Combination with TRAIL on Apoptosis in 
Multiple Myeloma Cells Lines in 3D Alginate Cell Culture Model vs. 
Suspension Cell Culture 
3.3.2.1 Effect of LMB in Combination with TRAIL on Apoptosis in Myeloma Cells 
Lines in 3D Alginate Cell Culture Model vs. Suspension Cell Culture 
The effect of LMB on TRAIL-induced apoptosis in 3D cell culture vs.  Suspension 
culture was studied using Hoechst 33342 staining of nuclear morphology. Multiple 
myeloma cells lines were treated with the lowest combination treatment doses which 
synergistically enhanced apoptosis in suspension as determined by Hoechst 33342/PI 
staining after 24 hours of treatment. MM cells were more sensitive to LMB in 3D 
culture conditions compared to suspension cultures and there was a significant increase 
in TRAIL-induced apoptosis by LMB treatment in NCI-H929, RPMI 8226, JJN3 and 
U266 cell lines (p<0.05) (Figure 3.4 a). In TRAIL-sensitive cell line NCI-H 929, an 
apoptotic response of 16.5±4.6% and 54.2±14.5 % was measured following treatment 
with low dose of LMB (1nM) for 24 h in suspension and 3D cultures respectively. 
Whereas, the apoptotic response for combined dose of 0.5 nM LMB and 2 ng/ml 
TRAIL was 37.5±0.5% in suspension cultures and 99.6±0.5% when cells were grown as 
a 3D culture model (p<0.05) (Figure 3.4 b). An example of NCI-H 929 cells on 
suspension and on 3D alginate culture model treated with LMB alone and in combined 
with TRAIL is shown in Figure 3.4 b.  
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Figure 3.4: Effect of LMB+/- TRAIL on apoptosis of multiple myeloma cell lines in 
suspension vs. 3D culture conditions. 
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b)                                                          
 
 
 
 
 
 
Figure 3.4: a) Effect of LMB+/- TRAIL on apoptosis of multiple myeloma cell lines in suspension vs. 3D culture conditions. Myeloma cells were 
treated with LMB+/- TRAIL determined by Hoechst 33342 and PI staining for 24 h. Multiple myeloma cells were more sensitive to a low dose of 
LMB in 3D based alginate culture compared to suspension culture and synergistic response of LMB and TRAIL in multiple myeloma cell lines was 
potentiated in 3D cell culture. Data is expressed as median with range (three independent experiments, each in triplicate). p< 0.05 was considered 
statistically signiﬁcant comparing to control. The synergistic response was defined as a comparison of combination treatment group with the sum of 
the effects of TRAIL alone +  LMB alone and significance determined by using by the Kruskal–Wallis test (p< 0.05). b) An example of NCI-H 929 cells 
in suspension and on 3D alginate culture model treated with Nuclear Export Inhibor (LMB) alone and in combined with TRAIL.
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3.3.2.2 Effect of SAHA in Combination with TRAIL on Apoptosis in Multiple 
Myeloma Cells Lines in 3D Alginate Cell Culture Model vs. Standard Cell 
Culture 
The effect of SAHA on TRAIL-induced apoptosis in 3D cell culture vs. suspension 
culture was studied using Hoechst 33342 staining of nuclear morphology. TRAIL-
sensitive cells NCI-H 929 and TRAIL insensitive cells U266 multiple myeloma cells 
line were treated with 1 μM SAHA or 0.1% DMSO vehicle control either alone or in 
combination with TRAIL for 24 h. The data illustrated in Figure 3.5 demonstrated that 
there was a significant increase in apoptosis in responce to SAHA and TRAIL 
individually in NCI-H 929, and a significant increase in apoptotic response to 
combination therapy in suspension culture (p<0.05) (Figure 3.5). NCI-H 929 cell lines 
were significantly more sensitive to TRAIL, SAHA and combination therapy in 3D vs. 
suspension (p<0.05) (Figure 3.4). Furthermore, TRAIL insensitive cells U266 were 
significantly more sensitive to TRAIL and combination therapy, but not SAHA in 3D 
culture (p<0.05) (Figure 3.5). An example of the 3D spheroid of morphological 
assessment of apoptosis following SAHA treatment alone and in combined with TRAIL 
on MM cells in situ in alginate beads of NCI-H 929 MM cell lines is shown in Figure 
3.5 b 
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Figure 3.5: Effect of SAHA+/-TRAIL on apoptosis of multiple myeloma cell lines 
in suspension vs. 3D culture conditions. 
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b) 
 
Figure 3.5: a) Effect of SAHA+/-TRAIL on apoptosis of multiple myeloma cell lines 
in suspension vs. 3D culture conditions. Myeloma cells were treated with SAHA+ /-
TRAIL determined by Hoechst 33342 and PI staining for 24 h. MM cells were more 
sensitive to SAHA in 3D based alginate culture compared to suspension culture and 
synergistic response of SAHA and TRAIL in multiple myeloma cell lines was potentiated 
in 3D cell culture. Data is expressed as median with range (three independent 
experiments, each in triplicate). p< 0.05 was considered statistically signiﬁcant 
comparing to control. b) An example of NCI-H 929 cells on suspension and in 3D 
alginate culture model treated with SAHA alone and in combined with TRAIL.  
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3.3.2.3 Effect of BIX 01294 in Combination with TRAIL on Apoptosis in Multiple 
Myeloma Cells Lines in 3D Alginate Cell Culture Model vs. Standard Cell 
Culture 
TRAIL-sensitive cells NCI-H 929 and TRAIL insensitive cells U266 multiple myeloma 
cells line were treated with BIX 01294 either alone or in combination with TRAIL for 
24 hours. Multiple myeloma cells were more sensitive to BIX 01294 in 3D culture 
conditions compared to suspension cultures and there was a significant increase in 
TRAIL-induced apoptosis by BIX 01294 treatment in U266 and NCI-H929 cell lines 
(p<0.05) (Figure 3.6). At the dose of drugs used, there was a significant increase in 
apoptosis in TRAIL-sensitive cell lines NCI-H 929 in response to TRAIL, BIXI 01294 
alone and combination therapy with TRAIL in suspension cultures (p<0.05) (Figure 
3.6). NCI-H 929 cell lines were significantly more sensitive to TRAIL, BIX 01294 and 
combination therapy in 3D vs. suspension (p<0.05) (Figure 3.4). Furthermore, TRAIL 
resistant cells U266 were significantly more sensitive to BIX 01294, TRAIL and 
combination therapy in 3D culture (p<0.05) (Figure 3.4). An example of the 3D 
spheroid of morphological assessment of apoptosis following BIX 01294 treatment 
alone and in combined with TRAIL on MM cells in situ in alginate beads of NCI-H 929 
MM cell lines is shown in Figure 3.6 b. 
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Figure 3.6: Effect of BIX 01294+/-TRAIL on apoptosis of multiple myeloma cell 
lines in suspension vs. 3D culture conditions 
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b) 
 
Figure 3.6: a) Effect of BIX 01294+/-TRAIL on apoptosis of multiple myeloma cell 
lines in 2D vs. 3D culture conditions. Myeloma cells were treated with BIX 01294+ /- 
TRAIL determined by Hoechst 33342 and PI staining for 24 h. multiple myeloma cells 
were more sensitive to BIX 01294 in 3D based alginate culture compared to suspension 
culture and synergistic response of BIX 01294 and TRAIL in MM cell lines was 
potentiated in 3D cell culture. The data is expressed as median with range (three 
independent experiments, each in triplicate). p< 0.05 was considered statistically 
signiﬁcant comparing to control. b) An example of NCI-H 929 cells on suspension and 
in3D alginate culture model treated with GSK343 alone and in combined with TRAIL.  
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3.3.2.4 Effect of GSK343 in Combination with TRAIL on Apoptosis in Multiple 
Myeloma Cells Lines in 3D Alginate Cell Culture Model vs. Standard Cell 
Culture 
3D cultures of TRAIL sensitive cells NCI-H 929 and TRAIL insensitive cells U266 
multiple myeloma were subjected to treated with the EZH2i   GSK343 treatment either 
alone or in combination with TRAIL for 24 hours. Myeloma cells were more sensitive 
to GSK343 in 3D culture conditions compared to suspension cultures and there was a 
significant increase in TRAIL-induced apoptosis by GSK343 treatment in multiple 
myeloma cell lines (p<0.05) (Figure 3.7). The data shows that at the dose of GSK343 
used, there was no significant increase in apoptosis in U266 cell lines, but a significant 
increase in response to TRAIL and in combination therapy in suspension culture 
(p<0.05) (Figure 3.7). Both NCI-H 929 and U266 cell lines were significantly more 
sensitive to TRAIL, GSK343 and combination therapy in 3D vs. suspension (p<0.05) 
(Figure 3.7). An example of the 3D spheroid of morphological assessment of apoptosis 
following GSK343 treatment alone and in combined with TRAIL on multiple myeloma 
cells in situ in alginate beads of NCI-H 929 cell lines is showed in Figure 3.7 b. 
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Figure 3.7: Effect of GSK343+/-TRAIL on apoptosis of MM cell lines in suspension 
vs. 3D culture conditions. 
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b) 
 
Figure 3.7: a) Effect of GSK343+/-TRAIL on apoptosis of multiple myeloma cell lines 
in suspension vs. 3D culture conditions. Myeloma cells were treated with GSK343+ /-
TRAIL determined by Hoechst 33342 and PI staining for  24 h. MM cells were more 
sensitive to GSK343 in 3D based alginate culture compared to suspension culture and 
synergistic response of GSK343 and TRAIL in multiple myeloma cell lines was 
potentiated in 3D cell culture. The data is expressed as median with range (three 
independent experiments, each in triplicate). p< 0.05 was considered statistically 
signiﬁcant comparing to control. b) An example of the 3D spheroid of morphological 
assessment of apoptosis following GSK343 treatment alone and in combined with 
TRAIL on alginate beads of NCI-H 929 cell lines. 
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3.4 Discussion 
Micro-environmental conditions control tumorigenesis and biomimetic culture systems 
that allow for in vitro and in vivo tumour modeling may greatly aid studies of cancer 
cells' dependency on these conditions (Fischbach et al., 2007). Numerous attempts have 
efficaciously led to develop effective culture systems.  In this study, alginate gel bead- 
3D tumour models were selected due to their ability to have representative features of 
the tumour microenviroment; this system was directly compared to the routine 
suspension culture. The data presented in this study showed that significantly higher 
sensitivity of cell spheroids in 3D alginate gel beads as the growth in a 3D alginate 
culture model sensitizes human myeloma cells to LMB, SAHA, BIX 01294 and 
GSK343+/-TRAIL to induce apoptosis with potent effect with TRAIL in comparing to 
suspension cultures.   
3.4.1 Multiple Myeloma Cell Line Developed Three-Dimensional Culture In Vitro 
Several models have been established to generate the 3D system recapitulating the 
specified characteristics of multiple myeloma microenvironment. These models 
included hydrogel systems such as collagen (Niemeyer et al., 2004; Yang et al., 2004), 
Matrigel (Kirshner et al., 2008), or synthetic polymers (Calimeri et al., 2011) or and 
specialized scaffolds like gelatin sponge collagen (Zdzisinska et al., 2009) or silk 
(Reagan et al., 2014); micro fluidic ossiffed tissues (Zhang et al., 2014; de la Puente et 
al., 2015) as well as bioreactor-based cultures. In addition to in vitro models, 3D in vivo 
models use fetal bone chips implanted in SCID mice; this required growth of the fetal 
bones in the mouse following by injected of myeloma cells into the bone (Urashima et 
al., 1997) as well as in vivo xenograft models of human myeloma cells in SCID mice. 
However, each has its own limitations (de la Puente et al., 2015). Here in this study, 
five out of six investigated multiple myeloma cell lines namely OPM2, RPMI 8226, 
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NCIH 929, U266 and JJN3 had the ability to form multicellular spheroids structures, 
while ADC-1 MM cell line form few loosely aggregated cells (Figure 3.1, 3.2 and 3.3). 
However, TRAILR cells did not grow in 3D. 
3.4.2 TRAIL Sensitizers Induce More Apoptosis of Multiple Myeloma Cells in 3D 
Culture Conditions 
Here, it was demonstrated for the first time that growing of human multiple myeloma 
cell in 3D alginate culture model significantly induced apoptosis in response to the anti-
tumour agents Nuclear Export Inhibitor (LMB) (Figure 3.4), Histone Deacetylase 
inhibitor (HDAC) SAHA (Figure 3.5), or inhibitors of the histone methyltransferases 
G9a and EZH2 (BIX 01294 and GSK343) alone (Figure 3.6 and 3.7). These anti-tumour 
agents enhance TRAIL-induced apoptosis with potent synergistic effect in 3D cell 
culture and show more potent responses than suspension.  
Recently, inconsistent responses were observed in studies conducted by de la Puente et 
al., (2015); they found that culturing of multiple myeloma cells in 3D tissue engineered 
bone marrow cultures (3DTEBM) facilitate proliferation of myeloma cells and induced 
drug resistance to myeloma therapy, including bortezomib and carfilzomib more than 
classic 2D mono-culture. Moreover, 3DTEBM cultures up-regulated cytokine secretion 
in the multiple myeloma environment, including pro-angiogenic molecules (VEGF, IL-
8 and OPN) and pro-inflammatory cytokines (IL-1α, IL-6, TNF-α, and IL-8). In 
addition to recreating of the hypoxic microenvironment in the 3DTEBM culture which 
was confirmed by induced HIF1α and PIM hypoxia markers associated with reduced of 
CD138 expression and induced expression of CXCR4 in the 3D cultures (de la Puente 
et al., 2015). Co-culture of patient-derived bone marrow mononuclear cells with 
mesenchymal stem cells in 3D model system in previous work induced cell 
proliferation, expression of C-X-C chemokine receptor type 4 (CXCR4) as well as 
reduced the sensitivity of myeloma cells to therapeutic agents (doxorubicin, 
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dexamethasone, melphalan, IMiDs, bortezomib, carlzomib) compared with 2D culture 
(Jakubikova et al., 2016). 
In another study, Chandrasekaran et al., 2014 demonstrated that cultured of the breast 
cancer cell lines as 3D tumour spheroids in vitro showed more TRAIL-resistant by 
reduced expression of death receptors DR4 and DR5 that initiate TRAIL-mediated 
apoptosis in comparison to cell cultured as traditional monolayer cells. In addition, 3D 
tumour spheroids are enriched with breast stem cell marker CD44HiCD24loALDH1Hi 
cells. Furthermore, Chandrasekaran and colleagues attributed the reduced sensitivity to 
TRAIL and cancer stem cell phenotype seen in 3D tumour spheroids to the upregulation 
of expression of cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway. COX-2 
is involved in the synthesis of the lipid signaling molecules named prostaglandins and 
has a role in cancer progression. COX-2 is one of the significant downstream targets of 
hypoxia inducible factors HIF-1a and HIF-1b and COX-2 knockdown sensitizes breast 
cell line to TRAIL-induced apoptosis (Chandrasekaran et al., 2014).  
The epigenetic modifier EZH2 play an important role in the control of gene expression 
via histone hypermethylation. Over-expression of EZH2 is found in several cancer types 
and involved in disease progression by silencing tumour suppressor genes. EZH2 
inhibitor, GSK126 in a study conducted by Tiffen et al., (2015) inhibited the growth, 
cell cycle arrest at G2/M phase in both 2D and 3D culture melanoma cells. In addition, 
EZH2 inhibitor leads to reactivate of some characterized tumour suppressor genes such 
as stress induced gene activating transcription factor 3 (ATF3) which induced apoptosis 
and decreased metastatic potential (Tiffen et al., 2015). 
The results from the current study are consistent with a study carried out by Amatangelo 
et al., (2013) that showed that EZH2 methyltransferase Inhibitors GSK343 significantly 
inhibited the growth and induces apoptosis of epithelial ovarian cancer cells cultured in 
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3D matrigel extracellular matrix, which more closely mimics the tumour 
microenvironment in vivo but not standard 2D culture model. These results propose that 
anti-cancer agents which display little effectiveness in conventional 2D or suspension 
culture models may still have therapeutic value within the solid ECM tumour 
microenvironment (Amatangelo et al., 2013).   
In addition, suspension culture does not allow for clonal responses to be seen. In this 
investigation, multiple myeloma colonies could have variable responses to therapy, 
where some colonies were significantly affected by treatment, whereas other remained 
viable. A study carried by Cross et al., (2008) hypothesized that OPG mediated TRAIL 
resistant in PC3 cell lines was due natural distinction through acquired heterogeneity 
within sub-cloned cancer population, as only certain colonies originated from the 
similar cloned cells, where affected by TRAIL treatment whereas neighboring colonies 
appeared unaffected. In addition, a wide range of TRAIL response in individual 
colonies was observed in TRAIL-sensitive breast cancer cell line (Cross et al., 2008). 
This emphasizing the phenotypic variation of drugs sensitivity within heterogeneous 
cell lines. 
The intracellular mechanisms of how these anti-tumour agents-induced apoptosis in 3D 
cultures are not entirely understood, although may relate to hypoxia and production of 
reactive oxygen species (ROS), glucose depletion and growth factor withdrawal that are 
TRAIL sensitizers. ROS has been reported to be involved in many biological processes, 
including programmed cell death or apoptosis (Buttke and Sandstrom., 1994; Jones et 
al., 2000). Accumulation of intercellular ROS resultant in disruption of the 
mitochondrial membrane potential, the release of pro-apoptotic protein cytochrome c 
into cytosol with subsequent stimulation of the caspase signals, and ultimately promotes 
apoptotic cell death (Woo et al., 2003). TRAIL has been reported to stimulate ROS 
generation in tumour cells (Mellier and Pervaiz., 2012).  In previous work, exposure to 
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TRAIL induces ROS generation and activation of p38 MAP kinase, and that 
subsequently activation of caspases and induce apoptosis in adenocarcinoma HeLa cells 
(Lee et al., 2002).  In addition, a number of anti-tumour agents sensitize TRAIL-
induced apoptosis through generation of ROS in various tumour types (Chen et al., 
2008; Kim et al., 2006; Lee et al., 2009). 
The effects of hypoxia environment on TRAIL-induced apoptosis remain to date 
controversial (Ehrenschwender et al., 2016) and there is a little information available on 
the apoptogenic activity of TRAIL in hypoxic conditions. Earlier work demonstrated 
that hypoxia induces a phenotype highly sensitive to apoptogenic effect of TRAIL in a 
number of cancer cell lines and hypoxia enhance TRAIL-induced apoptosis by the 
down-modulation of c-flip expression or by the increased expression of TRAIL-R2. In 
addition, the sensitive of cancer cell line to TRAIL under hypoxic environment is 
correlated with down-modulation of the epsilon isoform of protein kinase C (PKC) 
expression (Gobbi et al., 2010). PKC has an anti-apoptotic activity, preventing glioma 
cell lines from undergoing apoptosis (Okhrimenko et al., 2005). 
However, a low oxygen environment inhibits TRAIL-induced tumour cell death in oral 
squamous cell carcinoma cells by blocking the translocation of lysosomal cathepsin to 
the cytosol (Nagaraj et al., 2007). Recently, growth of colorectal cancer cells under 
hypoxic condition induced TRAIL-resistance. Combinatorial therapy approaches of 
TRAIL with SMAC mimetics or XIAP-targeting drugs might constitute a reasonable 
therapeutic approach and overcome hypoxia-mediated cell death resistance 
(Ehrenschwender et al., 2016).  
Metabolic stress by nutrient deprivation occurs commonly in cancer as well as normal 
tissues and triggers many potential cell death-inducing pathways (Iurlaro et al., 2017). 
Glucose depletion sensitizes tumour cells to death receptor-mediated apoptotic cell 
death via enhancement of DISC formation and caspase-8 activation (Munoz-Pinedo et 
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al., 2003). Glycolysis inhibition enhanced death receptor-induced apoptosis in a number 
of human tumour cell lines including Jurkat, HeLa, and U937 by Mcl-1 down-
expression (Pradelli et al., 2010). Suggesting that glucose depletion in cells grow in 3D 
cultures enhance sensitivity of cancer cells to anti-tumour agents 
3.4.3 3D Culture Enhancing Stem Cell Behavior 
Culture of cancer cells in a 3D model system helps in asses the efficiency of novel 
therapeutic strategies. It has been established that the response behaviors of cells in 2D 
traditional cell cultures and 3D cultures models differ (Zschenker et al., 2012; Hehlgans 
et al., 2009; Hehlgans et al., 2009). Some studies have been showed that 3D-grown 
cancer cells are chemo-resistant and radio-resistant compared with cells grown in 
traditional monolayers and theses cells exhibited resistance to apoptosis. However, the 
reason behind the difference therapy-resistance between 2D and 3D culture models still 
mainly unknown (Xue et al., 2015).  
It has been found that the expression of cancer stem cells-related genes Oct3/4 and 
Nanog genes was significantly increased in 3D alginate-grown liver and neck squamous 
cell carcinoma cell lines compared with 2D cultures (Xu et al., 2014). Furthermore, 
metastatic properties of hepatocellular carcinoma cells enhanced when cultured within 
alginate beads via up-regulating the expression of various matrix metalloproteinases 
(MMPs), including MMP2, MMP9 and MT1-MMP (Xu et al., 2013). Other groups 
showed that head and neck squamous cell carcinoma cells encapsulated in alginate 
scaffolds had characteristics of cancer stem cell such as high tumourigenicity and drug 
resistance as well as an increase in the proportion of stem cell marker gene expression 
Nanog, Oct3/4, CD44 and ABCG2 (Liu et al., 2015). The expression level of stem cell 
marker CD133, Bmi-1, nestin, and c-kit were increased in melanoma cells cultured in 
soft fibrin gels (Liu et al., 2015).  
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In addition, up-regulated expression of Hypoxia-inducible factors (HIFs) genes; HIF1A 
and HIF2A in cancer stem cells (CSCs) and their progenies have been seen as a result in 
the upregulation of cancer stem cells-related genes marker in 3D culture cells (Xu et al., 
2014). Moreover, cultured of cancer cells in a 3D matrigel microenvironment induced 
stem cell-like characters and significantly up-regulated the stem cell reprogramming 
factors expression such as Oct3, Lin28, Sox2, Nanog and miR-302a, compared with 
cells grown in 2D and in turn showed enhanced drug-resistance (Xue et al., 2015). 
These evidences suggested that grown of cancer cell as 3D culture model exhibit more 
undifferentiated characteristic in comparison to cancer cell cultured as traditional 
monolayer and this can be observed by an increasing in stem cell properties associated 
with 3D culture model. 
3.5 Conclusion 
Although multiple myeloma is a haematological malignancy, it forms solid bone 
tumours these are potentially more targeted using therapeutic agents than tumour in 
blood. This study showed for the first time that multiple myeloma cell lines are able to 
proliferate in the alginate beads and form 3D spheroid structures. Myeloma cells were 
more sensitive to LMB, SAHA, GSK343, and BIX 01294 alone in 3D and Nuclear 
Export Inhibitor and inhibitors of HDAC, EZH2 and G9a are potent sensitisers of 
TRAIL responses crucially in 3D cell culture, which may mimic physiological aspects 
of bone metastases. The development of 3D culture system is a crucial part of future of 
cancer research and advances in this field provide an emerging a clear picture of how 
3D cancer model mimic the human microenvironment and how it could be 
therapeutically targeted. 
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4. Selection of PKH26Hi Quiescent Populations 
Selects for Cells with Insensitivity to TRAIL 
and TRAIL Sensitizers 
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4.1 Introduction 
For many years, a growing incidence of cancer resistance to therapeutic agents has 
focused research to identify the cellular phenotype responsible for drug resistance. This 
lead to the recognition of so-called cancer stem cells (CSCs), which have been isolated 
in various cancer types, including prostate, ovarian, colorectal, breast and hematopoietic 
tumours (Al-Hajj et al., 2003; Alison et al., 2011; Collins et al., 2005; Wang and Dick., 
2005). These cancer cells are thought to play a vital role in cancer progression, 
metastasis, self-renewal, relapse and drug resistance in many types of cancer (Yang et 
al., 2015). Quiescent Multiple Myeloma-propagating cell populations have been shown 
to mediate resistance to anti-tumour agents including Bortezomib, Dexamethasone and 
Lenadilomide (Matsui et al., 2008; Vitovski et al., 2012). Despite recent advances in the 
study of pathogenesis and mechanisms of CSC-mediated disease recurrence and multi-
drug resistance, it is unclear exactly what role the quiescent population plays in drug 
resistance (Yang et al., 2015). 
According to the classical or stochastic CSC hypothesis which based on clonal theory of 
tumour initiation and progression, stem cells upon gaining a mutation gives rise to a 
neoplastic clone of homogenous cancer cells that have the capacity for expansion as 
well as cancer initiation and maintenance (Tan et al., 2006).  However, in the 
hierarchical hypothesis, the tumour sustained only by a small proportion of putative 
stem-like cells (Guzman-Ramirez et al., 2009). 
One of the main characteristics of CSCs is their capability to be quiescent; cancer 
dormancy usually correlated with quiescent CSCs fraction that is likely to persist after 
cancer therapy and drive to disease relapse. This quiescence state remains the most 
important hurdle in achieving absolute recovery from the disease (Kusumbe and Bapat., 
2009). It has been found that use of chemotherapeutic agents such as DNA modulating 
agents successfully kill the tumour bulk and rapidly dividing cells and tumour 
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regression is observed. However, the self-renewing population of CSCs is resistant and 
being to initiate a cancer re-growth (Zhou et al., 2009; Li et al., 2008). As a result, a 
large number of patients suffer from disease relapse, indicating the resistant character of 
specific cells to the initial therapy and initiate tumour progression several decades after 
therapy. Therefore, the supportive evidence for CSCs hypothesis suggests that targeting 
highly proliferative cells does not target the suspected source of the disease, and cancer 
could be completely eradicated if these CSCs eliminated (Hermann et al., 2008). 
In recent years, several in vitro methods have been established in order to study and 
isolate CSCs which include, colony formation assay, the microsphere assay, Labell-
retaining assay using PKH dyes, and using some CSC markers such as the aldehyde 
dehydrogenase (ALDH). ALDH enzyme has recently been known with the potential to 
isolate CSCs in various cancer types such as hematological malignancy (Podberezin et 
al., 2013). High enzyme levels being revealed to link to markedly increased aggressive 
phenotype and an indicator of poor survival rates in human breast cancer (Jiang et al., 
2009; Balicki., 2007). It has been found that ALDH enriched cancer cells have more 
clonogenic potential, re-initiate ability, self-renewal, and drug resistant and these 
represent a small subsite of highly tumourigenic cells. Consistent with this, the bulk of 
low ALDH activity cells appear to be differentiated cells with limited growth potential 
(Van den Hoogen et al., 2010; Ginestier et al., 2007). However, the ALDH activity 
assay has some limitations as the enzyme activity is influenced by the chemotherapy 
taking by the patients (Podberezin et al., 2013) and may be expressed in senescent cells 
(Doherty et al, 2011). 
Other surface biomarkers used to identify CSCs in a different type of cancer are CD133, 
CD44, and CD24 (Cojoc et al., 2015) however, these markers cannot uniformly mark 
the CSCs (Yang et al., 2015). For example, the expression of CD133 marker has 
demonstrated to correlate to stem cell population in oral squamous carcinoma, breast 
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and prostate, and many heamatological malignancies, but not in lung tumour (Felthaus 
et al., 2011). Moreover, in haematological malignancies, the expression of specific 
CSCs marker CD38 and CD34 have been characterized (Haase et al., 1995).  
Membrane labelling dyes such as PKH26/67, or DiD, irreversibly bind to the lipophilic 
layer of cell membranes and is evenly distributed among daughter cells during cell 
division. As a result, cells progressively lose the dye as these non-CSC cells proliferate 
and divide rapidly. In contrast, quiescent CSCs cells maintain the fluorescence dye 
owing to lack of cell proliferation (Huang et al., 1999; Lawson et al., 2015; Wang et al., 
2015; Zeuner et al., 2014). The decrease in fluorescence intensity over the time can be 
tracked using flow cytometry. In addition, it is possible to sort the cells into two 
populations of PKH26 positive and negative in order to study any phenotype differences 
and carry out further experimental analysis (Lanzkron et al., 1999).  Therefore, cell 
labelling method and using flow cytometric analysis has been widely applied for study 
and isolation of CSCs in different cancer types (Greve et al., 2012). Isolation of cancer 
initiating cells by PKH26 fluorescence tracking dye have been reported in number of 
cancers including breast cancer (Pece et al., 2010), colon cancer (O’Brien et al., 2012), 
ovarian cancer (Kusumbe and Bapat., 2009) and multiple myeloma (Chen et al., 2014). 
4.1.1 Hypothesis 
It is hypothesized that PKH26Hi cells are quiescent CSC-like cells and are one source of 
TRAIL-resistance in multiple myeloma. 
4.1.2 Aims  
The aims of the present study were first to determine if CSC-like cells could be 
identified and isolated through optimisation of the membrane labelling dye (PKH26), 
which is maintained in quiescent CSCs in multiple myeloma. This PKH26 is detectable 
by both flow cytometry and fluorescent microscopy. The small population retaining the 
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PKH26 dye can be physically sorting using flow cytometry (FACSAria). Secondly, the 
study aimed to establish whether the PKH26Hi population was characteristic of CSC-
like cells by assessed for proliferative potential post-sorting compared to PKH26Lo cells 
and unsorted labelledcells.  CD138 expression of sorted PKH26Hi cells population was 
also measured by flow cytometry and compared to parental un-labelled cells.  
Furthermore, the drug sensitivity of the PKH26Hi, PKH26Lo and unselected populations 
was determined by exposed to the potential anti-tumour agent TRAIL in the presence or 
absence of Leptomycin B (Nuclear export Inhibitor), SAHA (Histone Deacetylase 
inhibitor), BIX 01924 and GSK343 (Histone methyltransferase inhibitors), to determine 
if quiescent multiple myeloma cell populations responded differentially to the anti-
tumour agent TRAIL, and also to sensitizers of TRAIL signaling. Apoptosis was 
assessed by Hoechst 33342 staining and assessment of nuclear morphology coupled 
with Annexin V-FITC staining.  
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4.2 Materials and Methods 
4.2.1 Experimental Design  
Three multiple myeloma cell lines were used in this study: two TRAIL sensitive cell 
lines (NCI-H 929 and RPMI 8226) and one TRAIL insensitive cell line (U266). 
Multiple myeloma cells cultured as previously described (Chapter 2; Section 2.2.5.1) 
and incubated in humidified incubator at 37ºC with 5% CO2 atmosphere. Myloma cells 
were stained with the PKH26 membrane labelling kit and allowed to proliferate for 10-
14 days. PKH26Hi and PKH26Lo cell population were separated using a FACSAria and 
cultured in isolation. PKH26Hi and PKHLo cells were assessed for proliferative potential 
post-sorting, and exposed to the potential anti-tumour agent. Apoptosis was assessed by 
Hoechst 33342 staining and assessment of nuclear morphology coupled with Annexin 
V-FITC staining. The expression of CD138 in parental multiple myeloma cell lines and 
sorted cells was assessed using flow cytometry and analysed with FlowJo software. In 
addition, CD138 expression was detected in 3D growth using immunohistochemistry. 
4.2.2 Optimisation of PKH26 Red Staining 
Multiple myeloma cells were stained using the PKH26 membrane labelling kit (Sigma). 
Myeloma cells at density 1 x 106 cells/ml were centrifuged for 5 minutes at 400g and re-
suspended in medium without FCS. The cells were centrifuged at 400g for 5 minutes 
and the supernatant was carefully aspirated and 125 l of diluent C (PKH26 Red 
Fluorescent Cell linker Kits for general cell membrane labelling) was added. Then, 5 l 
of PKH26 dye solution was prepared by adding 30l of absolute ethanol to 4 l of 
PKH26 Linker at 1mM. After that, the cell/dye suspension was incubated for 5 minutes 
at room temperature with periodic mixing. In order to stop the staining reaction, 130 l 
of FCS was added and incubated for 1 minute at room temperature followed by 
centrifuged for 10 minutes. Finally, the cells were washed twice in 10 ml of complete 
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media to ensure removal of any residual dye prior to re-suspend in 2 ml of complete 
media and seeding into 6 well plates and media changes three times a week. Cell stain 
was verified by flow cytometry. 
4.2.3 Assessment of PKH26 by Flow Cytometry 
Multiple myeloma cell lines were stained using the optimised PKH26 staining protocol 
as mentioned above (Section 4.2.2) and allowed to proliferate for 10-14 days. Sample 
from the main cultures was taken three times a week to be assessed for stain intensity by 
both flow cytometry and IX81 fluorescence microscope (Olympus) and images captured 
using Cell-F software (Olympus) on a dual image of bright field and Texas Red Filters. 
Flow Cytometry was performed on a BD FACSCalibur™ (BD Biosciences) flow 
cytometer. Firstly, baseline measurements for the flow cytometry software template 
were set on day 0 by taking a sample of both unstained and stained cells at 1 x 105 
cells/ml re-suspended in 1ml of complete media and this template used throughout the 
experiment. Flow cytometry measured the side (cell granularity) and the forward (cell 
size) scatter to identify the viable cell population. In addition, a histogram plot of gated 
population to determine the percentage of stained cells in comparison to unstained cells. 
Ten thousand events were acquired per sample and data analysed with FlowJo software.   
4.2.4 Fluorescent Activated Cell Sorting (FACS) of PKH26 Labelling Cells 
Labelled multiple myeloma cells at day 14 were sorted using Becton Dickinson 
FACSAria at the Sheffield University flow cytometry facility. PKH26Hi and PKH26Lo 
cell population were separated by gating around the unstained cell population from an 
unlabeled cell sample. Cells with a PKH26 level comparable to unstained cells were 
classed as PKH26Lo whereas cells with a PKH26 level comparable to day 1 were 
classed as PKH26Hi. 
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4.2.5 Assessment of Proliferative Potential of Post-sorted PKH26Hi and PKH26Lo 
Cells 
Post-sorted PKH26Hi and PKH26Lo cells, in addition to unsorted cells population were 
cultured in isolation by seeding at 200 cells/well into 96 well plates in triplicate. Cells 
left to proliferate for one week in humidified incubator and the cell number assessed by 
a Cell Countless system (Invitrogen). 
4.2.6 Effect of PKH26 Status on LMB, SAHA, BIX 01294 and GSK343-Induced 
TRAIL Responses on Multiple Myeloma Cell Lines 
The effect of TRAIL+/-TRAIL sensitizers on apoptosis on PKH26Hi and PKH26Lo cells 
and unsorted multiple myeloma cells were assessed using double staining of Hoechst 
33342 (Chapter 2) and Annexin V-FITC staining. Briefly, those cells were treated with 
high dose of TRAIL +/- sensitizer and analysed for analysis by Hoescht 33342 and/or 
Annexin V staining. 
4.2.6.1 Assessment of Apoptosis in Quiescent Cells using Annexin V/ Hoechst 33342 
Staining 
Annexin V is a member of calcium-depending protein family that conjugates with 
phosphatidylserine (PS) intracellularly in order to detect apoptotic cells. In an early 
stage of cell death, phosphatidylserine translocates from cytoplasmic leaflet to outside 
leaflet of the plasma membrane creating potent charge asymmetry of the membrane. 
Staining with Annexin V precedes the loss of plasma membrane integrity which 
associated with latest stages of cell deaths due to either apoptosis or necrosis.  
Therefore, this technique is aimed to detect apoptosis immediately after onset of the 
execution stage of cell death (Balaji et al., 2013). Fluorescently labelled annexin V is 
used to definitely target and detect apoptosis in a calcium dependent process via the 
establishment of phospholipid-calcium complex (Tait and Gibson., 1992; Gerke et al, 
2005). This study used FITC-labelled Annexin V staining.  
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Briefly, PKH26Hi and PKH26Lo cells and unsorted multiple myeloma cells seeded at 
10,000 cell/well in 96 well plates and stimulated with the potential anti-tumour agents 
LMB (5nM), SAHA (10 µM), BIX 01924 (20 µM) and GSK343 (20 µM) in the 
presence or absence of TRAIL (50 ng/ml) at doses known to kill most unselected cells 
in 24 h. In order to detect apoptosis using Hoechst 33342 staining coupled with Annexin 
V staining, well plates containing PKH26Hi and PKH26Lo cells and unsorted cells 
treated with anti-tumour agents was centrifuged at 400g for 5 minutes. The supernatant 
was removed and 100l of Annexin V binding buffer (10 mM HEPES/NaOH, 140 mM 
NaCl, 2.5 mM CaCl2 at pH 7.4) was added to each well. Then, 5 l of Annexin V-FITC 
stain in addition to 10 l of Hoechst 33342 staining were added/well and incubated for 
20 minutes. Images were captured using Cell-F software (Olympus) using a triple filter 
and colour UC-30 camera on an Olympus IX-81 microscope and images analysed using 
Cell-F software (Olympus). 
4.2.7 Identification of CD138 Expression in Multiple Myeloma Cells 
CD138 expression was analysed by flow cytometry after sorting of PKH26Hi cell 
population and compared to parental un-labelled cells. Briefly, cells plated at a density 
of 1 x 106 cell/well were transferred into FACS tubes and centrifuged at 400g for 5 
minutes. 1ml of chilled 1% BSA was added to cell pellet and centrifuged again. The cell 
pellet was carefully re-suspend in its own volume and optimised volume of PE/Cy7 
anti-human CD138 (Syndecan-1) (Mouse Monoclonal Antibody (MI15) Mouse IgG1, 
κ) primary antibody (2.5l) (Biolegend) was added. 2.5  l of PE/Cy7 Mouse IgG1, κ 
Isotype control Antibody (Biolegend) was added to one tube as a negative  control  with 
no fluorescence stain in addition to an unstained sample without either primary antibody 
or isotope which was used to set the flow cytometer gate to establish the parameters for 
negative staining. Cells were incubated at 4C for 30 minutes prior to 300 l PBS/1% 
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FCS was added and centrifuged. Finally, samples re-suspend in 300l PBS/1% FCS and 
the stained cells analysis using flow Beckman Coulter Gallios flow cytometer 
instrument. Ten thousand events were acquired per sample and data analysis with 
FlowJo software.   
4.2.8 Immunohistochemistry for CD138 Expression in 3D Alginate Culture 
To prepare cells for immunohistochemistry (IHC), sections slides of MM cells cultured 
in alginate beads were prepared, de-waxed and rehydrated as described in Section 
3.2.4.2.  The slides were washing with deionized water for 5 minutes following by twice 
washed in TRIS-Buffered Saline (pH 7.5). 
In order to detect antigen successfully by IHC techniques, the antigen must be 
accessible for primary antibody conjugating. The antigen may be masking by formation 
of cross-links to inter-, intra- or extra-cell proteins. Furthermore, the processes of tissue 
preparation for IHC such as chemical fixation and paraffin embedding process catalyses 
further establishment of cross-links that may mask tissue antigens. The process of un-
masking cell antigen called Antigen Retrieval (AR) and there are a number of methods 
exist including, enzymatic digestion, use of heat, and treatment with protein denaturants 
(D'Amico et al., 2009; Emoto et al., 2005; Kim et al., 2004). In this study applying of 
heat and enzymatic digestion were investigated and heat-prompted AR by Microwave 
was adopted.  For heat applying by microwave irradiation section were immersed in 
antigen retrieval buffer (0.05 M Tris Buffer (6.05 g Tris in 1L dH2O - pH 9.5) pre 
heated to 60oC in a Sanyo microwave oven (800 watt), set to deliver 40% power for 
5mins. Section slides were cooled for 1 minute at room temperature. Sections were then 
subjected to irritation by microwave oven at 20% power for 5 mins and cooled at room 
temperatures for 15 minutes in order to allow re-folding of tissue antigen. 
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Sections were washed twice in TBS for 5 minutes. In order to block non-specific protein 
interactions from the secondary antibody, 200 µL of blocking solution was applied (1% 
BSA in 75% TBS and 25% normal serum from the animal in which the secondary 
antibody was raised) per slide for 2 hours at room temperature on slow moving shaker.  
This study used normal Rabbit Serum (abcam). 
The primary antibody (PE/Cy7 anti-human CD138 (Syndecan-1) (Biolegend) with 
optimised concentration were prepared and 200 µL (1:400) was added to each slide after 
tapping the excess of blocking solution then it incubated overnight at a humid 
atmosphere. Isotype control slides serve as negative control were incubated in the 
absence of the primary antibody but an inclusion of a control antibody of the same 
isotype and run alongside primary antibody section at matched protein concentration. 
Primary antibody binding was only considered to be specific when no binding was seen 
on matching isotype control slide and the lacks of immune staining confirmed that 
secondary antibody binding was specific to the existence of bound host species proteins 
either primary antibody or isotype control (True., 2008).  
Following overnight incubation with primary antibody, the slides were incubated with 
optimized concentration of Biotinylated Rabbit Anti-Mouse IgG Fc (Abcam) Rabbit 
polyclonal Secondary Antibody to Mouse IgG - H&L secondary antibody (1:1500) for 
30 minutes at room temperature after being washed three times in TBS washes. 
After three additional washes in TBS for 5 minutes per wash, the slides were treated 
with avidin-biotin-peroxidase (ABC, Vecta Laboratories) for 30 minutes.  Then, the 
slides were counter-stained with Hoechst 33342 (10 mg/ml) (Sigma-Aldrich) for 15 
minutes. After that, the slides were washed with TBS for three times for 5 minutes each 
wash. Finally, the slides were dehydrated, cleared and mounted in 90% glycerol/TBS 
and kept in dark at 4oC and viewed under the fluorescence microscopy.  
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4.2.8.1 Evaluation of Immunohistochemistry 
Evaluation of immuno-detection of a target protein (CD138) was by counting immuno-
positive colony within the alginate beads microscopy. Qualitative analysis of immuno- 
fluorescence was performed on Olympus, IX81fluorescence microscope and analysed 
by Cell-F software. 
4.2.9 Statistical Analysis 
Apoptotic cells were counted manually and percent apoptosis calculated based on 
duplicate representative fields of view each containing at least 100 cells for three 
independent experiments. Median with range was calculated and the Stats Direct 
software was used to determine whether the data followed a normal distribution. As the 
data did not follow a normal distribution, significance difference determined using a 
Kruskal-Wallis and Connover-Inman post-hoc test with a p value of 0.05. 
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4.3 Results 
4.3.1 Determination of PKH26 Fluorescent Intensity in Multiple Myeloma Cell 
Lines Over Time 
NCI-H 929, RPMI 8226, and U266 cell lines were labelled with the PKH26 membrane 
labelling kit and allowed to proliferate for 10-14 days in order to evaluate how rapidly 
the dye was lost due to cell division, and whether a PKH26Hi non-proliferating 
population remained. Assessment of PKH26 retention was through both flow cytometry 
and microscopy. During the first few days all cell lines remained bright red upon 
imaging by microscopy (Figure 4.1, 4.2 and 4.3), however, by day 14 there was a 
significantly reduced number of fluorescing cells as well as the intensity of dye where 
only a small population of red cells could be seen (Figure 4.1, 4.2 and 4.3). These 
results correlate with FACS data were the majority of multiple myeloma cells were 
positive (approximately 99%) on first days and by day 14 were an only small 
percentage of Myeloma cells were positive (<20%) (Figure 4.4). An example of PKH26 
fluorescent positivity in NCI-H929 cell lines by flow cytometry and analysed by FlowJo 
is shown in Figure 4.5. 
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Figure 4.1: Determination of PKH26 fluorescent intensity and positivity in NCI-H 
929 multiple myeloma cells over time 
 
 
Figure 4.1: Determination of PKH26 fluorescent intensity and positivity in NCI-H 
929 multiple myeloma cells over time by microscopy and flow cytometry.  On day 1 
majority of cells were positive, however, by day 14 there was a significantly reduced 
number of fluorescing cells. These results correlate with FACS data were the majority 
of multiple myeloma cells were positive (> 99%) on first days and the number of PKH 
retained dye cells over a period of 14 days were significantly reduced (<20%). The 
white arrow is indicated for example of PKH26-retained dye cells. 
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Figure 4.2: Determination of PKH26 fluorescent intensity and positivity in RPMI 
8226 multiple myeloma cells over time 
 
 
Figure 4.2: Determination of PKH26 fluorescent intensity and positivity in RPMI 
8226 multiple myeloma cells over time by microscopy and flow cytometry.  On day 1 
majority of cells were positive, however, by day 14 there was a significantly reduced 
number of fluorescing cells. These results correlate with FACS data were the majority 
of multiple myeloma cells were positive (> 99%) on first days and by day 14 were only 
small percentage of multiple myeloma cells were positive (<20%). The white arrow is 
indicated for example of PKH26 retained dye cells. 
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Figure 4.3: Determination of PKH26 fluorescent intensity and positivity in U266 
multiple myeloma cells over time 
 
 
Figure 4.3: Determination of PKH26 fluorescent intensity and positivity in U266 
multiple myeloma cells over time by microscopy and flow cytometry.  On day 1 
majority of cells were positive, however, by day 14 there was a significantly reduced 
number of fluorescing cells. These results correlate with FACS data were the majority 
of multiple myeloma cells were positive (> 99%) on first days and by day 14 were only 
small percentage of multiple myeloma cells were positive (<20%). The white arrow is 
indicated for example of PKH26 retained dye cells. 
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Figure 4.4: PKH26 fluorescent positivity in multiple myeloma cells 
 
 
Figure 4.4: Determination of PKH26 fluorescent positivity in multiple myeloma cells 
over time by flow cytometry. Three multiple myeloma cell lines were assessed for 
decreasing in PKH26 labelling by flow cytometry every 2-3 days. Data shows the 
decrease of the percentage of stained cells after in comparison to unstained cells which 
was determined by setting a template of un-stained cells on day 0/1. The multiple 
myeloma cells contain a small percentage of population of dye retained cells (<20%) at 
day 14.  
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Figure 4.5: PKH-26 fluorescent positivity in NCI-H 929 cell lines analysis by flow 
cytometry 
 
Figure 4.5: An example of histograms for PKH26 fluorescent positivity in NCI-H 929 
cell lines by flow cytometry analysis by FlowJo software.  FACS data showing PKH26 
labelled NCI-H 929 cells at day 1, 8 and 14 days. The majority of multiple myeloma 
cells were positive (> 99%) on first days and the number of PKH retained dye cells over 
a period of 14 days were significantly reduced.  
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4.3.2 Isolation of PKH26Hi/PKH26Lo Myeloma Cell by FACS  
Following stained of multiple myeloma cells with PKH26 and left to proliferate, they 
subjected to a flow-sort isolation of two distinctive populations (PKH26Hi and 
PKH26Lo) based on gating in comparison to unstained cells. An example of selection of 
PKH26Hi NCI-H 929 cells by cell sorting is shown in Figure 4.6. At least 50,000 cells 
were isolated after sorting. Immediately post-sorting, live cells counts were determined 
using a Cell Countless system (Invitrogen) and cell viability 80% was determined 
using trypan blue staining (Invitrogen) and cells were plated and assessed using 
microscopy and flow cytometry to confirm the purity was as indicated by the FACSaria. 
As shown in Figure 4.7, the PKH26Hi in multiple myeloma cell lines retained the 
PKH26 in microscopic imaging, while there were faint few fluorescence signs in 
PKH26Lo cells using the same exposure. Furthermore, this correlated with the PKH26 
positivity using flow cytometer, which demonstrated that PKH26Hi cells were >99 % 
positive for PKH26 fluorescence while the PKH26Lo population was only 
approximately 2-5 % PKH26 positive (Figure 4.7).  
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Figure 4.6: Selection of PKH26Hi NCI-H929 cells by cell sorting 
 
 
Figure 4.6: FACS Analysis of multiple myeloma unstained and PKH26 labelled cells. 
The population of unlabelled multiple myeloma cells was gated in order to determine 
the viable population and used as a template. Then the PKH26 labelled cells analysed 
by flow cytometry and PKH26Hi and PKH26Lo cell population were separated and 
cultured in isolation. 
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Figure 4.7: Determination of PKH26 fluorescence intensity and positivity 
determination post-sorting 
 
 
Figure 4.7: PKH26 fluorescence intensity and positivity determination post-sorting. 
Following FACS, PKH26Hi and PKH26Lo cells were cultured in isolation and 
fluorescence intensity was checked using fluorescence microscopy. The PKH26Hi 
population maintained fluorescence for PKH26 and faint/absent fluorescence was seen 
in PKH26Lo cells, or a small percent of contaminating PKH26Hi cells were observed in 
some samples and this correlated with the PKH26 positivity using flow cytometer.   
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4.3.3 Proliferation Rates of PKH26Hi and PKH26Lo cells Compared to Unsorted 
Population 
PKH26Hi/PKH26Lo cells isolated from the RPMI 8226 and NCI-H 929 multiple 
myeloma cell lines cells by FACSAria and post sorting analysis showed > 96% purity 
of cell populations with >80% cell viability. Moreover, cultured of PKH26Hi/PKH26Lo 
cells in isolation and left to proliferation displayed that PKH26-retaining cells 
(PKH26Hi) demonstrated more proliferative potential compared to PKH26Lo population 
in all multiple myeloma cell lines and to the unsorted population in NCI-H 929 and 
RPMI 8226 cell lines during the first 3 days. PKH26Hi cells from multiple myeloma cell 
lines had higher cell count than PKH26Lo populations due to these being CSCs and 
initiating the cell growth (Figure 4.8).  Following 1 week cultured, the sorted cells did 
not proliferate to the same extent as the unsorted cells whereas the unsorted population 
revealed high proliferating following culture. However, PKH26-retaining cells 
(PKH26Hi) demonstrated almost the same proliferative potential compared to PKH26Lo 
populations in all multiple myeloma cell lines (Figure 4.8).  
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Figure 4.8: Proliferation rates of PKH26Hi and PKH26Lo cells compared to 
unsorted multiple myeloma population 
 
 
 
Figure 4.8: Proliferation rates of PKH26Hi and PKH26Lo cells compared top unsorted 
population. PKH26Hi and PKH26Lo cells and unsorted population were cultured in 
isolation for one week following sorting and proliferation potential was assessed. 
Statistical significance was set at p< 0.05 by the Kruskal–Wallis test. 
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4.3.4 Effect of PKH26 Status on LMB, SAHA, BIX 01294 and GSK343-Induced 
TRAIL Responses  
PKH26Hi, PKH26Lo cell and unsorted cell population were stimulated with TRAIL+/-
sensitizers at doses known to induce apoptosis in the majority of unselected cells, and 
apoptosis assessed by Hoechst 33342 staining and assessment of nuclear morphology 
coupled with Annexin V-FITC. The data shows that PKH26-retaining cells (PKH26Hi) 
were less sensitive to TRAIL compared to unsorted parental populations in NCI-H 929 
and RPMI 8226. In contrast, PKH26Lo cells were similarly sensitive to TRAIL as 
compared to the parental cells.  LMB, SAHA, BIX 01294, and GSK343 were found 
significantly to induce apoptosis in PKH26Lo cell and unsorted cell population of 
myeloma cell lines NCI-H929 and RPMI 8226 following treatment for 24 h 
(p < 0.0001) (Figure 4.9, 4.10, 4.11, 4.12). However, no significant response was 
observed following the treatment with these TRAIL sensitizers combined with a high 
dose of TRAIL in PKH26Hi cell population. In NCI-H 929 cells, a high apoptotic 
response of 74.9±6.6%, 49.06±10.3%, and 75.2±4.4% (p < 0.0001) were measured in 
unsorted population following treatment with high dose of BIX 01294, TRAIL, and 
combined dose of 20 µM BIX 01294 and 50 ng/ml TRAIL respectively for unsorted 
population (Figure 4.11a, b). The apoptotic response of PKH26Lo for 20 µM BIX 
01294, 50 ng/ml TRAIL, and the drug combination was 97.3±2.3%, 77.3±2.5%, and 
100±0% respectively (Figure 4.11 a, b). Whereas, no significant apoptotic effect was 
seen in PKH26Hi cell population following treatment with high dose of BIX 01294 
either alone or in combination and apoptotic response of 16.6±5.6%, 15±2.7%, and 
16.2±4.4% were measured in PKH26Hi cell population following treatment with a high 
dose of BIX 01294, TRAIL, and co-treatment of both drugs respectively (Figure 4.11 a, 
b). The same effect was seen with a long-term culture where PKH26-retaining cells 
(PKH26Hi) were resistant to doses of drugs that induced significantly high apoptosis in 
PKH26Lo cells and unsorted parental populations of NCI-H 929 and RPMI 8226 cell 
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lines. These data suggest that PKH26Hi cells are much more resistant to apoptosis-
inducing therapies than parental cells, or PKH26Lo cells, and would likely result in 
treatment failure (Figure 4.9, 4.10, 4.11, 4.12). An example of the morphological 
assessment of apoptosis for TRAIL in combination with LMB in unsorted, PKH26Lo 
and PKH26Hi NCI-H929 cells is shown in Figure 4.9. 
 
 
Figure 4.9: Effect of PKH26 status on LMB-induced TRAIL responses in multiple 
myeloma cells 
a) 
 
 
 
Figure 4.9 a): Effect of PKH26 status on LMB-induced TRAIL responses in NCI-
H929. PKH26Hi, PKH26Lo cell and unsorted cell population were stimulated with high 
doses of TRAIL+ /-LMB and apoptosis assessed by Hoechst 33342 staining and 
assessment of nuclear morphology coupled with Annexin V-FITC. The data is expressed 
as median with range (three independent experiments, each in triplicate). The statistical 
significance was determined by comparison with the vehicle control, statistical 
significance was set at p< 0.05 by the Kruskal–Wallis test.  
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Figure 4.9 b) 
 
Figure 4.9 b): An example of the morphological assessment of apoptosis for TRAIL in combination with  LMB in unsorted, PKH26Lo and 
PKH26HI NCI-H929 cells. PKH26Hi and PKH26Lo and unsorted NCI-H929 cells with a high dose of LMB and TRAIL alone and in combined and 
assessment with double staining of Hoechst 33342 staining and Annexin V-FITC using fluorescence microscope. Microscopy showed the apoptosis 
pattern of bright condensed or fragmented chromatin, and increased signals of Annexin V (green). The white arrow indicated for example of 
PKH26 retained dye cells that did not undergo apoptosis . 
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Figure 4.10: Effect of PKH26 status on SAHA-induced TRAIL responses in 
multiple myeloma cells 
a) 
 
 
 
Figure 4.10 a): Effect of PKH26 status on SAHA-induced TRAIL responses in NCI-
H 929. PKH26Hi, PKH26Lo cell and unsorted cell population were treated with high 
dose of SAHA and TRAIL alone and in combined for 24 h and apoptosis assessed by 
Hoechst 33342 staining and assessment of nuclear morphology coupled with Annexin 
V-FITC. The data is expressed as median with range (three independent experiments, 
each in triplicate). The statistical significance was determined by comparison with the 
vehicle control, statistical significance was set at p< 0.05 by the Kruskal–Wallis test.  
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Figure 4.10 b) 
 
Figure 4.10 b): An example of the morphological assessment of apoptosis for TRAIL 
in combination with SAHA in unsorted, PKH26Lo and PKH26HI NCI-H929 cells. 
PKH26Hi and PKH26Lo and unsorted NCI-H929 cells with a high dose of SAHA in 
combination with TRAIL and assessment with double staining of Hoechst 33342 
staining and Annexin V-FITC using fluorescence microscope. Microscopy showed 
apoptosis pattern: bright condensed or fragmented chromatin and increased signals of 
Annexin V (green).  
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Figure 4.11: Effect of PKH26 status on BIX 01294-induced TRAIL responses in 
multiple myeloma cells 
a) 
 
 
 
 
Figure 4.11 a): Effect of PKH26 status on BIX 01294-induced TRAIL responses in 
NCI-H929 cells. PKH26Hi, PKH26Lo cell isolated from MM cells and unsorted MM cell 
population were treated with TRAIL and BIX 01294 alone and in combined for  24h 
using the high dose of drugs which induced significant induction apoptosis. The data is 
expressed as median with range (three independent experiments, each in triplicate). The 
statistical significance was determined by comparison with the vehicle control, 
statistical significance was set at *= p< 0.05 by the Kruskal–Wallis test. 
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Figure 4.11 b) 
 
Figure 4.11 b): An example of the morphological assessment of apoptosis for TRAIL 
in combination with BIX 01294 in unsorted, PKH26Lo and PKH26Hi NCI-H929 cells. 
PKH26Hi and PKH26Lo and unsorted NCI-H929 cells with a high dose of BIX 01294 in 
combination with TRAIL and assessment with double staining of Hoechst 33342 
staining and Annexin V-FITC using fluorescence microscope. Microscopy showed 
apoptosis pattern: bright condensed or fragmented chromatin and increased signals of 
Annexin V (green). The white arrow indicated for example of PKH26 retained dye 
cells. 
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Figure 4.12:  Effect of PKH26 status on GSK343-induced TRAIL responses in 
multiple myeloma cells 
a) 
 
 
 
 
Figure 4.12 a): Effect of PKH26 status on GSK343-induced TRAIL responses in 
NCI-H 929. PKH26Hi, PKH26Lo cell and unsorted cell population were stimulated with 
high dose of TRAIL+ /-GSK343 and apoptosis assessed by Hoechst 33342 staining 
coupled with Annexin V-FITC and examined with fluorescence microscopy. The data is 
expressed as median with range (three independent experiments, each in triplicate). The 
statistical significance was determined by comparison with the vehicle control, 
statistical significance was set at *= p< 0.05 by the Kruskal–Wallis test. 
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Figure 4.12 b) 
 
Figure 4.12 b): An example of the morphological assessment of apoptosis for TRAIL 
in combination with GSK343in unsorted, PKH26Lo and PKH26HI NCI-H929 cells. 
PKH26Hi and PKH26Lo and unsorted NCI-H929 cells with a high dose of GSK343 in 
combination with TRAIL and assessment with double staining of Hoechst 33342 
staining and Annexin V-FITC using fluorescence microscope. Microscopy showed 
apoptosis pattern: bright condensed or fragmented chromatin and increased signals of 
Annexin V (green). 
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4.3.5 PKH26Hi Population Contains the CD138-ve Sub-population 
Flow cytometric evaluation of Syndecan-1 expression by multiple myeloma cell lines 
showed that the majority of cells in both parental multiple myeloma cell lines RPMI 
8226 and NCI-H 929 expressed a high level of cell surface antigens CD138; however, 
each cell line contained a distinct population of CD138-ve cells that represented (Figure 
4.13). Following sorting, the PKH26 Hi and PKH26 Lo cell were stained with anti-human 
CD138 (PE/Cy7) or isotopic control antibodies. Cells were analysed to identify the 
expression of percentages of CD138 in PKH26Hi cells compared to unlabelled cells. 
Data demonstrated that the majority of the sorted PKH26Hi cells did not express the 
surface marker CD138.  Therefore, indicating that there may be small cell population 
with a stem cell-like phenotype within the main multiple myeloma population which 
also resists therapies (Figure 4.14).  
To further explore the phenotype of the multi-cellular tumour spheroid model formed in 
the alginate beads, the expression of marker for the CD138 was detected in 3D growth 
using immunohistochemistry. As shown in Figure 4.15 the expression of putative cancer 
stem cell marker CD138 in 3D cell culture was observed in some colonies after 14 days 
of seeding, while it was not observed in most of the colonies within the alginate beads 
and some colonies with variable positivity a cross the colony. In contrast, the expression 
of CD138 was retained in suspension cell culture using flow cytometry (Figure 4.13).  
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Figure 4.13: CD138 expression on multiple myeloma cell lines as detected by flow 
cytometry 
 
Figure 4.13: CD138 expression on myeloma cell lines as detected by flow cytometry. 
NCI-H 929 and RPMI 8226 multiple myeloma cell lines were incubated stained with 
syndecan-1(PE/Cy7). CD138 protein expression is represented as a histograms plot 
whereas red histograms represent staining with the isotype control antibody and black 
histograms represent staining with PE/Cy7 anti-human CD138 (Syndecan-1) 
fluorescence antibody.  
 
 
 
 
 
 
 
 
 192 
 
 
 
Figure 4.14: CD138 activity of sorting PKH26Hi cell population and compared to 
parental un-labelled cells by flow cytometry 
 
Figure 4.14: CD138 expression of sorting PKH26Hi cell population and compared to 
parental un-labelled cells by flow cytometry. Both parental and PKH26 Hi NCI-H929 
Cells at a density of 1 x 106/ml were stained with syndecan-1 and the level of syndecan-
1 was identified using flow cytometry. Flow cytometric analysis of CD138 expression 
are represented as histograms plot where red histograms represent parental cells 
staining with PE/Cy7 anti-human CD138 (Syndecan-1) fluorescence antibody and black 
histograms represent PKH26 Hi cell staining with anti-syndecan-1 (PE/Cy7).  
 Unsorted cells staining with 
anti-human CD138 antibody 
 PKH26Hi cells staining with 
anti-human CD138 antibody 
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Figure 4.15: CD138 activity of NCI-H929 alginate beads immunohistochemistry 
 
Figure 4.15: CD138 expression of NCI-H 929 alginate beads immunohistochemistry. NCI-H 929 cells in 3D alginate beads were immuno-stained 
with PE/Cy7 anti-human CD138 (Syndecan-1) (green) and DAPI (blue, for nuclear stain). Some colonies stained positive; some are negative and some 
those that are positive, the positivity variable across the colony. The fact that most colonies in 3D are Syndecan-1 negative is counter intuitive as in 
3D, CD138-ve cells are very TRAIL sensitive.
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4.4 Discussion 
Despite advancement in understanding of tumour mechanisms and therapy have 
significantly improved in recent years, cancer still one of the major health problem in 
many countries (Cojoc et al., 2015). Even though the majority of tumour bulk was 
eliminated by conventional therapeutic agents in some type of cancer including MM, 
the relapse from therapy consequently occurs. Disease relapse suggests to the existence 
of chemo-resistance cells population with tumour regrowth potential but the full 
understanding of the role of these cells in MM growth following treatment remains 
obscure (Matsui et al., 2008). Since the emergence of CSC hypothesis, evidence 
suggests that a curative therapy will be potential if the quiescent CSCs entirely 
eradicated and efficient therapy targeting all CSCs (Cojoc et al., 2015; Reya et al., 
2001). The aim of this investigation was to identify and isolate CSCs-like by optimising 
PKH26 membrane labelling dye and if quiescent multiple myeloma cell populations 
responded differentially to the Death Receptor agonist TRAIL in combination with 
TRAIL sensitizers. 
4.4.1 Isolation of CSCs using PKH26 Dye 
Firstly, this study optimised the PKH26 labelling of multiple myeloma cell lines using 
PKH26 membrane labelling kit in order to obtain uniformly fluorescence-stained cells.  
The fluorescence dye integrates into the cell membrane without any toxicity and is 
diluted during cell division leading to dyeing of quiescent CSCs cells within a 
proliferating cell population. (Chen et al., 2014; Fisher and Mackenson., 2003). 
Following dye optimisation, the decrease in fluorescence intensity was monitored using 
both flow cytometry and microscopy. Both approaches correlated with a reduction in 
red fluorescence dye observed over time with only a small population of PKH26 
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retained cells in multiple myeloma cell lines after two weeks (Figure 4.1, 4.2, 4.3 and 
4.4). Following separation of myeloma cells into PKH26Hi/PKH26Lo cells by FACS 
small number of PKH26-retaining cells (PKH26Hi) was obtained due to the low 
percentage of cells which were still red stained compared to the whole population 
(Figure 4.6, 4.7). PKH26Hi cell populations have been identified in many types of cancer 
(Kusumbe and Bapat., 2009; Pece et al., 2010; O’Brien et al., 2012; Chen et al., 2014). 
In addition, these cells displayed CSC markers such as CD44 in breast cancer besides 
having a self-renewing ability and drug resistance (Nakshatri., 2010).  
Previous study was able to isolate near purity of human normal mammary stem cells 
from cultured mammospheres using PKH26 labelling dye (Pece et al., 2010). These 
cells are quiescent and possess all the stem-like characteristics. Very few cells within 
mammospheres retained PKH26 fluorescence dye and around one mammosphere-
initiating cell is existing per mammosphere, and that this cell is likely located within the 
PKH26-positive cell population. By microscopically monitoring the growth of PKH 
positive cells cultured in methylcellulose, mammospheres were shown to be the result 
of the clonal expansion of single PKH-retaining cells, but not PKH26-negative cells. 
These PKH26Hi cells displayed the quiescent state features including retention of the 
modulated nucleotide BrdU, absence the proliferation marker Ki-67 expression, and 
asymmetrically division all consistent with stem cell behavior (Pece et al., 2010). 
Moreover, analysis the panel of marker on quiescent PKH26 positive cells in Pece et al 
work by immunofluorescence revealed that quiescent PKHHi cells expressed both 
epithelial (CD24+ /EpCAM+) and myoepithelial (CD49F+ /CK5+ /TP63+) cells; but, they 
did not express terminal differentiation markers, such as E-cadherin, ASMA and 
MUC1. However, PKHLo cells, displayed little or none of this marker compared to PKH 
positive cells. The study by Pece et al., (2010) proposed that PKH positive cell 
population in breast are bipotent and the majority of colonies obtained from PKH 
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positive cells expressed both epithelial and myoepithelial. In contrast, PKH negative 
cells population develop either pure epithelial or pure myoepithelial colonies (Pece et 
al., 2010). In addition, quiescent PKH positive cells were able to grow in 3D structures 
and can generate mammary gland organotypic outgrowths while PKH negative cells 
only grew as monolayers of terminally differentiated cells and did not generate 3D 
structures. Taken together, these data indicating that the PKH retaining dye cells 
possess all the characteristics expected for stem cells (Pece et al., 2010). 
PKH26 dye also has been used in colon cancer to isolate the quiescent cells. A study 
carried out by O’Brien et al., (2012) found a minor population of non-dividing cells 
within the colon cancer which can separate out and the PKH26 retained cells were able 
to establish spheres more quickly than the PKH26 negative cells when a sphere-forming 
assay was performed (O’Brien et al., 2012).  In addition, O’Brien et al., (2012) showed 
that the self-renewal capacity of cancer-initiating cells is dysregulated and these cell 
populations possess chemotherapy and radiation resistant properties due to the 
expression of genes that have been involved in self-renewal properties of stem cells 
(O’Brien et al., 2012). These proteins are the inhibitor of DNA binding proteins (IDs), a 
family of homologous helix-loop-helix (HLH) transcriptional regulatory factors (ID1–
ID4) with known functions in growth, differentiation, senescence, and migration (Fong 
et al., 2004). According to O’Brien et al., (2012) ID1 and ID3 proteins regulate self-
renewal capacity of cancer initiated cells isolated from primary colon cancer samples 
and the knockdown of these genes resulted in a dramatic loss of tumour-initiating 
capacity by down-regulation of a cell-cycle inhibitor p21.  p21 has a role in the 
prevention of exhaustion of cancer stem cells through cell-cycle restriction and 
protection from DNA damage (O’Brien et al., 2012).  
 197 
 
4.4.2 The proliferative Potential of PKH26 Retained Cells Isolated from Multiple 
Myeloma Cell Lines  
The PKH26Hi sorted cells were evaluated for proliferation potential as this investigation 
hypothesized that the cells that retained the dye would proliferate faster. Results from 
the current study showed that the PKH26Hi cell population exhibited similar 
proliferative potential compared to PKH26Lo cell populations but they were less 
proliferative in compared to the unsorted population in multiple myeloma cell lines 
(Figure 4.8). Moreover, labelling of ovarian cancer cells with PKH26 in previous study 
and sorted by FACS after being left to proliferate in vivo demonstrated that the 
quiescent PKH26Hi cells had highest self-renewal capabilities and higher proliferation 
rates as well as could initiate cancer re-growth in vivo even though significantly lower 
number of cells were injected when compared with the PKH26 negative cells 
population (Kusumbe and Bapat., 2009). Moreover, the isolated PKH26 negative 
population completely lacked the colony formation ability in vitro using the colony 
formation technique. In addition to the higher expression of stem cell marker Nanog, 
Oct4, Nestin, and Bmi in PKH26Hi subsets while lacked expression of all four stem cell 
markers in the PKH26Lo subset (Kusumbe and Bapat., 2009). These analyses suggested 
that the tumour-initiating potential of tumour lies mainly within the PKH26Hi. 
Furthermore, two different cell populations were identified within PKH26 retained cells 
population; these comprised the CSCs in addition to aneuploidy cells population which 
seemed to have a dormant phenotype, most likely senescent cells. In the majority of 
cancers, cancer stem cells are thought to survive, persist and maintain functionality 
through therapy regimes; thus contributing to tumour dormancy and represent a difficult 
obstacle in limiting drug outcomes, while the genetic heterogeneity raised by quiescent 
or cell cycle arrested aneuploid sub-population may effect tumour therapy resistance by 
re-entry into the cell cycle to generate a disease progression (Kusumbe and Bapat., 
2009).  
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The reduced cell production capacity of sorted PKH26Hi and PKH26Lo cells may be a 
consequence of a period of dormancy post-sorting. Alternatively, PKH26Lo are 
exhausted, PKH26Hi are quiescent and PKH intermediate is transit amplifying. 
Following a certain number of cell divisions, cells depart the stem cell pool and terminal 
differentiation is unavoidable, therefore PKH26Lo may represent terminally 
differentiated cells (Young et al., 1996). It has been found that isolation of 
hematopoietic cells CD34+/Thy-+1/Lin- from bone marrow or mobilized peripheral 
blood (MPB) by labelled with the fluorescent dye PKH26 and cultured in vitro in the 
presence of interleukin-3, interleukin-6, c-kit ligand, and leukemia inhibitory factor 
(LIF) resulted in retention of primitive quiescent cells. Following 14 days of the 
expansion period, was sorted into two population CD34+/Lin-/dyeBright and CD34'/Lin-
/dyeDim fractions and sub-cultured for more four weeks and single-cell proliferation 
assay was performed in order to identify the proliferative capacity of each cell 
population. A high percent of progenitors remaining dye were observed to proliferate in 
compare to dye dim cells which shown a lower average proliferative capacity. These 
results indicate that cells with a higher proliferative potential recover following culture 
expansion with cytokines were those that established quiescent behavior and 
progressive loss of production capacity of the cell seemed to be a consequence of cell 
division under the experimental culture conditions used in this study (Young et al., 
1996). 
4.4.3 PKH26-retaining Cells Demonstrated Resistant Potential to Anti-tumour 
Agents Compared to Unsorted Parental Populations in Multiple Myeloma 
Cell Lines 
The sorted PKH26Hi cells isolated from multiple myeloma cell lines following cultured 
in isolation and unsorted cells were assessed for drugs sensitivity as this investigation 
hypothesized that the PKH26Hi cells are quiescent CSC-like cells and are the source of 
TRAIL-resistance in Multiple Myeloma given that CD138-ve cells are generally TRAILR 
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(Vitovski et al., 2012). Here in this study, the isolated PKH26-retaining multiple 
myeloma cells were less sensitive to all of the anti-tumour drugs compared to PKH26Lo 
and unsorted parental populations (Figure 4.9, 4.10, 4.11 and 4.12). Results from the 
current study consistent with a work carried out by Chen et al., (2014) and they found 
that the quiescent PKH26Hi multiple myeloma cells (RPMI 8226 and NCI-H 929) 
isolated using PKH26 dye exhibited enriched stem-like properties by the ability of 
forming colonies in semi-solid medium as well as more resistant to anti-tumour agents 
including cyclophosphamide, bortezomib, vincristine, prednisone, and rituximab in 
vitro compared with PKH26Lo cell populations. In addition, the injection of PKH67Hi 
multiple myeloma cells into NOD/SCID mice showed that quiescent PKH
+
cells were 
preferred to inhabit in the osteoblastic regions niche of the bone marrow compared with 
the spleen or vascular niche. These data also confirmed by immunohistochemistry 
analyses. Moreover, PKH+ cells that expressed CD138 were generally found away from 
bone lining regions, however, PKH+ cells that were CD138-ve were also found following 
48 h of in vivo growth. This result suggests that most quiescent multiple myeloma 
populations did not express the surface marker CD138. On the other hand, isolation of 
CD138+ve and CD138-ve myeloma cells followed by staining with PKH dyes and 
injected into irradiated mice revealed that CD138-ve cells isolated from myeloma cells 
retained the PKH67 dye preferentially than CD138+ve myeloma cells in vivo, 
demonstrating that CD138-ve cells persisted as quiescent cells in vivo compared with the 
PKH+ cells that expressed CD138 (Chen et al., 2014). Other studies showed that human 
prostate cancer cell lines PC3 and LNCaP and its variant C4 2B4 contain populations of 
cells that are slow growing/quiescent but not specifically stem like. The mitotically 
quiescent population was very significantly more tumourigenic in vivo compared to the 
rapidly proliferating cells and had a distinctive gene expression profile in vitro such as 
CXCR4 which has been implicated in prostate cancer cell migration (Wang et al., 
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2015).  
Other studies have shown that breast cancer initiating cells are not only the surviving 
sub-population of ionizing radiation but also retain the cancer stem phenotype in 
compare to non-tumourigenic counterparts (Nakshatri., 2010). Irradiated cancer 
initiating cells in breast cancer are resistant to ionizing radiation and retained their self-
renewal potential, and become more aggressive compared to non-irradiated stem cell 
control. The radiation-resistant cells exhibit the characteristics of CICs including 
expression of CD44+/CD24- marker, low proteasome activity, and retained PKH26 dye.  
In addition, fractionated radiation not only induces proliferation of a sub-population of 
PKH retained cells or cancer initiating cells but also mobilized them from a 
quiescent/G0 phase to a proliferative state (G2
 
phase) of the cell cycle, whereas the non-
irradiated cancer stem cells are non-proliferating and are mainly in the G0 phase of the 
cell cycle and the surviving non-tumourigenic cell population were driven into 
senescence (Lagadec et al., 2010; Nakshatri., 2010). 
In other studies, quiescent cells in myeloma resist proteasome inhibitors bortezomib and 
bortezomib-surviving MM cells characterised by upregulation of p21CIP1 and GRP78, an 
unfolded protein response survival factor, and downregulated CDK6, Ki67 and pRb. 
Moreover, the combination treatment of bortezomib and 5-azadeoxycitidine induced 
apoptosis and quiescence stability and might represent a novel approach treatment of 
MM (Adomako et al., 2015). In addition, the quiescent sub-population in glioblastoma 
has been shown to selectively resist temozolomide therapy (Chen et al., 2012). 
Furthermore, Dormant DiD-retained myeloma cells (analogous to PKHHi cells) are 
resistant to melphalan (Lawson et al., 2015). These results suggest that target this 
population has the potential novel therapeutic approaches for multiple myeloma. 
In contrast, quiescent or PKHHi non-small cell lung cancer were significantly more 
sensitive to Bcl-XL inhibition, ABT-737 than rapidly proliferating PKHLo cells, 
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indicating that quiescent lung cancer cells strongly depend on Bcl-XL Bcl-2 family 
proteins for their survival (Zeuner et al., 2014). 
4.4.4 PKH26Hi Cells are CD138–ve 
The data presented in this study shows that the majority of the sorted PKH26Hi cells did 
not express the surface marker CD138 (Figure 4.14), indicating that there may be small 
cell population with a stem cell-like phenotype within the main multiple myeloma 
population. In addition, the immunofluorescence data suggested that most of the 
colonies within the alginate beads did not expresse CD138 in NCI-H 929 MM cell line 
in 3D culture (Figure 4.15).  
In a study conducted by Matsui et al., (2004) they demonstrated that human MM cell 
lines RPMI 8226 and NCI-H 929 contained a high percentage of CD138+ve cells with 
only small populations (<5%) that lacked CD138 expression. These subpopulations had 
significantly more clonogenic potential as well as expressed a higher level of 
proliferation marker Ki67 than the CD138+ve cells. In addition, CD138-ve expressed 
CD19, CD20 antigens and accordingly, none of the CD138+ve of both MM cell lines 
expressed these antigenic markers. These data propose that stem cells of MM are 
CD138-ve sub-population with the capability to replicate and consequently differentiate 
into malignant CD138+ve plasma cells (Matsui et al., 2004). Later, Matsui et al., (2008) 
demonstrated that CD138+ve multiple myeloma cells cannot undergo long-term 
proliferation but rather devolve from clonogenic CD138-ve cells population. CD138+ve 
MM plasma cells more sensitive to clinical used anti-myeloma therapy dexamethasone, 
lenadilomide, bortezomib, and 4-hydroxycyclophosphamide compared to CD138-ve 
precursors in vitro. Moreover, CD138-ve cells population possesses high drug efflux 
capacity and intracellular drug detoxification activity as identified by Hoechst side 
population analysis and Aldefluor assays.  In addition to the expression of the memory 
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B-cell markers CD20 and CD27 that give rise to the clonogenic growth of MM cells in 
vitro (Matsui et al., 2008). The week staining of PKHHi cells with Hoechst 33342 
further support the notion that PKHHi cells are CSC-like cells. 
These results are consistent with a study carried out by Holen et al., (2001). Flow 
cytometric analysis of CD138 expression on the surface of MM cell lines NCI-H929, 
RPMI 8226, U266 and JJN3 showed that multiple myeloma cell lines expressed 
different level the surface marker CD138 that was shed constitutively (Holen et al., 
2001). 
Findings from the current investigation are consistent with those of a previous study 
undertaken by Vitovski et al., (2012) which found out that exposure of cultured multiple 
myeloma cell to TRAIL results in the preferential killing of CD138+ve compared to 
CD138-ve cells population isolated from bone marrow patients with multiple myeloma. 
In addition, these CD138-ve cells were less sensitive to doxorubicin and TRAIL alone, or 
the combination treatment than CD138+ve cells population and have a lower level of 
TRAIL death receptors expression (Vitovski et al., 2012). Earlier work has shown that 
sequential exposure to the sub-toxic concentration of proteasome inhibitor bortezomib 
in conjunction with HDAC inhibitors SAHA potently induces mitochondrial 
dysfunction. Moreover, the bortezomib/HDAC inhibitor treatment significantly triggers 
ROS generation. In addition, co-treatment with bortezomib/HDAC inhibitors induced 
marked lethality in CD138+ve cells, but not in the CD138-ve multiple myeloma cells (Pei 
et al., 2004). Kawano et al., (2012) reported that CD138-ve cells exhibited decreased 
sensitivity to lenalidomide compared with CD138+ve cells fraction and high expression 
of genes expressed at the immature B-cell stage such as BCL6 and low expression of 
genes associated with mature plasma cells such as IRF4 that may explain the poor 
response of low expression of CD138 patients to therapy (Kawano et al., 2012).  
Other studies showed that CD138-ve cells have high ALDH1 activity, a hallmark of 
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normal and cancer stem cells and the CD138-ve ALDH+ population showed more 
clonogenic expansion than CD138+ve ALDH- population when plated into 
methylcellulose medium and only CD138-ve cells differentiated into CD138+ve 
population. In addition, increase expression of self-renewal and proliferation genes in 
the CD138-ve fraction such as STAG2, RB1CC1 and Polycomb Repressor Complex 
(PRC) genes and their target genes including EZH2 compared to CD138+ve population. 
Importantly, CD138-ve cells were more sensitive to the EZH2 inhibitor, DZNep (Chung 
et al., 2013). In addition, CD138+ve myeloma cells isolated from multiple myeloma 
patients in recent work responded to specific EZH2 inhibitor UNC1999 treatment, at the 
same dose range that was used in unsorted multiple myeloma cell lines (Agarwal et al., 
2016). 
This the first time a study has been studied the effect of the interaction between TRAIL 
and LMB, SAHA, BIX 01294 and GSK343 in quiescent myeloma cells PKH26Hi 
compared to PKH26Lo and unsorted parental populations. These evidences taken 
together, suggesting that quiescent low CD138-ve expression cells are more resistant to 
therapy and establishment of a novel treatment strategy that target this cell population 
that represents miner fraction of multiple myeloma cells is necessary in order to 
improve their poor outcome. 
4.5 Conclusion 
Many therapeutic agents are effective in treatment multiple myeloma, but the majority 
of myeloma patients relapses. The precise mechanisms responsible for the resistance of 
multiple myeloma cells to chemotherapeutic agents are unknown, but chemo-resistance 
usually arises through multifactorial processes (Matsui et al., 2008). In this study, the 
emergence of the TRAIL-resistant population that readily arise from multiple myeloma 
cell lines in response to the anti-tumour agent TRAIL in presence of TRAIL sensitisers 
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most likely arise from the quiescent PKH26-retaining population. Therefore, PKH26Hi 
cells may represent Myeloma-initiating population. Results from current investigation 
suggest that these stem-like cells contribute to the multiple myeloma drug resistance, 
persisting of disease and mediate it relapses in patients initially responding. Thus the 
development of a therapeutic approach that targets this minor sub-population within the 
tumour is urgently needed. Further studies are required to explore more about the 
mechanisms of resistant of these therapeutic resistant cells.   
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5. The Potential Targets of TRAIL-sensitizers in 
Mediating Apoptosis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 206 
 
5.1 Introduction 
It has been demonstrated that TRAIL induces apoptosis and LMB, SAHA, BIX 01294 
and GSK343 synergistically enhancing TRAIL responses in multiple myeloma cell lines 
(Chapters 2-3). Here, the potential mechanisms of enhancement of apoptosis were 
examined. Firstly, it was essential to determine whether TRAIL alone and/or in 
combination with TRAIL sensitizers stimulated apoptosis via extrinsic or intrinsic 
apoptosis pathways, as this could influence the possible apoptosis regulatory molecules 
that TRAIL and TRAIL sensitizers may modulate. Secondly, specific apoptotic 
modifiers were investigated in response to TRAIL sensitisers, and finally, preliminary 
experiments performed on an apoptosis protein array to identify likely targets. 
5.1.1 Extrinsic and Intrinsic Apoptotic Pathways 
According to Mahmood and Shukla., (2010), apoptosis or programmed cell death is an 
active process that plays an important role in many physiological processes; most of the 
chemotherapeutic and radio-therapeutic agents mediate their affect by triggering of 
apoptosis (Paraoan et al., 2006; Igney and Krammer., 2002) either through stimulating 
extrinsic and/or extrinsic apoptotic pathways (Ivanov et al., 2011). The extrinsic 
pathways are stimulated from outside by binding pro-apoptotic ligands such as the 
tumour necrosis factor (TNF) to the specific death receptors on the cell membrane 
(Pennarun et al., 2010) (Chapter 1). In contrast, the intrinsic pathway of the apoptosis 
begins from inside the cell via members of Bcl-2 protein family which prompt 
mitochondrial disruption resulting in pores formation in the outer-mitochondrial 
membrane that leads to initiating the apoptotic cascade by the caspase activating 
(Chapter 1) (Elmore., 2007). 
Caspases as a family of cytokine proteases are crucial for the transduction cellular 
signal pathways that regulate the apoptosis. These caspases are usually synthesised as 
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inactive pro-caspase that is activated by cleavage (Elmore., 2007; Falschlehne et al., 
2007). In apoptotic signaling, caspase-8 and -9 are believed to be the regulative or are 
initiator caspases that activate downstream effector or executioner caspase-3 (Pan et al., 
1997). Caspase-8 is activated in an extrinsic pathway of apoptosis and it is responsible 
for eliminating unwanted cells during development and other stimulation signals while 
caspase-9 is responsible for stimulating the intrinsic apoptotic pathway in response to 
the number of stimuli such as DNA damage, irradiation and cytotoxic therapeutic agents 
(Elmore., 2007). The extrinsic and the intrinsic apoptotic pathways are stimulated by the 
recruitment and activation of caspase-8 into the DISC or by caspase-9 into the 
apoptosome respectively. This will in turn stimulate the downstream apoptosis cascade 
by activating the executioner caspase-3, -6 and -7 (Figure 1.6) (Shankar and Srivastava, 
2004; Elmore, 2007).  
It is significant to know that the exact molecular mechanism for the stimulation of 
initiator caspases is not fully understood. Previous study by Vitovski et al., (2012) who 
showed that TRAIL induced apoptosis in the multiple myeloma cell lines; the apoptosis 
was mediated via the activation of both extrinsic and intrinsic apoptotic pathways 
through stimulating caspase-8 (the early initiator caspase of the extrinsic pathway), 
caspase-9 (the early initiator caspase of mitochondrial pathway) as well as caspase-3 
and caspase-7 (the effector caspases of the both apoptotic pathways) (Vitovski et al., 
2012). Moreover, the mechanisms by which HDACi SAHA enhances apoptosis in 
myeloma cells are still largely unclear. The earlier works reported that the cytotoxic 
effect of SAHA on the multiple myeloma cell lines was caspase-independent (Fandy et 
al., 2005; Mitsiades et al., 2003), however since not all effects of SAHA are apoptotic, 
this does not address the direct apoptotic effects. Other studies illustrated that co-
treatment of HDACi SAHA and TRAIL on leukemic cell lines activated both the 
extrinsic and intrinsic pathways of apoptosis by activating caspase-3 and -8 (Rosato et 
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al., 2003). In addition, recent studies provided evidence that HMTasei BIX 01294 and 
EZH2i GSK343 stimulate apoptosis through both intrinsic and extrinsic pathways 
involving caspase-3, -8 and -9 (Cui et al., 2015; Agarwal et al., 2016). 
5.1.2 Potential Targets of the NEI, HDACi and HMTasei Mediated Apoptosis and 
Cell Cycle 
5.1.2.1 Bcl-2 Family Member Proteins  
Bcl-2 family proteins are the regulators of cell death and they mediate their action 
through intrinsic or mitochondrial apoptotic pathway by controlling the mitochondrial 
outer membrane permeabilization (MOMP) (Hardwick and Soane., 2013). Bcl-2 family 
member proteins are subdivided into pro-apoptotic or anti-apoptotic proteins (Petros et 
al., 2004). Although most of the Bcl-2 homologs suppress apoptosis, pro-apoptotic 
subset including Bax, Bid, and Bak are activated in response to stress or cell damage 
causing the loss of mitochondrial integrity and forming a channel in the mitochondrial 
outer membrane through which a pro-apoptotic proteins including cytochrome c exit 
mitochondria (Elmore., 2007). The release of these proteins stimulates caspase 
activation in the cytosol and ultimately cell death.  The pro-apoptotic protein Bax plays 
a vital role in triggering apoptosis mediated by certain anti-tumour agents in the human 
cancer cells. For example, it has been shown that Bax contributes to the mitochondrial 
pathway of the cell death and that Bax-null colon cancer cells are resistant to apoptosis 
mediated by TRAIL (Deng et al., 2002; Leblanc et al., 2002) 
The role of Bcl-2- anti-apoptotic proteins such as Bcl-2, Bcl- XL, Bcl-w, A1/Bfl-1, and 
Mcl-1 is to block their pro-apoptotic partners and apoptosis (Martinou and Youle., 
2011). Over-expression of anti-apoptotic proteins including Bcl2 and Bcl-XL inhibits 
apoptotic cell death (Yip and Reed., 2008). Furthermore, Wang et al., (2010) pointed 
out that a number of anti-tumour agents induced programmatic cell death through the 
up-regulation of pro-apoptotic genes and down up-regulating anti-apoptotic genes 
 209 
 
(Wang et al., 2010). 
Harakiri, BCL2 Interacting Protein (HRK) also called DP5 is a pro-apoptotic BH3 
member of the Bcl2 family which involved in promoting apoptosis (Coultas et al., 
2007). This protein activates apoptosis by selectively interacts with the anti-apoptotic 
Bcl-2 and Bcl-X(L) through its BH3 domain. HRK is commonly expressed in 
hematopoietic and cultured tissues, however, has also been found in the liver, pancreas, 
lung, prostate and kidney. Over-expression of HRK mediates GSK343-induced 
apoptosis in 3D culture epithelial ovarian cancer cells, (Amatangelo et al., 2013), and so 
was a key target in this study. Induction of apoptosis by HRK also requires the 
expression of pro-apoptotic Bax (Harris and Johnson., 2001). High levels of apoptosis 
inhibitor Bcl-2 or Bcl-xL suppress the stimulation of HRK and inhibit apoptosis 
following growth factor withdrawal (Sanz et al., 2000). Enforced co-expression of HRK 
and Bcl-2 or Bcl- XL, suppress the death-inducing activity of HRK (Inohara et al., 
1997).  
5.1.2.2 Inhibitor of Apoptosis Proteins (IAP) 
The inhibitor of apoptosis protein (IAP) family plays a key role in regulating cell 
division, apoptosis, or survival pathways. Apoptosis inhibition has a mediating role 
either through suppressing the executioner caspase catalytic activity or modulating the 
signaling pathway of the nuclear factor κB (NF-κB) (Smolewski and Robak., 2011; 
Zhang and Fang, 2005). Several IAP proteins have been identified, including eight 
members of BIRC protein (BIRC1–BIRC8) or neuronal apoptosis inhibitory protein 
(NAIP), cIAP2, cIAP1, X-linked inhibitor of apoptosis (XIAP), survivin (BIRC5) and 
ILP2. Each of the IAP protein members is characterized by the presence of one or three 
tandem conserved repetitions known as the baculovirus inhibitory repeat (BIR) 
(Zhang and Fang., 2005). The over-expression of IAPs is present in many malignancies 
including hematological malignancies and it can result in resistance to TRAIL-induced 
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apoptosis. There was a correlation between hematological disease progression and 
increased levels of the IAP protein XIAP. In addition, the over-expression of these anti-
apoptotic proteins is an indication of poor prognostic factors (Smolewski and Robak., 
2011; Zhang and Fang., 2005).  
XIAP, a commonly expressed IAP protein is considered the most potent anti-apoptotic 
caspase inhibitor protein. Moreover, the presence of a Really Interesting New Gene 
(RING), the zinc finger domain gives it an ubiquitin ligase activity that facilitates the 
degradation of pro-apoptotic proteins such as caspases (Droin et al., 2013). A number of 
XIAP inhibitors such as embelin suppresses the proliferation of various cancer cells and 
induces apoptosis (Heo et al., 2011).   
5.1.2.3 c-flip 
Similar to IAP anti-apoptotic proteins, cellular FLIC inhibitory protein (c-flip) is 
associated with TRAIL resistance in numerous types of cancers. c-flip interacts with 
FADD and/or caspase-8 and death receptors (DR5) and forms an apoptosis inhibitory 
complex (AIC) which in turn prevents DISC formation and consequently inhibited the 
activation of caspase cascade signals (Sophonnithiprasert et al., 2015). In addition, c-
flip has been reported to activate pro-survival signaling pathways such as NF-κB (portt 
et al., 2011; Safa., 2012). High expression of c-flip has been shown in a number of 
cancer types such as colon cancer and lymphoma (Safa., 2012). Several natural 
compounds have been reported to sensitization of TRAIL-resistant cancer cells to 
TRAIL-mediated apoptosis through down regulation of c-flip (Sophonnithiprasert et al., 
2015). Apoptosis induction by SAHA in cutaneous T-Cell lymphoma cells is associated 
with c-flip down-regulation (Al-Yacoub et al., 2012). Moreover, SAHA treatment 
sensitizes MM cells (Mitsiades et al., 2003) and glioblastoma cells to TRAIL-mediated 
apoptosis by down-regulating expression of c-flip (Bangert et al., 2012). Furthermore, 
inhibition of methyltransferases with DZNep enhanced lymphoma sensitivity to TRAIL 
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through c-flip degradation (Braun et al., 2015). Therefore c-flip is a potential modulator 
of TRAIL sensitive in this study. 
5.1.2.4 p21 
p21WAF1/CIP1   is one of the cyclin-dependent kinase (CDK) inhibitor (CDKi) families 
and it is a target of tumour suppressor; p53 plays a central role in regulating the cell 
cycle, in transcription regulation, cell motility as well as apoptosis. Though it is known 
to protect various cell types from apoptosis, its role in apoptosis is still controversial and 
its over-expression in tumour cells lines enhances its apoptosis (Lee et al., 2009). In 
previous studies, SAHA treatment resulted in an increase in the level of p21 in B-cell 
malignancies (Mitsiades et al., 2003) and co-treatment of SAHA and proteasome 
inhibitor bortezomib synergistically induced apoptosis of Burkitt's lymphoma cells by 
up-regulating p21 expression (Hui et al., 2014). LMB treatment induces apoptosis in 
prostate cells with increased expression of p53-responsive genes including p21 (Lecane 
et al., 2003). Moreover, G9a inhibitor BIX 01294 inhibited proliferation as well as 
induced cell cycle arrest in foetal pulmonary artery smooth muscle cell (PASMC) by 
upregulating the expression of p21 (Yang et al., 2012). Co-treatment of EZH2 inhibitor 
and HDAC inhibitor synergistically increased the expression p21 in melanoma cells 
(Fan et al., 2011).  
5.1.2.5 MMSET  
The increase in the level of the histone methyltransferase (MMSET) changes the 
epigenetic landscape of (4; 14) translocations multiple myeloma subtype which is 
supposed to be the driving factor in the pathogenesis of this subtype (Asangani et al., 
2013). The over-expression of MMSET results in a global induction in H3K36 
methylation and decreases the global levels of H3K27 methylation. Although the 
majority of the genome decreases the methylation of H3K27 in the presence of 
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MMSET; specific loci show increased the recruitment of EZH2 and increased H3K27 
methylation, contributing to transcriptional suppression. The suppression of these genes 
likely plays an important role in the disease. It has been reported that MMSET-over-
expressing cells display higher response to the inhibitors targeting EZH2-mediated 
methylation (Popovic et al., 2014). This suggests that the agents that block the 
enzymatic activity of MMSET and EZH2 are therapeutic potential for multiple 
myeloma. Unfortunately, up to now, no MMSET inhibitor agent has been identified 
(Popovic et al., 2014). Knockdown of MMSET leads to a inhibit cell proliferation, 
activation of caspase, decreased expression of adhesion molecules and affects the 
progression of cell cycle in myeloma cells harboring t(4;14) (Brito et al., 2009). 
5.2 Introduction to Methods for Mechanistic Characterization 
5.2.1 Caspase-GloTM Luminescent 8 and 9 Assays 
Caspase has a key role in stimulation of cell death (Lavrik et al., 2005). In apoptotic 
pathways, caspase-3, which shown to be activated by either TRAIL or TRAIL 
sensitizers (Chapter 2) is activated by either initiator caspase-8 via the mitochondrial or 
extrinsic pathway, or caspase-9 via death receptor or intrinsic pathway (Ivanov et al., 
2011). Caspase-Glo 8 and 9 luminescent assay were used to determine the effect of 
TRAIL or TRAIL sensitizers on the activation of caspase-8 and -9 to investigate 
whether cell death was triggered via extrinsic and/or intrinsic cascade. The addition of 
Caspase-Glo®-9 or-8 luminogenic substrates promotes cell lysis, followed by detection 
of luminescent signals due to caspase cleavage of the substrate. This generated 
luminescent signal is proportional to the amount of caspase 9 and 8 activity present. 
5.2.2 Real Time RT-PCR 
Real-time RT-PCR is a highly sensitive, precise and simple method used in the 
molecular diagnosis and in analysing the gene expression and it has become the most 
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widely used techniques for validating the data of the whole-genome microarray as well 
as a smaller set of genes. One of the main PCR applications is relative 
comparative quantification, where the target gene expression gene is displayed as a ratio 
to a stably expressed reference gene, known as the housekeeping gene.  These internal 
standard genes are used for normalizing the quantification of the mRNA so it 
overcomes the problems related to reproducibility.  Moreover, they are used as an 
internal standard because they display a stable expression in the various cell types of 
different tissues at the diverse stages of development under various extreme 
experimental conditions (Carraro et al., 2005; Jain et al., 2006). 
5.2.3 Proteome Profiler Array   
Investigating the expression of a number of apoptosis-related proteins using human 
proteome profiler apoptosis array is useful for understanding the roles these apoptotic 
molecules perform in apoptosis and disease mechanisms. It is a sensitive and rapid 
method to determine the relative expression level of 35 different apoptosis-related 
proteins involved in both intrinsic and extrinsic apoptotic cascades (Table 5.1). See 
appendix (Figure V) and (Table I) of Human apoptosis proteome profiler Array 
Coordinates. 
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Target Target 
Bad 
Bax 
Bcl-2 
Bcl-x 
Pro-Caspase-3 
Cleaved Caspase-3 
Catalase 
cIAP-1 
cIAP-2 
Claspine 
Clustrine 
Cytochrome C 
TRAIL R1/DR5 
TRAIL R2/DR4 
FADD 
Fas/TNF6/CD95 
HIF-1α 
HO-1/HMOX1/HSP32 
HO-2/HMOX2 
HSP27 
HSP60 
HSP70 
HTRA2/Omi 
Livin 
PON2 
p21/CIP1/CDKN1A 
p27/Kip1 
Phospho-p53 (S15) 
Phospho-p53 (S46) 
Phospho-p53 (S392) 
Phospho-Rad17 (S635) 
SMAC/Diablo 
Survivin 
TNF RI/TNFRSF1A 
XIAP 
 
Table 5.1: Apoptotic-related proteins spotted on array membrane of human 
proteome apoptosis profiler array 
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5.2.4  Hypothesis 
It is hypothesized that TRAIL, NEI, HDACi and HMTasei agents alter key pro- and 
anti-apoptotic genes in both suspension and 3D cultures models as well as in parental 
and TRAILR multiple myeloma cells and that their effects are mediated by caspase 
activation. 
5.2.5 Aims  
The aims of this study were to examine the effect of TRAIL alone and in combination 
with TRAIL sensitizer on the activity of initiator caspase (-8 and -9) of apoptotic 
cascade using Caspase-Glo-8 and -9 Luminescent Assays in multiple myeloma cell 
lines. Additionally, this study aimed to investigate the effect of these therapeutic agents 
alone on regulating key pro- and anti-apoptotic genes using Real-time PCR in parental 
and TRAILR multiple myeloma cells as well as in 3D culture. In the absence of key 
regulator genes identified by qRT-PCR number of apoptotic related genes was screened 
by proteome profiler apoptotic array. The NCI-H929 multiple myeloma cell line 
responded well to TRAIL and TRAIL sensitizers and was thus selected to be 
investigated using the proteomic array. 
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5.3 Materials and Methods 
5.3.1 Experimental Design  
Six multiple myeloma cell lines were used in this study OPM2, NCI-H 929, RPMI 
8226, U266, JJN3 and ADC-1 (Chapter 2). Cells were cultured as previously described 
(Chapter 2) and incubated under standard cell culture conditions at 37ºC with 5% CO2 
atmosphere.  
All therapeutic agents were prepared as described in Chapter 2. Multiple myeloma cell 
lines were treated with different concentration dose of TRAIL sensitizers -/+TRAIL 
including those combinations which induced synergistic induction of apoptosis as 
determined by Hoechst 33342/PI staining (Chapter 2) to investigate their effects on 
Caspase-8, and -9 activation following 24 h (Table 5.1). In addition, Real-time PCR was 
used for detection the expression of a number of apoptotic genes in parental multiple 
myeloma cells vs. TRAIL R cells treated with anti-tumour agents alone (Chapter 2) as 
well as in suspension vs. 3D culture models following treatment with concentration of 
drugs that induced low levels of apoptosis (Chapter 3) (Table 5.2). In this work, a small 
number of likely targets for RT-PCR studies was selected, including Bax, c-flip, p21, 
Bcl-2 and HRK. Moreover, the expression of range of pro- and anti-apoptotic proteins 
was tested on TRAIL sensitive cell line NCI-H929 treated with high concentration of 
drugs alone for 24 h using proteomic apoptotic array (Table 5.2). MM cells lines and 
different concentration of drugs for each technique are shown in Table 5.2. 
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Method MM Cell line Drug concentration 
Caspase-GloTM 
Luminescent 8 and 
9 Assays 
All six MM cell lines: OPM2, NCI-H 
929, RPMI 8226, U266, JJN3 and 
ADC-1 
LMB: 0, 0.5, 2 and 5 nM 
SAHA: 0, 1, 5 and 10 μM 
BIX 01294: 0, 5, 10 and 15 μM 
GSK343: 0, 5, 10 and 15 μM 
Either alone and in combination 
with TRAIL 
Real-time PCR. NCI-H 929 vs. TRAILR NCI-H 929 
RPMI 8226 vs. TRAILR RPMI 8226 
 
 
Suspension U266 vs. 3D U266 
Suspension NCI-H 929 vs. 3D NCI-H 
929 
For parental and TRAILR 
cells: LMB (1 nM), SAHA (10 
μM), BIX 01294 (10 μM) and 
GSK343 (15 μM). 
For both suspension U266 and 
3D U266: LMB (0.5 nM), 
SAHA (1 μM), BIX 01294 (5 
μM) and GSK343 (5 μM). 
Proteomic 
Apoptotic Profiler 
Array 
TRAIL sensitive cell line 
(NCI-H 929) 
SAHA (10 μM), BIX01294: (15 
μM) and GSK343 (15 μM). 
 
Table 5.2: Multiple myeloma cells lines treated with variuos concentrations of 
drugs for 24 h and investigated with different techniques. 
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5.3.2 Caspase-GloTM Luminescent 8 and 9 Assays 
Caspase-8 and -9 activities in multiple myeloma cells were determined using the 
Caspase-Glo® 8/9 Assay (Promega, Southampton, UK) according to manufacturer’s 
instructions. Cells were lysed as Caspase-Glo reagent added, followed by detection of 
luminescent signals due to caspase cleavage of the substrate. Briefly, multiple myeloma 
cell lines were treated with selected dose of TRAIL and chemotherapy agents (LMB, 
SAHA, BIX 01294 and GSK343) (Table 5.2) in white 96 well-plates (Fisher Scientific). 
All treatments were performed in triplicate, in three independent experiments. 
Following 24 h incubation, 50 µl of Caspase-Glo 8 Reagent or Caspase-Glo 9 Reagent 
(Promega) with the proteasome Inhibitor MG-132 to reduce nonspecific background 
activity were added to each well. After incubation for 90 minutes at room temperature 
luminescence was measured using Wallac Victor 2 1420 luminometer.  
5.3.3 Real Time PCR 
5.3.3.1 RNA Isolation and cDNA Synthesis  
5.3.3.1.1 RNA Extraction from Monolayer Cultures 
 
Following treatment with anti-tumour agents, TRAIL, SAHA, BIX01294, and GSK343 
(Table 5.2), cells suspensions containing multiple myeloma cells from the well plate 
were transferred into an Eppendorf tube and centrifuged at 400g for 10 minutes. 1ml of 
Trizol (Invitrogen) was added to cell pellets after removing of the supernatant and 
incubated for 10 minutes at room temperature in order to lyse the cells. 200 μL of 
Chloroform (Sigma) was added per sample; samples were mixed by vortexing and 
incubated for 10 minutes at room temperatures prior to centrifugation at 12,000g for 15 
minutes at 4°C to facilitated separation of RNA, protein and DNA layers. 500 μL of the 
upper aqueous phase containing the RNA was transferred to a new tube and 500 μL 
isopropanol (Fisher) was added to the tube sample and mixed by pipetting. Samples 
were incubated at room temperature for 10 minutes followed by stored at -80 °C for 1 
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hour in order to allow RNA precipitation. Cell pellets were re-suspended in 70% 
ethanol (v/v) (Fisher) after being centrifuged for 30 minutes at 12000g at 4°C. RNA 
samples were eluted in 50 μL sterile deionised water and used immediately for the 
synthesis of cDNA. 
5.3.3.1.2 RNA Extraction from Alginate Bead Cultures 
 
RNA was extracted using Trizol reagent (Invitrogen). Prior to Trizol extraction, alginate 
beads were removed from well plate and transferred into Eppendorf tubes and 500 µl 
alginate dissolving buffer (55 mM sodium citrate, 30 mM EDTA, 0.15 M NaCl; pH 6) 
were added and incubated rotating at 37°C for 15 and cells were then subsequently 
centrifuged at 600g for 5 minutes followed by washing in PBS twice. Then, RNA 
extraction by Trizol as described in Section 5.3.3.1.   
RNA extracted from monolayer and alginate cultures were assessed for purity by 
subjected to nanodrop spectrophotometer analysis. See appendix for Figure VI. 
Absorbance at wave lengths of 260 and 280 nm was measured and used as an indicator 
of RNA integrity.  The integrity of the extracted RNA was confirmed by 1% agarose gel 
electrophoresis and ethidium bromide staining. See appendix for Figure VII. 
5.3.3.2 cDNA Synthesis 
 
The purified RNA was quantitated and transcribed to cDNA using superscript reverse 
transcriptase (Bioline). RNA samples were incubated at 60°C for 5 minutes in order to 
denature RNA prior to Reverse Transcriptase (RT) mastermix was added. 36 l of RT 
mastermix per 14l RNA sample was added made up as shown in Table 5.3. Reactions 
were incubated at 42°C for 1 h followed by denaturation at 95°C for 10 minutes prior to 
PCR amplification. As a negative control, Reverse Transcriptase was omitted from 
reactions.   
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Master mix for 1 Reaction 14μL RNA 
Sample 
dNTPs (40mM) (Bioline) 1.5 
Random Hexamers (Applied 
Biosystems) 
1.0 
Bioscript 5x RT Buffer (Bioline) 5.0 
Bioscript RT Enzyme (Bioline) 0.5 
Sterile deionised PCR H2O 28.0 
 
Table 5.3 Reverse transcription mastermix used in cDNA synthesis reaction 
 
5.3.3.3 Quantitative Real Time-Polymerase Chain Reaction 
 
qRT-PCR was performed on cDNA samples using a StepOnePlus™ Real-Time PCR 
System (Applied Biosystems). A small number of likely HDAC and HMTase targets for 
RT-PCR studies were selected including Bax, p21, c-flip, Bcl-2 and HRK (Applied 
Biosystems) and gene expression level of these target genes was performed. TFRC 
Transferrin receptor (Applied Biosystems) was used as housekeeping genes to allow the 
comparative CT methods to calculate relative gene expression. 10 µL reactions were 
prepared using TaqMan Universal PCR Mastermix (Applied Biosystems), made up as 
shown in Table 5.4. 2 µL of cDNA sample was loaded in duplicate into a Fast PCR 
plate (Applied Biosystems) and 8µL of prepared TaqMan Universal PCR Mastermix 
was added as shown in Table 5.4. PCR Plates were sealed with adhesive film and run on 
the StepOnePlus Real-Time PCR machine. 
 
Universal PCR Master Mix For 1 
Reaction: µL 
Taqman Gene Expression Assay 0.5 
2X Taqman Fast Mastermix 5.0 
Sterilised deionised PCR H2O 2.5 
Cdna 2 
 
10.0 
 
Table 5.4: TaqMan universal PCR mastermix 
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5.3.3.4 Analysis of qRT-PCR 
CT (Cycle threshold) values of the amplification plots and relative fold changes in target 
gene expression were analysed using the comparative method (2-ΔΔCT method) and 
expressed as relative gene expression normalized to the housekeeping gene. In order to 
produce reliable data, threshold setting has to be maintained across the entire 
investigated sample as well as the selection of the most stably expressed internal 
reference genes are required. Mean of the two duplicated wells was calculated.  Then, 
for each sample, ΔCT values were determined using the equation:  
ΔCT = CT (gene of interest) - CT (mean of reference) 
Relative gene expression was then determined by the equation:  
Relative gene expression= 2-ΔCT 
 
The arithmetical mean ΔCT and standard error of mean (ΔCT SE) were calculated using 
the equation: 
ΔΔCT = ΔCT (tested sample) – ΔCT (untreated sample) 
 
Finally, the range for target gene relative to an internal gene sample is calculated by the 
equation:  
Relative gene expression= 2-ΔΔCT 
 
5.3.4 Proteome Profiler Array Investigating the Anti-tumour Agents Induced 
Apoptosis Mechanisms in Multiple Myeloma 
Following treatment of NCI-H929 multiple myeloma cell line with TRAIL, SAHA, BIX 
01294 and GSK343 alone (Table 5.2), cells were washed twice with PBS. Cell lysate 
prepared from CelLyticTM (Sigma, C2978, 10 ml/g) supplemented with protease 
inhibitor cocktail (Sigma, P2714, 1:100) was added in order to breakdown the cell 
membrane and inhibit degradation of protein by endogenous protease present in the cell 
extract. The total protein was quantified using Pierce™ BCA protein assay kit 
(Thermofisher scientific, 23225). 
The proteomic profile array was performed following manufacturer’s recommendations. 
Briefly, each antibody–coated profiler membrane was incubated with 300 μg of 
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prepared cell lysates and incubated for 1 hour on a rocking platform shaker and the 
protein extracts from control and treated sample were added to proteome membrane and 
incubated at 2-8 °C with shaking overnight. Antibody-coated nitrocellulose membranes 
were washed in triplet with IX wash buffer and 1.5 ml lyophilized biotinylated 
antibodies was added and incubated for 1 hour on a rocking platform shaker followed 
by washing with IX wash buffer for three times 10 minutes each. IRDye® 800CW 
Streptavidin (LI-COR, 926-32230) diluted at 1:2000 using the array buffer 5 (R&D 
Systems, ARY002B) was added and membrane incubated for 30 minutes on rocking 
platform followed by three times washing with IX wash buffer. Finally, the arrays 
membranes were scanned with LI-COR Odyssey® Infrared Imaging System and 
quantified with Image Studio™ software (LI-COR). Data was quantified by scanning 
the array and exploring signal values of each spot on the array membrane and the mean 
of two spot representing each apoptosis-related protein was calculated. Comparison of 
corresponding signals intensity among membrane array image was used to identify the 
relative difference expression level of apoptosis-related protein between control and 
treated samples.  
5.3.5 Statistical Analysis 
Median with range was calculated for CellTiter- GloTM, Caspase-8, -9 activity and PCR. 
To test the effect of TRAIL resistant development mRNA levels it compared in 
untreated cells vs. treated in both TRAIL sensitive and TRAIL resistant cells as well as 
compared between TRAIL sensitive cells vs. TRAIL resistant cells. Moreover, the gene 
expression was determined by comparison the treated cells with the vehicle control and 
by comparison the suspension cells with 3D cultures. Relative gene expression 
determined by the 2-ΔΔCT method. Stats Direct software was used to determine whether 
the data followed a normal distribution.  As the data did not follow a normal 
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distribution, significance difference determined using a Kruskal-Wallis and Connover-
Inman post hoc test with a p value of 0.05. 
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5.4 Results 
5.4.1 Effect of Anti-Tumour Agents on Caspase Activity in Multiple Myeloma 
Cells  
5.4.1.1 Effect of LMB on Caspase Activity in Multiple Myeloma Cells  
To determine which apoptotic pathway was responsible for LMB-mediated enhanced 
TRAIL-signaling, the activity of caspase-8 (early initiator caspase of the extrinsic 
pathway), caspase-9 (early initiator caspase of the intrinsic pathway) was measured with 
cell-based homogenous Caspase-Glo kit assay. Multiple myeloma cell line OPM2, 
RPMI 8226 NCI-H929, U266, JJN3 and ADC-1 cells treated with LMB at 
concentrations of 0, 0.5, 2, 5 nM alone and in combination with TRAIL for 24 hours 
and compared with vehicle control. TRAIL alone enhanced caspase-8 and caspase-9 
activity in RPMI 8226, OPM2, and U266 cell lines (p < 0.05).  
In response to TRAIL alone at the lowest dose that induced apoptosis, caspase-8 and -9 
were induced in all cells except NCI-H929 (caspase-8 only), ADC-1 (caspase-9 only) 
and JJN3 no caspase induction at 50 ng/ml TRAIL (Figure 5.1). The TRAIL sensitizer 
LMB alone also enhanced caspase-8 and -9 activities in NCI-H929, RPMI 8226, JJN-3, 
and U266 (p < 0.05) and a significant increase was only seen in caspase-9 and caspase-8 
following treatment with LMB alone in ADC-1 and OPM2 cell line respectively 
(p < 0.05), (Figure 5.1). The combination treatment further elevated caspase-8 and -9 
consistent with morphological observations in all multiple myeloma cell lines (Figure 
5.1). RPMI 8226 activated caspase-8 and -9 after dual treatment of 0.5 nM LMB and 
TRAIL whilst NCI-H929, U266, ADC-1, OPM2, and JJN3 potentially activated 
caspase-8 and -9 by LMB alone.  
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Figure 5.1: Effect of LMB+/-TRAIL on caspase-8 and caspase-9 activity of 
multiple myeloma cell lines 
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Figure 5.1: continued 
 
 
 
 
 
 
 
Figure 5.1: Effect of LMB+/-TRAIL on caspase-8 and caspase-9 activity of multiple 
myeloma cell lines. Multiple myeloma cells treated with LMB either alone or in 
combination with TRAIL for 24 h. Data was normalized to the vehicle control which 
was set to 100%. Caspase activation data is consistent with apoptosis induction as 
observed in chapter 2. The data is expressed as median with range (three independent 
experiments, each in triplicate). The statistical significance was determined by 
comparison with the vehicle control (*= p< 0.05) (Kruskal–Wallis). 
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5.4.1.2 Effect of the HDACi SAHA on Caspase Activity in Multiple Myeloma Cells  
SAHA caused a significant increase in both caspase-8 and -9 activities at 24 h in all 
multiple myeloma cell lines (p < 0.05) (Figure 5.2) and the co-treatment with TRAIL 
further elevated caspase-8 and -9 consistent with morphological observations in all 
multiple myeloma cell lines (Figure 5.2). RPMI 8226 activated caspase-8 and -9 after 
dual treatments of 1 M SAHA and TRAIL and in NCI-H929 caspase-8 activation 
observed following combination treatment. However, U266, ADC-1, OPM2, and JJN3 
activated caspase-8 and -9 by SAHA alone. The results confirm that both TRAIL and 
SAHA significantly increased both cellular caspase-8 and -9 activities and that 
enhanced apoptosis from dual treatment is in part via the intrinsic pathway.  
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Figure 5.2: Effect of SAHA +/-TRAIL on caspase-8 and caspase-9 activity of 
multiple myeloma cell lines 
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Figure 5.2: continued 
 
 
 
 
 
 
Figure 5.2: Effect of SAHA +/-TRAIL on caspase-8 and caspase-9 activity of multiple 
myeloma cell lines. Myeloma cells treated with SAHA either alone or in combination 
with TRAIL for 24 h. Data was normalized to the vehicle control which was set to 
100%. The data is expressed as median with range (three independent experiments, 
each in triplicate). The statistical significance was determined by comparison with the 
vehicle control (*= p< 0.05) (Kruskal–Wallis). 
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5.4.1.3 Effect of the HMTasei BIX01294 on Caspase Activity in Multiple Myeloma 
Cells  
BIX 01294 alone or in combination with TRAIL significantly increased caspase-8 and -
9 activity in NCI-H929, RPMI 8226, JJN3, U266 and ADC-1 cell lines (p 0.05). In 
OPM2 cell lines, BIX 01294 alone significantly increased caspase-8 activity while 
combination treatment with TRAIL significantly elevated caspase-9 activity (p 0.05) 
(Figure 5.3). NCI-H929 activated caspase-8, after dual treatment of 5 M BIX 01294 
and TRAIL whilst in U266, ADC-1, OPM2, and JJN3 potentially activated caspase-8, -
9 by BIX 01294 alone and in RPMI 8226 activated caspase-8 and -9 by TRAIL alone.  
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Figure 5.3: Effect of BIX 01294 +/-TRAIL on caspase-8 and caspase-9 activity of 
multiple myeloma cell lines 
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Figure 5.3: continued 
 
 
 
 
 
 
 
Figure 5.3: Effect of BIX 01294 +/-TRAIL on caspase-8 and caspase-9 activity of 
multiple myeloma cell lines. Multiple myeloma cells treated with BIX 01294 either 
alone or in combination with TRAIL for 24 h. Data was normalized to the vehicle 
control which was set to 100%. The data is expressed as median with range (three 
independent experiments, each in triplicate). The statistical significance was determined 
by comparison with the vehicle control (*= p< 0.05) (Kruskal–Wallis). 
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5.4.1.4 Effect of the HMTasei GSK343 on Caspase Activity in Multiple Myeloma 
Cells  
Treatment with GSK343 in the presence of TRAIL resulting in significant increase of  
caspase-8 and -9 activity in OPM2, NCI-H929, RPMI 8226, and U266 cell line (p 
0.05) (Figure 5.4). While in ADC-1 cell line a significant increase was only seen in 
caspase-9 and no significant effect in caspase-8 following treatment with GSK343 alone 
and in combined with TRAIL except the highest combination dose. GSK343 did not 
affect caspase-9 activity, but significantly increased caspase-8 activity in JJN3 cell line 
(Figure 5.4). RPMI 8226 and U266 activated caspase-8 and -9 after dual treatment 
potentially by TRAIL as well as in NCI-H929 potentially activated caspase-8 by 
TRAIL.  
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Figure 5.4: Effect of GSK343 +/-TRAIL on caspase-8 and caspase-9 activity of 
multiple myeloma cell lines 
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Figure 5.4: continued 
 
 
 
 
 
 
Figure 5.4: Effect of GSK343 +/-TRAIL on caspase-8 and caspase-9 activity of 
multiple myeloma cell lines. Multiple myeloma cells treated with GSK343 either alone 
or in combination with TRAIL for 24 h. Data was normalized to the vehicle control 
which was set to 100%. The data is expressed as median with range (three independent 
experiments, each in triplicate). The statistical significance was determined by 
comparison with the vehicle control (*= p< 0.05) (Kruskal–Wallis). 
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5.4.2 Effect of TRAIL Treatment on Expression of Pro-Apoptotic and Anti-
Apoptotic Genes in Multiple Myeloma Cells 
Next, we determined the effects of TRAIL on the levels of the pro-apoptotic protein; 
Bax and HRK, cell cycle regulators; p21 and anti-apoptotic genes; c-flip and Bcl-2 in 
parental cells vs. TRAIL resistant cells. TRAIL-resistant cells were generated by acute 
exposure of the TRAIL sensitive cells with a high/lethal dose of TRAIL (50ng/ml) 
followed by a selection of TRAIL-resistant cells (Chapter 2). Treatment with TRAIL 
was accompanied by a significant increase in pro-apoptotic gene HRK in parental NCI-
H929 and significant up regulation of c-flip and p21 in TRAILR NCI-H929 cells. 
Moreover, a significant increase in the expression of p21 and modest increase in Bcl-2 
but it failed to reach significance in RPMI 8226 TRAIL-resistant cells compared to 
parental cells. In addition, a significant increase in expression of Bax as well as decrease 
but not significant in HRK expression in TRAIL-resistant cell lines compared to 
parental cells (Figure 5.6).  
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Figure 5.5: Basal gene expression in parental vs. TRAIL resistant cells 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: qRT-PCR demonstrates the fold changes in expression of Bax, c-flip, p21, 
Bcl-2 and HRK in parental vs. TRAIL resistant cells relative to the internal control 
gene TFRC. The graph shows that there was a small increase in expression in Bax, c-
flip, p21 and HRK in TRAIL resistant RPMI 8826 cells and decrease expression of all 
genes in TRAIL resistant NCI-H929 cells vs. parental cells.  
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Figure 5.6: Effect of TRAIL on gene expression in parental vs. TRAIL resistant 
cells 
 
 
 
 
 
Figure 5.6: The expression of Bax, c-flip, p21, Bcl-2 and HRK in parental and 
TRAIL resistant cells RPMI 8226 and NCI-H929 cells stimulated with TRAIL. The 
anti-apoptotic genes expression Bcl-2 and c-flip was amplified by qRT-PCR in the 
TRAILR cell lines in response to TRAIL treatment as well as decrease expression of pro-
apoptotic HRK genes. The statistical significance was determined by comparison with 
the vehicle control and by comparison of parental with TRAILR cells (*= p< 0.05) 
(Kruskal–Wallis). 
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5.4.3 Effect of LMB Treatment on Expression of Pro-apoptotic and Anti-
Apoptotic Genes on Parental vs. TRAIL-Resistant and in 3D Culture  
This study sought to examine the potential involvement of signaling mechanisms in 
proliferation inhibition and apoptosis induction by LMB in TRAILR MM cells. qRT-
PCR used to determine the expression levels of a number of pro-apoptotic and anti-
apoptotic genes. The results showed increase expression of p21 in parental RPMI 8226, 
U266 and NCIH929 cell lines. In addition, a significant increase in Bcl-2 expression 
(p < 0.05) and a small decrease but non-significant in Bax, c-flip and MMSET as a 
result of treatment with LMB in RPMI 8226 TRAILR cells compared to parental cells 
(Figure 5.7). 
Furthermore, the effects of LMB on the expression of apoptosis-related genes in 
multiple myeloma cells in 3D vs. suspension cultures condition was investigated in 
TRAIL-sensitive cell line NCI-H929 and TRAIL-resistant cell line U266. The data 
shows a significant up-regulation of pro-apoptotic gene Bax and HRK (p < 0.05) in 3D 
cultures U266 and NCI-H 929 cell line and a decrease but non-significant in p21 in 3D 
cultures treated with LMB (Figure 5.8) 
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Figure 5.7: Effect of LMB on the expression of the pro-apoptotic and anti-
apoptotic genes in parental cells vs. TRAIL resistant RPMI 8226 cells 
 
 
Figure 5.7: Effect of LMB on the expression of the pro-apoptotic and anti-apoptotic 
genes in parental cells vs. TRAIL resistant cells. TRAIL sensitive cells RPMI 8226 
were treated with LMB (1nM) for 24 hours and the gene expression of Bax, c-flip, p21, 
Bcl-2 and MMST was determined by qR-PCR. TFRC was as an endogenous control. 
The statistical significance was determined by comparison with the vehicle control and 
by comparison of parental with TRAILR cells (*= p< 0.05) (Kruskal–Wallis). 
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Figure 5.8:  Effect of LMB on the expression of the pro-apoptotic and anti-
apoptotic genes in suspension vs. 3D cell culture 
 
 
 
 
 
 
Figure 5.8:  Effect of LMB on the expression of the pro-apoptotic and anti-apoptotic 
genes in suspension vs. 3D cell culture. U266 and NCIH 929 cells were treated with 
LMB (1 nM) for 24 hours and the gene expression of Bax, c-flip, p21, Bcl-2 and HRK 
was determined by qR-PCR in suspension vs. 3D. RT-PCR demonstrates that LMB 
significantly increases the expression of Bax and HRK genes of U266 and NCI-H929 in 
3D cultures vs suspension cultures. The statistical significance was determined by 
comparison with the vehicle control and by comparison the suspension cells with 3D 
cultures (*= p< 0.05) (Kruskal–Wallis). 
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5.4.4 Effect of SAHA Treatment on Expression of Pro-apoptotic and Anti-
Apoptotic Genes in Parental vs. TRAIL-Resistant and 3D Culture Myeloma 
Cells 
SAHA treatment (10µM) significantly up-regulation of p21 in both parental and 
TRAILR RPMI 8226 cells (p < 0.05) (Figure 5.14). In contrast, SAHA increased Bcl-2 
in TRAILR cells and decrease Bcl-2 in parental cells. SAHA caused a modest decrease 
in c-flip in parental cells only (Figure 5.9). In U266 cell line, SAHA caused a 
significant up-regulation of p21 expression, and a significant decrease in c-flip 
expression was seen (p < 0.05). Moreover, significant up-regulated Bcl-2 expression 
(p < 0.05) and a non-significant increase in c-flip following treatment with SAHA in 
RPMI 8226 TRAIL resistant cells compared to parental cells (Figure 5.9). 
In addition, the effects of SAHA on the expression of a pro-apoptotic and anti-apoptotic 
target genes in multiple myeloma cells in 3D vs. suspension cultures condition was 
investigated. A significant down-regulation of p21 in addition to significant up-
regulation of HRK genes in 3D cultures NCI-H 929 cell line treated with SAHA in 3D 
compared with suspension cultures was seen (p < 0.05). In addition, increased 
expression of pro-apoptotic Bax was seen but, it failed to reach significance in 3D vs. 
suspension cultures condition (Figure 5.10) 
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Figure 5.9: Effect of SAHA on the expression of the pro-apoptotic and anti-
apoptotic genes in parental cells vs. TRAIL-resistant RPMI8226 cells 
 
 
 
Figure 5.9: Effect of SAHA on the expression of the pro-apoptotic and anti-apoptotic 
genes in parental cells vs. TRAIL resistant cells. TRAIL sensitive cells RPMI 8226 
were treated with SAHA (10µM) for 24 hours and the gene expression of Bax, c-flip, 
p21, Bcl-2 and MMSET was determined by qRT-PCR. The statistical significance was 
determined by comparison of the vehicle control with SAHA treated cells and by 
comparison of parental with TRAILR cells (*= p< 0.05) (Kruskal–Wallis). 
 
Figure 5.10:  Effect of SAHA on the expression of the pro-apoptotic and anti-
apoptotic genes in suspension vs. 3D cell culture 
 
Figure 5.10:  Effect of SAHA on the expression of the pro-apoptotic and anti-
apoptotic genes in suspension vs. 3D cell culture. U266 cell line was treated with 
SAHA (1 µM) for 24 hours and the gene expression of Bax, c-flip, p21and HRK was 
determined by qR-PCR in suspension vs. 3D. The statistical significance was 
determined by comparison with the vehicle control and by comparison the suspension 
cells with 3D cultures (*= p< 0.05) (Kruskal–Wallis). 
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5.4.5 Effect of BIX 01294 Treatment on Expression of Pro-apoptotic and Anti-
Apoptotic Genes in Parental vs. TRAIL-Resistant and 3D Culture Myeloma 
Cells 
The potential mechanism of BIX 01294 to induce apoptotic cell death in TRAILR 
population on number of pro-and anti-apoptotic genes was investigated using qRT-PCR. 
The data showed that significant up-regulation of p21 and down-regulation of MMSET 
in RPMI 8226 treated with BIX 01294 (p < 0.05). Moreover, BIX 01294 induced a 
significant up-regulation of Bcl-2, c-flip and MMSET in TRAILR RPMI 8226 compared 
to parental cells (p < 0.05) (Figure 5.11) that could explain the resistant behavior of this 
cell line to BIX 01294. However, the pro-apoptotic gene Bax significantly increased in 
TRAILR RPMI 8226 cell line compared to parental cells (Figure 5.11). 
In addition, the result showed a significant up-regulation of HRK genes in 3D cultures 
TRAIL insensitive cell line U266 when treated with BIX 01294 (p < 0.05) (Figure 
5.12), potentially contributing to the increase TRAIL sensitivities seen in 3D culture. 
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Figure 5.11: Effect of BIX 01294 on the expression of the pro-apoptotic and anti-
apoptotic genes in parental cells vs. TRAIL resistant RPMI8226 cells 
 
Figure 5.11: Effect of BIX 01294 on the expression of the pro-apoptotic and anti-
apoptotic genes in parental cells vs. TRAIL resistant cells. TRAIL sensitive cells RPMI 
8226 were treated with TRAIL or BIX 01294 (10µM) for 24 hours and the gene 
expression of Bax, c-flip, p21, Bcl-2 and MMSET was determined by qRT-PCR. The 
statistical significance was determined by comparison of the vehicle control with BIX 
01294 treated cells and by comparison of parental with TRAILR cells (*= p< 0.05) 
(Kruskal–Wallis). 
Figure 5.12:  Effect of BIX 01294 on the expression of the pro-apoptotic and anti-
apoptotic genes in suspension vs. 3D cell culture 
 
Figure 5.12:  Effect of BIX 01294 on the expression of the pro-apoptotic and anti-
apoptotic genes in suspension vs. 3D cell culture. U266 cell line was treated with 
SAHA (1 µM) for 24 hours and the gene expression of Bax, c-flip, p21and HRK was 
determined by qRT-PCR in suspension vs. 3D. The statistical significance was 
determined by comparison with the vehicle control and by comparison the suspension 
cells with 3D cultures (*= p< 0.05) (Kruskal–Wallis). 
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5.4.6 Effect of GSK343 Treatment on Expression of Pro-apoptotic and Anti-
Apoptotic Genes in Parental vs. TRAIL-Resistant and 3D Culture Myeloma 
Cells 
Our results showed non significant up-regulation of p21 expression in parental RPMI 
8226 and U266 cells treated with GSK343 as well as a non significant decrease in 
expression of HRK in U266 cell lines. In addition, treatment of TRAILR MM cell lines 
with GSK343 significantly increase the expression of cell cycle regulator p21, anti-
apoptotic Bcl-2 genes (p < 0.05) in TRAILR RPMI 8226 cell that could explain the 
earlier finding in which TRAILR cells were less sensitive to GSK343. However, the pro-
apoptotic gene Bax was also significantly increased (p<0.05) in TRAIL R RPMI 8226 
cells upon stimulation with GSK343 compared with parental cells (Figure 5.13). 
Similar to LMB, SAHA and BIX01294, GSK343 treatment exhibit a significant up-
regulation (p < 0.05) of pro-apoptotic HRK expression in 3D culture U266 cell line 
compared to suspension cells (Figure 5.14). 
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Figure 5.13: Effect of GSK343 on the expression of the pro-apoptotic and anti-
apoptotic genes in parental cells vs. TRAIL resistant RPMI8226 cells 
 
Figure 5.13: Effect of GSK343 on the expression of the pro-apoptotic and anti-
apoptotic genes in parental cells vs. TRAIL resistant cells. TRAIL sensitive cells RPMI 
8226 were treated with TRAIL or GSK343 (10µM) for 24 hours and the gene expression 
of Bax, c-flip, p21, Bcl-2 and MMSET was determined by qRT-PCR. The statistical 
significance was determined by comparison of the vehicle control with GSK343 treated 
cells and by comparison of parental with TRAILR cells (*= p< 0.05) (Kruskal–Wallis). 
 
Figure 5.14:  Effect of GSK343 on the expression of the pro-apoptotic and anti-
apoptotic genes in suspension vs. 3D cell culture 
 
Figure 5.14:  Effect of GSK343 on the expression of the pro-apoptotic and anti-
apoptotic genes in suspension vs. 3D cell culture. U266 cell line was treated with 
GSK343 (1 µM) for 24 hours and the gene expression of Bax, c-flip, p21and HRK was 
determined by qRT-PCR in suspension vs. 3D. The statistical significance was 
determined by comparison with the vehicle control and by comparison the suspension 
cells with 3D cultures (*= p< 0.05) (Kruskal–Wallis). 
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5.4.7 Effects of TRAIL and TRAIL Sensitizers on the Apoptosis-Related Proteins 
in Multiple Myeloma cells using the Apoptotic Proteome Profiler Array  
In order to determine the mechanisms of apoptosis induction by TRAIL and the 
epigenetic modifies, SAHA and BIX 01294 and GSK343 in multiple myeloma cells, a 
number of apoptosis-related protein expression was investigated in a TRAIL sensitive 
MM cell line NCI-H929 using apoptotic proteome profiler array. Treatment of NCI-
H929 with a high dose of SAHA and BIX 01294 and GSK343 for 24 h showed some 
changes in apoptotic related proteins (Figures 5.15, 5.16, 5.17, 5.18 and 5.19). 
Epigenetic modifying agents: SAHA, and BIX 01294 and GSK343 treatment alone 
inhibited DR4 and anti-apoptotic protein XIAP, survivin, cIAP-1, pro-caspase 3 and 
Claspin expression (Figure 5.16). In addition, treatment with GSK343 caused a 
reduction in expression of anti-apoptotic Bcl-X (Figure 5.6). An increase in cleaved 
caspase-3 expression was seen following the treatment with BIX01294 (Figure 5.16). 
NCI-H929 cells showed a decrease in protein expression of heat shock proteins; HSP27, 
HSP60 and HSP70 in addition to a reduction in oxidative protein paraoxonase-2 
(PON2) and heme oxygenase isoforms (HO-2) (Figure 5.17). In comparison with 
control treatment, a reduction of p53 isoforms phosphorylated at S15, S46 and S392 
was seen in NCI-H929 cell line following treatment with SAHA, BIX 01294 and 
GSK343 alone for 24 h (Figure 5.18).  
TRAIL alone induced Death Receptors DR5, FADD, Fas/TNFRSF6, TNFR-1 (Figure 
5.16) and cleaved caspase-3 expression accompanied by decreased pro-caspase-3 and 
anti-apoptotic protein XIAP as well as a reduction in Survivin, and cIAP-1 expression 
(Figure 5.19). In addition, TRAIL treatment decreased HSP60, HSP70 and HO-
2/HMOX2 expression in TRAIL sensitive cell line NCI-H929 compared to control cells 
(Figure 5.17). Importantly, epigenetic treatment as well as TRAIL potently decreased 
expression of catalase (Figure 5.15) however the basal expression was higher than the 
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maximum detection limit that can be accurately quantified by LI-COR Odyssey®. 
Figure 5.15: Human Apoptosis Proteome Profiler Array 
 
 
Figure 5.15: Human Apoptosis Proteome Profiler Array control membrane and 
treated multiple myeloma cells membrane. Approximately 1 ×  107 NCI-H929 cells/ml 
were treated with SAHA, BIX01294, GSK343 and TRAIL and apoptotic-related proteins 
were detected by apoptosis proteomic array. The arrays membranes were scanned with 
LI-COR Odyssey® Infrared Imaging System and quantified with Image Studio™ 
software (LI-COR). Reduction in Catalase protein expression was seen in treated cell 
compared to control untreated cell. The site of catalase proteins are indicated by white 
arrows.  
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Figure 5.16: Expression of some pro-apoptotic and anti-apoptotic proteins 
investigated with apoptotic proteome profiler array in NCI-H929 cells 
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Figure 5.16: Expression of pro-apoptotic Cleaved Caspase and anti-apoptotic proteins 
Survivin, Bcl-X, Claspin and cIAP-1 investigated with apoptotic proteomic array. 
NCI-H929 cells were treated with TRAIL, SAHA, BIX01294 and GSK343 alone for 24 h 
and the protein expression was detected by apoptotic proteome profiler. The result of 
untreated control was cells normalized to 1. 
Figure 5.17: Expression of heat shock proteins investigated with apoptotic 
proteome profiler array in NCI-H929 cells 
Figure 5.17: Expression of heat shock proteins HSP 27, HSP60, HSP70 and PON2 
and HO-2 investigated with apoptotic proteomic array. NCI-H929 cells were treated 
with TRAIL, SAHA, BIX01294 and GSK343 alone for 24 h and the protein expression 
was detected by apoptotic proteome profiler. The result of untreated control was cells 
normalized to 1. 
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Figure 5.18: Expression of p53 isoforms phosphorylated at S15, S46, S392 and 
S635 investigated with apoptotic proteome profiler array in NCI-H929 cells 
 
Figure 5.18: Expression of phosphorylated p53 isoforms S15, S46, S392 and S635 
investigated with apoptotic proteomic array. NCI-H929 cells were treated with TRAIL, 
SAHA, BIX01294 and GSK343 alone for 24 h and the protein expression was detected 
by apoptotic proteome profiler. The result of untreated control was cells normalized to 
1. 
Figure 5.19: Expression of Death Receptors investigated with apoptotic proteome 
profiler array in NCI-H929 cells 
 
Figure 5.19: Expression of Death Receptors DR4, DR5, FADD, Fas and TNF R1 
investigated with apoptotic proteome profiler array. NCI-H929 cells were treated with 
TRAIL, SAHA, BIX01294 and GSK343 alone for 24 h and the protein expression was 
detected by apoptotic proteome profiler. The result of untreated control was cells 
normalized to 1.  
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5.5 Discussion 
In the TRAIL-mediated apoptosis process, initiator caspase-8 transducers trigger the 
apoptotic cascades either directly by means of activation of effector caspase-3/7 or via 
the pro-apoptotic Bid in the mitochondrial pathways. A number of involved factors have 
identified that influence on the TRAIL sensitivity of cancer cells; however, the exact 
underlying molecular mechanisms are still not fully understood. These factors include 
the up-regulation of pro-apoptotic genes and down up-regulation of anti-apoptotic genes 
(Wang et al., 2010). 
This investigation has previously shown that TRAIL and TRAIL sensitizers induce 
apoptosis in multiple myeloma cell lines (Chapter 2). Here, the potential mechanisms by 
which these agents mediate apoptosis were investigated. As a result, this study has 
demonstrated that TRAIL and TRAIL sensitizers induce both the intrinsic and extrinsic 
apoptotic cascades characterized by increases of initiator caspases 8/9 (Figure 5.1, 5.2, 
5.3 and 5.4). qRT-PCR data reveled that upregulation of p21 expression in parental 
multiple myeloma cells lines as a result of treatment with LMB, SAHA, BIX 01294 and 
GSK343 which further increase in resistant cell lines (Figure 5.7, 5.9, 5.11, and 5.13). 
Moreover, SAHA treatment resulted in decreased expression of anti-apoptotic Bcl-2 and 
c-flip genes in myeloma cells (Figure 5.9). Furthermore, the decreased expression of 
MMSET was observed in RPMI 8226 cells upon treatment with BIX 01294 (Figure 
5.11). In addition, increase expression of pro-apoptotic genes HRK and Bax in MM cell 
lines growing in 3D cultures models compared to suspension cultures as a result of 
treatment with these anti-tumour agents (Figure 5.8, 5.10, 5.12, and 5.14). 
TRAIL treatment also shown to up-regulate pro-apoptotic Death Receptors and cleaved-
caspase-3 expression (Figure 5.19 and 5.16). In addition, TRAIL and TRAIL sensitizers 
down-regulate anti-apoptotic protein (XIAP, survivin, cIAP-1, and claspin) (Figure 
5.16) in NCI-H929 cells together with decrease in catalase (Figure 5.15), protein 
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expression of heat shock proteins, heme oxygenase isoforms (HO-2) and anti-oxidative 
protein paraoxonase-2 (PON2) (Figure 5.17).  
5.5.1 Effect of the TRAIL and TRAIL Sensitizer on Intrinsic and Extrinsic 
Pathways: Caspase-8/-9 Activity 
5.5.1.1 The Effect TRAIL and LMB on Caspase-8/-9 Activity 
TRAIL alone enhanced caspase-8 and caspase-9 activity in RPMI 8226, OPM2, and 
U266. While in NCI-H929 cell line a significant increase was only seen in caspase-8 
activity and in caspase-9 in ADC-1 cell line. These results are consistent with earlier 
study which found that TRAIL trigger multiple myeloma cell death by stimulation both 
extrinsic and intrinsic and extrinsic apoptotic cascades via the activation of caspase-3, -
7, -8 and -9 in RPMI 8226 myeloma cell lines (Vitovski et al., 2012).  
LMB alone also enhanced both caspase-8 and -9 activities in NCI-H929, RPMI 8226, 
JJN, and U266 and combination treatment further elevated caspase-8 and -9 consistent 
with morphological observations in all multiple myeloma cell lines. However, a 
significant increase was only seen in caspase-9 and caspase-8 in OPM2 cell lines 
following treatment with LMB alone in ADC-1 and OPM2 cell line respectively. This 
work is considered as the first study investigated the effect of LMB alone or in 
combination with TRAIL in multiple myeloma, concluding that LMB targets intrinsic 
and/or extrinsic pathways to trigger apoptosis in multiple myeloma, although responses 
differ between cell lines tested. Consistent with data in the current study, U937 
leukemic cells showed that treatment with LMB induced apoptosis in leukemia cell 
lines via the mitochondrial pathways related to cytochrome c release and the activation 
of caspase-3, and -9 (Jang et al., 2004). To date there are no studies investigating the 
effect of LMB on caspase activation on multiple myeloma. Together, these earlier 
studies and these results are shown in this work evidently revealed that TRAIL-and-
 254 
 
LMB induced apoptosis is mediated through activation of both intrinsic and extrinsic 
pathways. 
5.5.1.2 Effect of SAHA on Caspase-8/-9 Activity 
Epigenetic modification of gene expression has an essential role in cancer initiation and 
progression (Zhou et al., 2016). The non-selective HDACi SAHA inhibits HDAC I and 
II class activity causes growth inhibition and death in various cancer types both in vivo 
and in vitro such as multiple myeloma (Marks., 2007; Hideshima and Anderson, 2013). 
The mechanisms of action of HDACi in myeloma therapy in preclinical studies have not 
yet been fully understood. Inhibition of histone deacetylation mainly induces 
transcription of positive and negative regulators of proliferation and/or the survival of 
the cell and growth inhibition or cytotoxicity. (Mitsiades et al., 2003; Fandy et al., 
2005; Hildesheim and Anderson., 2013). This study examined the relation of TRAIL 
and TRAIL sensitizers SAHA and the activities of cellular caspase-8 and -9 in multiple 
myeloma cell lines. It was found that HDACi SAHA can activate caspases -8 and -9 in 
these cell lines. 
These results are consistent with the previous study in which the combination therapy of 
TRAIL with HDACi SAHA or sodium butyrate synergistically induces apoptosis in 
human myeloid leukemia cells through activating both the extrinsic and intrinsic 
pathways of apoptosis by activation of caspase-3 and -8 (Rosato., et al 2015). 
Gillenwater et al., (2007) showed that SAHA selectively induced apoptosis in head and 
neck squamous carcinoma cell lines, through the mitochondrial pathway via increase 
release of cytochrome c, caspase-3 cleavage in addition to activation of and Fas death 
signaling via up-grade the expression both Fas and Fas ligand, caspase-8 activation and 
Bid cleavage (Gillenwater et al., 2007). 
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However, these results were inconsistent with two earlier studies which showed SAHA 
treatment in B-cell malignancy including multiple myeloma (Mitsiades et al., 2003) and 
human multiple myeloma cell lines (Fandy et al., 2005) induced growth arrest and 
triggered apoptosis in a caspase-independent without activate cleavage of caspase-8, -9, 
or -3 and was mediated via the release of mitochondrial apoptosis-inducing factor (AIF) 
(Mitsiades et al., 2003; Fandy et al., 2005).  
5.5.1.3 Effect of the HMTasei BIX 01294 on Caspase-8/-9 Activity 
Histone lysine methyltransferase EHMT2/G9a is a key enzyme for dimethylation of 
H3K9 at lysine-9 (H3K9) in euchromatin (Savickiene et al., 2014). Aberrant or over 
expressed of EHMT2/G9a has been observed in various types of human cancers 
including hepatocellular carcinoma (Kondo et al., 2007), lung cancer and bladder cancer 
(Cho et al., 2011). BIX 01294 is a specific G9 histone lysine methyltransferase inhibitor 
stimulates apoptosis in human neuroblastoma cells and decrease the growth of bladder 
cancer cells (Lu et al., 2013; Cui et al., 2015; Kim et al., 2013; Varier and Timmers., 
2011). G9 knockdown in aggressive lung cancer cells suppressed cell migration and 
invasion in vitro and metastasis in vivo (Chen et al., 2010), suggesting that BIX 01294 
is a potential therapeutic agent (Kim et al., 2013; Varier and Timmers, 2011). However, 
the specific mechanism of the apoptosis mediated by BIX 01294-mediated apoptosis in 
cancer cells is still unclear. In the present study, BIX 01294 either alone or in 
combination with TRAIL significantly increased caspase-8 and -9 activity in NCI-
H929, RPMI 8226, JJN3, U266 and ADC-1 cell lines; suggested that BIX 01294 act via 
both the intrinsic and extrinsic apoptotic pathways in these cell lines. However, in 
OPM2 cell lines BIX 01294 alone only significantly increased caspase-8 activity while 
combination treatment with TRAIL significantly elevated caspase-9 activity. This work 
is considered as the first study investigated the effect of HMTasei BIX 01294 alone or in 
combination with TRAIL on caspase in multiple myeloma; concluding that BIX 01294 
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target both intrinsic and extrinsic pathways to trigger apoptosis in multiple myeloma. 
Similar findings were observed in the previous studies that investigated the effect of 
BIX 01294 on bladder cancer cell lines. Cui et al., (2015) demonstrated that BIX 01294 
stimulated caspase-dependent apoptosis by significantly activation of caspase-8, -9, -3 
and cleaved the caspase-3, PARP1 substrate (Cui et al., 2015). Another study found that 
treatment of neuroblastoma cell lines with BIX 01294 activating caspase-3 and -8 (Lu et 
al, 2013) as well as induced capase-3 cleavage in oral squamous cell carcinoma (Ren et 
al., 2015). In addition, BIX 01294 treatment suppressed proliferation and enhanced 
apoptosis of glioma cell line U251 via activation of caspase-9 and -3 (Guo et al., 2016). 
To date, there are no studies of the effect of BIX 01294 alone or in combination with 
TRAIL on caspase in MM. Based on earlier studies and with evidence shown in this 
study support that BIX 01294 is able to trigger apoptosis by activation of caspases, 
however, whether this lead to the stimulation of intrinsic and or extrinsic apoptotic 
pathways differs depending on the cell lines, and the apoptotic pathway mechanism of 
action may be cell lineage-specific. 
5.5.1.4 Effect of the HMTasei GSK343 on Caspase-8/-9 Activity 
EZH2 catalyzes trimethylation of lysine 27 (Lys 27) on histone H3 (H3K27) (Popovic 
et al., 2014) and EZH2 dysregulation has been correlated with poor cancer progression 
(Verma et al., 2012) and inhibition of EZH2 has been reported as an effective approach 
for the cancer treatment (Lund et al., 2014).  GSK343 is a potent and selective inhibitor 
of EZH2 (Verma et al., 2012) that can inhibit the viability, restrained cell cycle 
progression as well as induce cell death of osteosarcoma cells (Xiong et al., 2016). 
However, the molecular basis of mechanisms of apoptosis inhibition by EZH2 is not 
fully understood (Zhang et al., 2014). Here, GSK343 in the presence of TRAIL 
resulting in significant increase of caspase-8 and -9 activity in OPM2, NCI-H929, 
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RPMI 8226, and U266 cell lines at 24 h; suggested that GSK343 act via both the 
intrinsic and extrinsic apoptotic pathways in these cell lines. However, GSK343 
significantly increased only caspase-9 activity in ADC-1 cell lines and caspase-8 
activity in JJN3 cell line; suggested that the apoptosis induction is via extrinsic and/or 
intrinsic pathways activation, however, effects are differentially modulated in different 
cell lines. 
This work is considered as the first study investigated the effect of EZH2 inhibitor 
GSK343 alone or in combination with TRAIL on caspase in MM; concluding that 
GSK343 target both intrinsic and extrinsic pathways to trigger apoptosis in MM. 
However, recent work exhibited that inhibition of EZH2 by UNC1999 and GSK343 
alone stimulate apoptosis in multiple myeloma cell lines INA-6, LP-1 and RPMI-8226 
and the induction of apoptosis by UNC1999 was via both intrinsic and extrinsic 
pathways through cleavage of caspase-3, -8 and -9 (Agarwal et al., 2016). These earlier 
studies and with evidence shown in this study support that the GSK343 is able to trigger 
apoptosis by activation of caspases, however, whether this leads to the stimulation of 
intrinsic and or extrinsic apoptotic pathways differs depending on the cell lines, the 
apoptotic pathway mechanism of action may be cell lineage specific and that the 
combination with TRAIL could have promise in the treatment of multiple myeloma. 
5.5.2 Effects of TRAIL Sensitizers on Gene Expression  
5.5.2.1 LMB 
To investigate the apoptosis effect of TRAIL and TRAIL senstizers in myeloma cells, 
qRT-PCR was performed and the expression of pro-apoptotic genes Bax, anti-apoptotic 
genes; c-flip and Bcl-2 cell and cycle regulators p21 was determined. Results from the 
current study showed upregulation of p21 expression in parental multiple myeloma cell 
lines RPMI 8226, NCI-H929 and U266 as a result of treatment with LMB. Previous 
work has reported that induction of apoptosis in leukemia cells by LMB through 
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cytochrome c release, caspase activation, and decrease expression of Mcl-1 and XIAP 
while there was no change in the expression of Bcl-2 or Bax (Jang et al., 2004). In 
another study, Lecane and colleagues demonstrated that LMB induces apoptosis in a 
p53-dependent manner. The treatment with LMB in the prostate cell line LNCaP cell 
that contains wild-type p53 gene increased the transcription activity of p53 by nuclear 
entrapment and the expression of p53 responsive genes includes p21, Bax and DR5 by 
interfering with their nucleo-cytoplasmic export and subsequent protessomal 
degradation. However, the null-p53 DU 145 cells did not activate the downstream target 
genes (Lecane et al., 2003). This suggests that LMB-dependent effects are in part 
mediated by p53, although other pro-apoptotic transcription factors are known to the 
trapped in the nucleus. Furthermore, unpublished work conducted in our laboratory by 
Haywood-Small et al shows LMB-mediated TRAIL enhancement apoptosis to be p53 
independent in breast and prostate cells (Haywood-Small et al., 2011). 
5.5.2.2 SAHA 
Here, SAHA treatment resulted in a significant increase in p21 expression and 
decreased in anti-apoptotic genes Bcl-2, c-flip expression in multiple myeloma cells. 
These finding are consistent with a previous study on B-cell malignancies which 
showed an induction in the level of p21 and p53, and Bid cleavage after treatment with 
SAHA and that SAHA sensitizes myeloma cells to TRAIL-induced apoptosis with 
reduced expression of the anti-apoptotic proteins XIAP, c-flip, and cIAP2 (Mitsiades et 
al., 2003). 
However, other studies reported that the upregulation of p21 level blocked the TRAIL-
induced apoptosis, which contributed to decrease SAHA sensitivity in human leukemia 
cell lines by delayed cleavage of PARP, caspase-8 and silencing of p21 enhanced 
SAHA–mediated cell death (Wu et al., 2014). Burgess et al., (2001) in a previous study 
showed that treatment of human melanoma cell lines with HDACi azelaic bis-
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hydroxamic acid (ABHA) results in up-regulate expression of p21 and correlated with 
decreased sensitivity and inhibiting apoptosis, suggesting that p21 may provide a 
significant protection against SAHA-mediated apoptosis in leukaemic cells. Earlier 
work has shown that the expression of Bcl-2 was significantly down-regulated after 
treatment of cells with HDACi, Trichostatin A and Valproic Acid on leukaemia cells 
(Jasek et al., 2012).  
Previous work has reported that majority of multiple myeloma tumour cells express 
high levels of c-flip and there was a correlation between c-flip over-expression and 
TRAIL resistance in myeloma cells (Wu et al., 2016). In addition, apoptosis induction 
by SAHA in cutaneous T-Cell lymphoma cells is associated with c-flip down regulation 
(Al-Yacoub et al., 2012) and HDACi sensitize glioblastoma cells to TRAIL-mediated 
apoptosis by c-myc-mediated downregulation expression of anti-apoptotic genes c-flip 
(Bangert et al., 2012). 
5.5.2.3 BIX 01294 
In this study, increased expression of p21 as well as decreased expression of MMSET in 
RPMI 8226 cells upon treatment with BIX 01294. This finding are confirmed by earlier 
work which showed that inhibition of G9a inhibitor BIX 01294 inhibited proliferation 
and induced cell cycle arrest in foetal pulmonary artery smooth muscle cell (PASMC) 
was accompanied by upregulating p21 expression (Yang et al., 2012). However, the 
expression of p21 mRNA in other studies was not induced in neuroblastoma cell line 
LA1-55n treated with BIX 01294 (Lu et al., 2013). Other studies have reported that BIX 
01294 stimulated autophagy-related cell death in colon cancer cells via selectively 
stimulated tumour suppressor p53 target genes, such as p21, but did not activate 
expression the of PUMA, a typical p53 target gene involved in apoptosis (Fan et al., 
2015). Moreover, BIX 01294 suppressed the proliferation of glioma cells and induced 
apoptosis via decreased expression of Bcl-2 as well as increased expression of Bax 
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(Guo et al., 2016).   
MMSET positive cells were more sensitive to BIX 01294 (Chapter 2). It is known that 
multiple myeloma cells are epigenetically altered as part of transformation process. 20% 
of cases have MMSET over-expression presumably inducing oncogene expression from 
transcriptionally active chromatin (H3Kme36) (Popovic et al., 2014). Other cases have 
increase EZH2 and decrease EZH2 induce myeloma-associated oncogene expression, 
including c-MYC, and re-express many miRNAs with TSG activity (Alzrigat et al., 
2017). Furthermore, Zeng et al., (2017) showed that EZH2 decrease stem-like activity 
in multiple myeloma (Zeng et al., 2017). This suggests that targeting histone 
methyltransferase may useful in myeloma although most of the data suggests EZH2 and 
to date, no data is available on G9a. 
5.5.2.4 GSK343  
In the current study, treatment with GSK343 was accompanied with increase expression 
of cell cycle regulatory gene p21. This result is consistent with those of a study 
conducted by Fan, et al., (2011) which showed that the depletion of EZH2 resulting in 
proliferation inhibition of melanoma cells and restoring the cellular senescence 
characteristics. Furthermore, the combination treatment of EZH2 depletion and HDACi 
synergistically increase the expression p21/CDKN1A in melanoma cells via removing 
histone deacetylase 1 (HDAC1) form the transcriptional start site CDKN1A as well as 
the downstream sites (Fan et al., 2011). Moreover, inhibition of methyltransferase 
activity by DZNep enhanced B-Cell lymphoma sensitivity to TRAIL-induced apoptosis 
through caspase-activation and accelerated c-flip degradation (Braun et al., 2015).  
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5.5.3 Effects of TRAIL and TRAIL Sensitizers on Gene Expression in TRAIL-
Resistant Cells   
To investigate the gene expression changes of likely apoptotic and cell cycle modulators 
in parental TRAIL-sensitive NCI-H-929 and RPMI 8226 cells vs. TRAIL resistant cells, 
qRT-PCR was performed. In the current study, prolonged incubation of TRAIL 
sensitive cells with TRAIL significantly increased the expression of c-flip and p21 in 
NCI-H 929 TRAIL resistant cells and a significant increase in p21 in RPMI 8226 
TRAIL resistant cells compared to parental cells, as well as a decrease in HRK 
expression in TRAIL resistant cell lines in comparing to parental cells (Figure 5.6).  
Moreover, LMB treatment showed a significant increase in expression of the anti-
apoptotic gene Bcl-2 (Figure 5.6) in TRAIL resistant cells vs. parental cells in spite of 
the fact that TRAIL-resistant cells were more sensitive to LMB compared to parental 
cells (Chapter 2). Based on these results, it can be suggested that the expression of anti-
apoptotic gene Bcl-2 is not enough to inhibit apoptosis of TRAIL resistant cells by 
LMB.  
This investigation also showed that SAHA treatment increased expression of c-flip and 
Bcl-2 and p21 in TRAIL resistant cells RPMI 8226 compared to parental TRAIL 
sensitive (Figure 5.9)   This is consistent with earlier findings in which SAHA failed to 
sensitize TRAIL resistant cell lines to TRAIL (Chapter 2). The treatment with BIX 
01294 resulted in a significant increase in p21. Moreover, a significant increase in anti-
apoptotic Bcl-2 was observed in RPMI 8226 TRAIL RESISTANT cells (Chapter 2) 
(Figure 5.11) that could partly explain the resistant behavior of this cell line to BIX 
01294. However, the pro-apoptotic gene Bax was significantly increased in TRAIL 
resistant  RPMI 8226 cell line compared to parental cells.  
In addition, increased expression of Bcl-2, p21 and MMSET was observed following 
treatment with GSK343 in RPMI 8226 TRAIL resistant cells compared to parental cells 
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(Figure 5.13). That may explain the earlier finding in which there was significant 
reduction of percentage of apoptosis in response to GSK343 in TRAIL resistant cell 
compared to parental cells (Chapter 2). Earlier work demonstrated an interaction 
between MMSET and EZH2 in MM oncogenesis and MMSET over-expression change 
patterns of EZH2 chromatin binding and methylation status. This work is considered as 
the first study investigating the possible mechanistic by which TRAIL effect on 
TRAILR MM population through examine numbers of apoptotic genes. However, the 
number of target genes that were tested was small making it difficult to draw a 
conclusion and hence a larger number of proteins were subsequently analysed using a 
proteome array. 
5.5.4 Effects of TRAIL and TRAIL Sensitizers on Gene Expression in 3D vs. 
Suspension Cell Culture 
In the current study, challenging the multiple myeloma cells with LMB, SAHA, BIX 
01294 and GSK343 induced the expression of pro-apoptotic gene HRK and Bax in 
investigated multiple myeloma cell lines in 3D cultures condition compared to 
suspension culture, thus potentially overcoming anti-apoptotic Bcl-2 which is the HRK-
interacting protein. That may explain the higher sensitivity of myeloma cells growing in 
3D cultures compared to suspension cultures and these anti-tumour agents sensitize 
myeloma cell lines to TRAIL as this investigation has previously shown (Chapter 3).  
A few investigations on HRK protein expression have been performed, and little is 
known about the epigenetic or post-transcriptional mechanisms that may involve in 
HRK inactivation (Nakamura et al., 2008). HRK inactivation apparently appears in a 
large proportion of all cancer phenotypes and as a potential pro-apoptotic gene, HRK 
may participate in the growth and progression of numerous types of human tumours 
(Nakamura et al., 2008). The HRK role in cell death has been illustrated mostly in 
hematopoietic and neural tissues (Harris and Johnson., 2001; Sanz et al., 2000) and high 
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levels of HRK was found in an embryonic neuronal culture that undergoes apoptosis 
(Imaizumi et al., 1997). Only one published work has investigated the effect of GSK343 
on pro-apoptotic gene HRK while working on EOC cells; it found that EZH2 inhibitor 
GSK343 increased the expression of the pro-apoptotic H3K27Me3 targeted gene HRK 
in 3D, but not in 2D cultures models consistent with this study (Amatangelo et al., 
2013). 
5.5.5 Effects of TRAIL and TRAIL Sensitizers on the Expression of Apoptosis-
Related Proteins in Multiple Myeloma Cells  
After investigating Bax, c-flip, p21, MMSET and HRK gene expression at qRT-PCR 
this investigation further clarify the potential involvement mechanisms of apoptosis 
induction by TRAIL and epigenetic modifiers agents: SAHA, BIX 01296 and GSK343 
in a TRAIL sensitive multiple myeloma cell line NCI-H929, a number of apoptosis-
related protein expression was determined using proteomic profiler array. Here, TRAIL 
treatment induced cleaved caspase-3, DR5, FADD, Fas/TNFRSF6 and TNF R1 proteins 
expression in TRAIL sensitive cell line NCI-H929 compared to control cells (Figure 
5.19). In addition, TRAIL and epigenetic modifiers agents alone inhibited anti-apoptotic 
protein XIAP, survivin, and claspin expression (Figure 5.16), heat shock proteins 
(Figure 5.17), phosphorylated p53 isoforms and heme oxygenase isoforms (HO-2) 
(Figure 5.18). These finding consistent with a recent study by Zhou et al., (2016) using 
an apoptotic proteomic array and qRT-PCR it has been found that SAHA inhibited the 
expression of Bcl-2, Bcl-x and Phospho p53 (S46) and increasing DR5, CDKN1A and 
caspase-3 in breast cell lines. Whereas TRAIL alone significantly up-regulated the 
expression of Bax, caspase-3 and DR5, and down-regulated the expression of Bcl-2, 
Bcl-x, CDKN1A in breast MDA-MB-231 cells. Moreover, the combination therapy 
significantly induced the pro-apoptotic modulating proteins, and they also significantly 
suppressed anti-apoptotic molecules expression in breast cell lines (Zhou et al., 2016).  
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It has been reported that TRAIL treatment significantly up-regulated the Death 
Receptors and pro-apoptotic proteins and down-regulated the anti-apoptotic members of 
the Bcl-2 family in many type of cancer (LeBlanc and Ashkenazi., 2003; Zhou et 
al.,2016).  
In current work, decrease expression of IAP family protein members cIAP, XIAP and   
survivin were accompanied with TRAIL or epigenetic modifiers agents in MM cell line 
compared to untreated cells (Figure 5.16). Survivin is one of important apoptosis 
inhibitor and it contributes to the malignant progression of lymphoma (Aoki et al., 
2003). Previous studies linked between survivin over-expression and the resistance and 
sensitivity to TRAIL-mediated apoptosis in uveal melanoma (Li et al., 2005).  A study 
on malignant gliomas cell lines, XIAP inhibitor embelin acted in synergy with the 
TRAIL and induced the TRAIL-mediated apoptosis by decrease the expression of 
survivin, IAP, and c-flip that conferred TRAIL resistance in glioma cells (Siegelin et 
al., 2009). Moreover, SAHA-induced apoptosis in colon cancer through down-
regulation of anti-apoptotic survivin (Huang and Guo., 2006). 
Here, TRAIL and epigenetic modifier agents alone inhibited heat shock proteins in 
multiple myeloma cell line compared to control cells (Figure 5.17). The effects of heat 
shock proteins including HSP27 and HSP70 have been known to have an important role 
in protection against apoptosis and promote cell survival (Franklin et al., 2005; Garrido 
et al., 2003). Over-expression of HSP27 and HSP60 was observed in many cancer types 
and linked to oncogenesis and therapy resistance. Inhibitions of heat shock proteins 
result in reduced tumour size and could constitute a novel strategy for the cancer 
therapy (Garrido et al., 2003). These findings are consistent with previous works which 
showed that HSP70 inhibited both caspase-dependent and -independent cell death in 
Jurkat T-cells. This suggests that heat shock proteins may be a key anti-apoptotic 
regulator at a very early stage in the cell death signaling cascades (Creagh et al., 2000).  
 265 
 
5.5.5.1 Effects of TRAIL and TRAIL Sensitizers on the Expression of Oxidative 
Enzyme Catalase in Multiple Myeloma Cells 
 In the current work, the level of oxidative enzyme catalase was decreased in TRAIL or 
TRAIL senstizers treatment multiple myeloma cell line compared to control group. 
Generation of ROS has a key role in cell death mediated by TNF-  while Heme-
oxygenase isoform HO-2 maintain cellular protection against oxidative stress and 
apoptosis (Basuroy et al., 2006). In order to protect the cell from oxidative injury and 
the stimulation of apoptotic pathways, ROS must be neutralized by enzymes that 
catalyze hydrogen peroxide, such as catalase and antioxidant metabolites like 
glutathione (GSH) to prevent possible cellular damage and stimulation of the apoptotic 
pathways (Evens et al., 2005). Disruption of these enzymatic antioxidant defense 
systems can thus contribute to increases in ROS (Ikeda et al., 2004). ROS is known to 
induce apoptosis in tumour cells, however, the mechanisms are poorly understood 
(Borutaite and Brown., 2001). High ROS level has been identified in cells undergoing 
apoptosis. Treatment of cells with hydrogen peroxide (H2O2) in vitro alone causes either 
apoptosis or necrosis depending on the concentration of H2O2 and the cell type being 
investigated (Bai and Cederbaum., 2000). Importantly, cell death in multiple myeloma 
cells correlated with the generation of ROS and the myeloma cell sensitivity was 
dependent on cellular catalase activity. In addition, treatment with catalase inhibitor 
induced ROS-dependent apoptosis (Wang et al., 2006). In a clinical study investigated 
the role of ROS in the pathogenesis of multiple myeloma by measuring the level of 
enzyme activities and oxidative stress parameters such as catalase in 14 newly 
diagnosed multiple myeloma patients (Kuku et al., 2005). It was found that all 
parameters of oxidative stress and enzymes activities were significantly reduced 
following therapy. This data propose that ROS may be participating in multiple 
myeloma pathogenesis (Kuku et al., 2005). On the basis of the above findings, these 
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results indicating the important role of oxidative stress and catalase in multiple 
myeloma mechanism.   
 However, although the vast majority of studies suggest oxidative stress can stimulate 
apoptosis, some reports showed that it can inhibit apoptosis and stimulate survival 
pathways. The mechanism by which ROS inhibits apoptosis is unclear; it has been 
found that H2O2-induces inactivation of caspase-3 (Borutaite and Brown., 2001). 
Moreover, high level of H2O2 can inhibit Fas-induced apoptotic cell death in Jurkat T-
cells, by reversibly inactivating caspase activity (Hampton, and Orrenius,.1997). 
However, over-expression of catalase in either the mitochondrial or cytosolic 
compartment induced sensitivity of a human liver cancer cell line (HepG2) to caspase-3 
dependent-TNFα-mediated apoptosis (Bai and Cederbaum., 2000).  
In summary, this work for the first time have shown some idea about the effect of LMB 
and G9a inhibitor, BIX 01294 and GSK343 on cell viability, cell cycle and caspase 
cascade and stimulated apoptosis in multiple myeloma cell lines. From this results can 
be concluded that the targeting of pro- and anti-apoptotic modulating molecules induce 
anti-tumour agents-mediated apoptosis in cancer cells and LMB, SAHA, BIX 01294 
and GSK343 may be a potential novel epigenetic therapy for multiple myeloma cells.  
5.6 Conclusion 
TRAIL and TRAIL sensitizers (LMB, SAHA, BIX 01294, and GSK343) either alone or 
in combination were previously shown to activate effector caspase-3 and confirm 
morphological changes of apoptotic in multiple myeloma cell lines (Chapter 2). Here, 
TRAIL and TRAIL sensitizers induced apoptosis via both extrinsic and intrinsic 
pathways via activation of both caspase 8 and 9 in multiple myeloma cell lines with 
varies effect depending on cell lines.  
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TRAIL treatment increased the expression of Death Receptors DR5, FADD, 
Fas/TNFRSF6 and TNF R1, and decreased expression of anti-apoptotic genes XIAP, 
Survivin, and cIAP-1. Pro-caspase-3, anti-apoptotic protein (XIAP, survivin, cIAP-1, 
and claspin), heat shock proteins; HSP27, HSP60 and HSP70, heme oxygenase 
isoforms (HO-2), anti-oxidative protein paraoxonase-2 (PON2) and phosphorylated p53 
isoforms were down-regulated following treatment with epigenetic modifiers for 24 h. 
Importantly, TRAIL and epigenetic modifiers were able to decrease expression of 
catalase in comparison with untreated cells. Providing a number of potential 
mechanisms by which TRAIL and TRAIL sensitizers trigger apoptosis in multiple 
myeloma cells. These results established that the combination treatments used in this 
study may target multiple signaling pathways and could act as an effective therapeutic 
approach against cancer. An advanced understanding of the underlying molecular 
mechanisms may facilitate either TRAIL or TRAIL sensitizers targeted use and the 
selection of appropriate combinations and determine the precise signaling of apoptosis 
mediated by these therapies requires further explore in future works.   
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6. General Discussion 
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The current study aimed to address the hypothesis that small molecule anti-tumour 
agents can enhance TRAIL sensitivity in multiple myeloma cells, both in suspension 
and 3D cell culture. 
6.1 Key Findings 
6.1.1 Effect of TRAIL and TRAIL Senstizers in Suspension multiple myeloma 
Cell Lines 
This study has illustrated that several novel classes of agents are TRAIL sensitizers, 
including NEI (LMB), HMTi BIX01294 and EZH2i GSK343. These agents displayed 
potential anti-tumour effect through reduction of ATP level as a marker of proliferation, 
induction of apoptosis, and cell cycle arrest in addition to the synergistic effects 
observed in combination with TRAIL. This work demonstrated that these anti-tumour 
agents that enhanced TRAIL responses in a caspase-3-dependent manner and resulted in 
characteristic apoptotic morphological changes in all multiple myeloma cell lines. 
TRAIL sensitizers induced both caspase-8 and -9 activities in most of cell lines, 
confirming that apoptotic signaling used both the intrinsic and extrinsic pathways. 
For the first time, the current study has shown that TRAIL displayed a synergistic 
induction of apoptosis by the NEI LMB and also the HMTasei BIX 01294 which 
inhibits G9a methyl transferase. None of these agents or even other agents from these 
classes of agents has been reported to interact with TRAIL in any cells in the published 
literature, although initial studies in our laboratory have shown NEIs (LMB) to enhance 
TRAIL in breast and prostate cancer cells (Haywood-Small et al., 2011). Interestingly, 
TRAIL alone and in combined with these agents showed a lower level of toxicity 
toward the non-tumours cell lines CD133+ haematopoeitic stem cells, and also normal 
renal cells (HREC). The differential sensitivity patterns observed within multiple 
myeloma cell lines to TRAIL are consistent with previous studies and likely reflect 
differential expression of apoptotic modifyers (Fandy and Srivastava., 2006).  
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The synergistic effect of TRAIL on induction of apoptosis and suppression of cell 
proliferation when combined with SAHA in ARP-1 multiple myeloma cell line have 
been previously reported in only one study via up-regulated transcription and the 
expression of surface TRAIL DR4/DR5 death receptors and pro-apoptotic protein and 
down-regulated expression of anti-apoptotic proteins Bcl-2 and IAPs (Fandy et al., 
2005). In addition, earlier studies have shown that malignant mesothelioma (Neuzil et 
al., 2004), melanoma (Zhang et al., 2003) leukemia (Rosato et al., 2003), and breast 
cancer (Zhou et al., 2016) can be sensitized with HDACi SAHA to undergo apoptosis 
by TRAIL. The sensitization of TRAIL resistant cells seems to be through up-regulation 
of pro apoptotic genes Bax, Bak, TRAIL-R2/DR5, and activation of caspases and down-
regulation the expression of other anti-apoptotic proteins: Bcl-2, Bcl-XL and IAPs and 
cIAP2 and c-flip (Neuzil et al., 2004; Rosato et al., 2003; Zhang et al., 2003; Mitsiades 
et al., 2003; Zhou et al., 2016). 
In this study, BIX 01294 was found to produce significant increasing of apoptosis and 
decreasing the ATP levels in MMSET positive cells (NCIH-929, OPM2 and ADC-1); 
whereas in combination with TRAIL, BIX 01294 synergistically enhanced TRAIL 
responses on induction of apoptosis and reduced ATP production in MMSET-negative 
cell lines (RPMI 8226, U266 and JJN3) and caused arresting cell cycle. Earlier work 
has shown that G9a inhibitor BIX01294 induced apoptosis number of cell lines: oral 
squamous cell carcinoma cell lines (Ren et al., 2015) breast cancer (Huang et al, 2010), 
neuroblastoma cells (Lu et al., 2013) and bladder cancer cell lines (Cho et al., 2011; Cui 
et al., 2015). This study is the first study to investigate the effect of specific G9 inhibitor 
BIX01294 in multiple myeloma and to date there are no previous work to link HMTasei 
inhibition to sensitisation of TRAIL in any tumour type. Further in vivo work is needed 
to support that a small molecule G9 inhibitor, BIX 01294 enhance TRAIL-induced 
apoptosis and may act as a clinically useful TRAIL sensitizer.   
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In the current work, EZH2 inhibitor GSK343 and TRAIL displayed synergistic effect on 
reduction of ATP level and induction of apoptosis in multiple myeloma cell lines. Very 
few studies have investigated the effects of GSK343 on apoptosis induction in cancer. 
Only one published work has investigated the apoptotic effect of EZH2 inhibitor 
GSK343 in MM cell line and showed that inhibition of EZH2 by using UNC1999 and 
GSK343 decreases viability and induced apoptosis (Agarwal et al., 2016). Recent work 
on osteosarcoma has shown that GSK343, a potent EZH2 inhibitor suppressed cell 
viability, restrained cell cycle and stimulated apoptosis (Xiong et al. 2016). Moreover, 
the combination of EZH2 (GSK343) and EHMT2 inhibitor (UNC0638) demonstrates a 
synergistic inhibition in growth of human breast adenocarcinoma cells (Curry et al., 
2015). To date there are no studies of effect of the GSK343 in combination with TRAIL 
in any tumour types. However, only one published work reported that the interaction of 
other class of EZH2 inhibitor, DZNep and TRAIL displayed synergistically induced 
apoptosis in colon cancer cells (Benoit et al., 2013).  
In addition, TRAIL-resistant cells were generated by culture of RPMI 8226 and NCI-
H929 by acute exposure to TRAIL, followed by selection of TRAIL-resistant cells. Our 
results showed that nuclear export inhibitor, and epigenetic modifiers may be a 
therapeutic option in combination with TRAIL and may increase TRAIL sensitivity in 
insensitive cells, but not in cells that have specifically been selected for acquired 
TRAIL-resistance. These results highlight that some TRAIL-insensitive cells are likely 
to be intrinsically apoptosis resistant, which may be overcome by TRAIL combined 
with senstisers. In contrast, when cells are selected specifically for TRAIL resistance, 
the mechanisms of apoptosis is likely very different in different tumours. 
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6.1.2 Effect of TRAIL and TRAIL Sensitizers in 3D Multiple Myeloma Cell 
Cultures 
Although multiple myeloma is a hematological malignancy, it forms solid bone lesions 
and these are potentially more targeted using therapeutic agents than tumour in blood. 
In addition, solid tumours might respond differently. This study has shown for the first 
time that myeloma cell lines are able to proliferate in the alginate beads and form 3D 
spheroid structures. In the current work, MM cells were more sensitive to LMB, SAHA, 
GSK343, and BIX 01294 alone in 3D cell culture.  In the 3D alginate model, all drugs 
synergistically induced apoptosis with TRAIL more potently than in suspension.  
Consistent with these findings there is only one previous study that shows that EZH2 
inhibitor, GSK126 inhibit the growth, induce apoptosis and cell cycle arrest in both 2D 
and 3D culture models in melanoma (Tiffen et al., 2015). In contrast, results from the 
current study are inconsistents with in earlier observation which reported that culturing 
of multiple myeloma cells in 3D model system induced cell proliferation and reduced 
the sensitivity to myeloma therapeutic agents in comparison to cell cultured as 
traditional monolayer cells (Jakubikova et al., 2016; de la Puente et al., 2015). 
However, differential responces between anti-tumour agents are expected, especially 
where proliferation is required for drugs activity e.g. DNA damage agents in contrast to 
TRAIL. Growing of mesothelioma cell lines in multicellular spheroids contributes to 
acquire a chemo-resistance character to a variety of apoptotic induction agents, 
including TRAIL, histone deacetylase, ribotoxic stressors, and proteasome inhibitors 
compared to 2D cultures (Barbone et al., 2008). Culture of breast cancer cell lines in 3D 
culture models showed more TRAIL-resistance by reduced expression of death 
receptors DR4 and DR5 that initiate TRAIL-mediated apoptosis in comparison to cell 
cultured as traditional monolayer cells (Chandrasekaran et al., 2014). In contrast to the 
current studies, 3D culture of B and T cell lymphoma showed increased proliferation 
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potential and drug resistance to the chemotherapeutics and a new class of HDACi, 
Panobinostat (Tian et al., 2015).   
This is the first time a study has been made of interaction between TRAIL and LMB, 
SAHA, GSK343, and BIX 01294 in 3D cell culture and compared with 2D cultures in 
any tumour types. Effective targeting of an anti-apoptotic Bcl-2 family member myeloid 
cell leukemia-1 (Mcl-1) in TRAIL resistant glioblastoma cells in previous work induced 
TRAIL sensitivity in both 2D and 3D culture (Murphy et al., 2014). Studies in small 
cell lung cancer cells reported that inhibition of the mitochondrial pyrimidine 
biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) sensitizes small cell 
lung cancer cell line U1690 to TRAIL-mediated apoptosis both within cancer cells 
grown as monolayers 2D and in a 3D culture model accompanied by inhibited 
expression of apoptotic inhibitory molecules c-flipL (He et al., 2014). Recent work by 
Ciardiello et al., (2016), showed that HDACi such as vorinostat when used in combined 
with anti-ErbB3 monoclonal antibody caused synergistic anti-cancer activity in non-
small cell lung cancer in both 2D and 3D conditions (Ciardiello et al., 2016).  
6.1.3 Potential Targets of TRAIL and Epigenetic Modifiers HDACi and HMTi –
Mediated Apoptosis 
In response to HDACi and HMTasei, NCI-H929 cells showed a significant decrease in 
protein expression of anti-apoptotic proteins; XIAP, survivin, heat shock proteins, anti-
oxidative protein paraoxonase-2 (PON2) and phosphorylated p53 isoforms following 
treatment with epigenetic modifiers for 24 h.  Importantly; epigenetic treatment as well 
as TRAIL decreased expression of catalase in comparison with control cells. Apoptosis 
involves generation of reactive oxygen species and cell sensitivity is inversely related to 
cellular catalase activity (Wang et al., 2006). Catalases protect cells against hydrogen 
peroxide (H2O2) stress by converted H2O2 into H2O and O2 (Zhao et al., 2005), H2O2 at 
high concentration is toxic, triggering programmed cell death (Martins and English., 
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2014). Conversely, inhibition catalase by 3-amino-1, 2, 4-triazole enhance the incidence 
apoptosis cell death (Sancho et al., 2003). Recent unpuplished work from our lab 
confirms that decrease catalase activity with 3-amino-1, 2, 4-triazole enhances TRAIL 
responces, and that in NCI-H 929, SAHA decreased catalase gene expression. This new 
data validates the observation of decreased catalase via the proteome array and highlight 
catalase as a potential target of apoptotic senstizers. Furthermore, ROS are very low in 
quiesent cells, supporting data on PKHHi cells (Tang et al., 2010). 
This study is considered as first work showed that TRAIL and TRAIL sensitizers down-
regulate the expression of catalase in multiple myeloma cells and further in vivo 
investigation is require to performed and developing of catalase inhibitor may enhance 
anti-cancer activity of multiple myeloma therapeutic agents.  
6.1.4 Isolation PKH26Hi Quiescent Populations were Less Sensitive to TRAIL 
and TRAIL Sensitizers 
In this study we were able to purify a minority of PKH-retained dye cells (PKHHi) by 
fluorescence-activated cell sorting (FACS) to TRAIL sensitive cell lines (RPMI 8226 
and NCI-H929). Our results showed that the PKH26Hi cell population exhibited less 
sensitivity to TRAIL, LMB, SAHA, BIX 01294, and GSK343 at doses known to kill 
most unselected cells compared to PKH26Lo and unsorted parental populations in two 
investigated TRAIL-sensitive multiple myeloma cell lines NCI-H929 and RPMI 8226. 
Isolation of cancer initiating cells by PKH26 fluoresce tracking dye have been reported 
in number of cancers including breast cancer (Pece et al., 2010), colon cancer (O’Brien 
et al., 2012), ovarian cancer (Kusumbe and Bapat., 2009) and multiple myeloma (Chen 
et al., 2014). In addition, these cells displayed cancer stem cell features such as 
expression of stem cell markers, having self-renewing ability as well as resistant to 
chemotherapeutic agents (Kusumbe and Bapat., 2009; Pece et al., 2010; O’Brien et al., 
2012; Chen et al., 2014) 
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These results are consistent with a previous study which found that the quiescent 
PKH26Hi multiple myeloma cells (RPMI 8226 and NCI-H929) exhibited enriched stem-
like properties by the ability of forming colonies in semi-solid medium as well as more 
resistant to anti-tumour agents including cyclophosphamide, bortezomib, vincristine, 
prednisone, and rituximab in vitro compared with PKHLo cell populations (Chen et al., 
2014). 
Most quiescent multiple myleoma populations could be either CD138+ve and CD138–ve. 
Those which were quiescent CD138–ve cells survived in vivo (Chen et al., 2014). A 
previous study demonstrated that CD138–ve sub-populations had significantly more 
clonogenic potential and expressed higher level of proliferation marker Ki67 than the 
CD138+ve cells. This study proposed that these CD138-ve sub-populations were multiple 
myeloma stem cells, and had the capability to replicate and consequently differentiate 
into malignant CD138+ve plasma cells (Matsui et al., 2004). Later, Matsui et al., (2008) 
demonstrated that CD138+ve multiple myeloma cells cannot undergo long-term 
proliferation but rather develop from clonogenic CD138 ve cells population (Matsui et 
al., 2008). Other studies showed that CD138-ve ALDH+ve population showed more 
clonogenic expansion than CD138+ve ALDH-ve population and only CD138-ve cells 
differentiated into CD138+ve population (Chung and Chng., 2013). 
6.1.5 Future Directions 
In order to examine the safety and efficiency of TRAIL alone and in combined with 
anti-tumour agents for possible human therapy, considerable in vitro and in vivo studies 
are required prior to any clinical intervention in humans. 
The majority of anti-tumour agents used within this work are not currently used 
clinically for multiple myeloma. Therefore, it would be crucial to determine whether 
these drugs act synergistically with TRAIL this could possibly result in reducing the 
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treatment doses and decrease their side effect. Firstly, in vivo safety studies are required 
as nothing is known how these agents act in combination in live animals NEIs are toxic 
and poorly tolerated but newer agents better tolerated in mice (Mutka at el., 2009) and 
certainly no studies using NEI in combination with targetted anti-tumour agents, such as 
TRAIL. 
6.1.6 Further Investigation on the Effect of TRAIL and Epigenetic Modifier 
Agents on Inhibition of Catalase 
This study demonstrated that TRAIL and the epigenetic modifiers SAHA, BIX01294 
and GSK343 decrease the level of catalase. The down-regulation of this protein is 
essential in order to inhibition of cellular growth and /or trigger apoptotic cell death. 
The sensitivity to anti-tumour agents on multiple myeloma cells is depend on cellular 
catalase activity and suppression of catalase by catalase inhibitor enhanced myeloma 
cell death (Wang et al., 2006). In addition, the level of oxidative stress parameters and 
enzyme activities give a preliminary idea of disease severity and evaluation of therapy 
response (Kuku et al., 2005). Further in vitro study using a catalase inhibitor (3-amino-
1,2,4-triazole) to enhanced therapeutic-mediated apoptosis in multiple myeloma cells, 
and repeating experiments but adding exogenous catalase are necessary in order to 
further elucidate the mechanisms by which these anti-tumour agents effect multiple 
myeloma cells and establish whether activities are dependent on catalase, althogh initial 
prelimiary studies from our laboratory are supportive of the notion that decrease 
catalase is a key mediator of TRAIL sensitization. Future crucial experiments will 
addrese whether catalase is not altered in quiesent cells, which is of particular relevance 
as ROS are very low in quiesent cells. 
6.1.7 In vivo Animal Studies 
In order to confirm whether the results have the potential to be clinically useful, the 
effect of TRAIL alone or in combination with other chemotherapy in animal models 
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would require determining prior to clinical trails. Animal studies are crucial to establish 
whether anti-tumour agents are feasible options for human disease, and if so which are 
the most effective combination treatments. Previous work assessing the novel 
combination therapies of HDACi and TRAIL in human multiple myeloma cell lines (in 
vitro) and preclinical screening using syngeneic transplanted Vk*MYC multiple 
myeloma (in vivo) showed that in vitro studies give some insight into activity of drug 
and synergistic effect of drug combination that kill myeloma cells, but, they do not 
always expect in vivo efficacy or toxicity. HDACi/rhTRAIL-combination based 
strategies, established dose-limiting toxicities that prohibited long term treatment 
(Matthews et al., 2013). 
Successive development and improvement in G9a inhibitors resulted in the discovery of 
more selective and potent inhibitors such as UNC0638 (Liu et al., 2013; Vedadi et al., 
2011). Unfortunately, these G9a inhibitors displayed poor pharmacokinetic properties 
that limited the further in vivo pre-clinical studies. However, the discovery of UNC0642 
maintained excellent selectivity, high in vitro potency as well as displayed better in 
vivo pharmacokinetic properties making it appropriate target for experimental animal 
studies (Liu et al., 2013). Since G9a inhibitors are well tolerated in animal studies, 
combination of G9a inhibitors with TRAIL in in vivo studies is worthy of further 
investigation. 
The effect of combination of LMB, epigenetic agents (BIX01294 or GSK343) with 
TRAIL on multiple myeloma therapy has not been investigated on multiple myeloma 
animal model. Therefore, testing of these drugs on pre-clinical model will be very 
crucial to determine non-toxic therapeutic dose as well as the maximum levels of these 
combination treatments that can be obtained. In particular, some death receptor agonists 
are known to induce liver toxicity (Lawrence et al., 2001) and any enhancement to off-
target TRAIL responses may render the therapeutic window too small for therapeutic 
 278 
 
benefit, however in vivo studies with initial dose escalation studies in healthy animals 
would be an initial experiment prior to any attempt to affect tumour burden. 
6.2 Final Conclusions 
For the first time this study clearly demonestrates that the NEI Leptomycin B, the G9a-
inhibitor BIX 01294 and the EZH2-inhibitor GSK343 can enhance TRAIL-induced 
apoptosis and target TRAIL resistance in both suspension culture, and in a 3D cell 
culture as a model of solid disseminated multiple myeloma lesions and that toxicity seen 
was lower in non-tumour control cells. These anti-tumour agents stimulated apoptosis 
through extrinsic or intrinsic apoptosis pathways resulting in decrease XIAP, survivin, 
heat shock proteins, and decreased catalase expression. These results suggest that 
TRAIL in combination with TRAIL sensitizers LMB, SAHA, BIX01294 and GSK343 
hold promise for MM treatment. Further in vivo studies are urgently required in order to 
develop these promising drugs as future therapy. However, studies on quiescent cells 
suggest that these treatments do not kill all cells.  Current studies are aimed at 
investigating the relevance of PKHHi cells to relapse from therapy in long-term studies, 
both in vitro and in vivo, and the role of catalase in quiesent cells and the development 
of TRAIL resistance. 
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8. Appendices 
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Figure I:  Effect of LMB in combination with TRAIL on cell cycle progression in 
multiple myeloma cells 
 
Figure I:  Effect of LMB in combination with TRAIL on cell cycle progression in 
multiple myeloma cells. The cells were treated with LMB and TRAIL alone and in 
combined for 24 hours. The data is expressed as median with range (three independent 
experiments). The statistical significance was determined by comparison with the 
vehicle control and statistical significance of combined therapy was determined by 
comparison the percentage of treated cells in each phase to both the vehicle control and 
individual treatment (*= p< 0.05) (Kruskal–Wallis). 
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Figure II:  Effect of SAHA in combination with TRAIL on cell cycle progression in 
multiple myeloma cells 
 
Figure II:  Effect of SAHA in combination with TRAIL on cell cycle progression in 
multiple myeloma cells. The cells were treated with SAHA and TRAIL alone and in 
combined for 24 hours. The data is expressed as median with range (three independent 
experiments). The statistical significance was determined by comparison with the 
vehicle control and statistical significance of combined therapy was determined by 
comparison the percentage of treated cells in each phase to both the vehicle control and 
individual treatment(*= p< 0.05) (Kruskal–Wallis).  
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Figure III:  Effect of BIX 01294 in combination with TRAIL on cell cycle 
progression in multiple myeloma cells 
 
Figure III: Effect of BIX 01294 in combination with TRAIL on cell cycle progression 
in multiple myeloma cells. The cells were treated with BIX 0-1294 and TRAIL alone 
and in combined for 24 hours. The data is expressed as median with range (three 
independent experiments). The statistical significance was determined by comparison 
with the vehicle control and statistical significance of combined therapy was determined 
by comparison the percentage of treated cells in each phase to both the vehicle control 
and individual treatment(*= p< 0.05) (Kruskal–Wallis). The percentage of cells in each 
phase was analyzed with Flow Jo software. High concentration of BIX 01294 in 
combination with TRAIL significantly induced accumulation in G2/M-phase (p< 0.05).          
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Figure IV:  Effect of GSK343 in combination with TRAIL on cell cycle progression 
in multiple myeloma cells 
 
Figure IV:  Efect of GSK343 in combination with TRAIL on cell cycle progression in 
multiple myeloma cells. The cells were treated with GSK343 and TRAIL alone and in 
combined for 24 h. The data is expressed as median with range (three independent 
experiments). The statistical significance was determined by comparison with the 
vehicle control and statistical significance of combined therapy was determined by 
comparison the percentage of treated cells in each phase to both the vehicle control and 
individual treatment(*= p< 0.05) (Kruskal–Wallis). 
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Target Target Target Target 
A1, A2 
A23, A24 
B1, B2 
B3, B4 
B5, B6 
B7, B8 
B9, B10 
B11, B12 
B13, B44 
B15, B16 
B17, B18 
B19, B20 
B21, B22 
B23, B24 
C1, C2 
C3, C4 
C5, C6 
C7, C8 
C9, C10 
Reference Spots 
Reference Spots 
Bad 
Bax 
Bcl-2 
Bcl-x 
Pro-Caspase-3 
Cleaved Caspase-3 
Catalase 
cIAP-1 
cIAP-2 
Claspine 
Clustrine 
Cytochrome C 
TRAIL R1/DR5 
TRAIL R2/DR4 
FADD 
Fas/TNF6/CD95 
HIF-1α 
C11, C12 
C13, C14 
C15, C16 
C17, C18 
C19, C20 
C21, C22 
C23, C24 
D1, D2 
D3, D4 
D5, D6  
D7, D8 
D9, D10 
D11, D12 
D13, D14 
D15, D16  
D17, D18 
D19, D20 
D21, D22 
D23, D24 
E1, E2 
HO-1/HMOX1/HSP32 
HO-2/HMOX2 
HSP27 
HSP60 
HSP70 
HTRA2/Omi 
Livin 
PON2 
p21/CIP1/CDKN1A 
p27/Kip1 
Phospho-p53 (S15) 
Phospho-p53 (S46) 
Phospho-p53 (S392) 
Phospho-Rad17 (S635) 
SMAC/Diablo 
Survivin 
TNF RI/TNFRSF1A 
XIAP 
PBS (Negative Control) 
Reference Spots 
 
Table I.: Human apoptosis proteme profiler array coordinates 
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Figure V: Human apoptosis proteome profiler array coordinates. 
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Figure VI: RNA sample purity assessment by NanoDrop-1000 spectrophotometer 
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Figure VII: The integrity of the extracted RNA confirmed by 1% agarose gel 
electrophoresis 
 
